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Abstract 
One of the open challenges in chemical biology is to identify reactions that proceed with large rate 
constants in water at neutral pH values. Once assembled, these conjugates may be used for a broad 
variety of applications (e.g., therapeutics, imaging probes or as a catalytic system). Herein we describe 
a novel approach for the chemical modification of nucleic acids using guided organometallic-catalysts. 
Customized dirhodium complexes were prepared using modular ligands bearing various functional 
groups and connected to peptide nucleic acids through stable oxime linkages. The final constructs 
have been optimized for aqueous catalysis and were tested in preliminary alkylation studies of single-
stranded DNA via dirhodium-carbenoids generated from -diazocarbonyl compounds. During the 
course of optimizing the rather slow kinetics of oxime formation, we have developed two highly 
efficient methods for rapid oxime-based bioconjugations. (1) Dialdehydes were found to react with O-
alkylhydroxylamines at rates of 500 M
-1
 s
-1
 in neutral aqueous buffer in the absence of a catalyst. The 
key to these conjugations is an unusually stable cyclic intermediate, which ultimately undergoes 
dehydration to yield an oxime. The scope and limitations of this method are outlined, as well as its 
application in bioconjugation with a DNA 41-mer and a mechanistic interpretation that will facilitate 
further developments of reactions with O-alkylhydroxylamines at low substrate concentrations. (2) 
Oximes proximal to boronic acids form in neutral aqueous buffer with rate constants of more than 10
4
 
M
−1
 s
−1
, the largest to date for any oxime condensation. The reaction tolerates a variety of biological 
interfering additives and is suitable for the rapid modification of short peptide sequences. Once 
formed, the oxime products are stable for days and undergo slow interconversion through a 
hydrolysis-based mechanism. Boron's dynamic coordination chemistry confers an adaptability that 
seems to aid a number of elementary steps in the oxime condensation. 
In conclusion both methods represent important improvements for oxime-based bioconjugations in 
water (pH 7) at low equimolar concentrations. The high reaction kinetics are achieved without the 
need for additional reagents, catalysts or variations of the reaction conditions. In addition, the 
possibility of using reacting pairs that are commercially available will greatly enhance the applicability 
of these methods for efficient conjugations of precious biomolecules in the future. 
 
 
1 
 
1 Thesis Outline 
 
The main goal of the present thesis was to develop a new method for the catalytic, structure-selective 
nucleic acid modification using guided organometallic-catalysts in aqueous media under neutral 
conditions. This architecture was planned to be constructed from short peptide nucleic acid (PNA) 
sequences which are covalently connected to a dirhodium catalyst through a rapid and robust 
bioconjugation technique. Once assembled, these organometallic-catalysts will WATSON-CRICK base-
pair to complementary nucleic acid sequences in a dynamic fashion. The addition of -diazocarbonyl 
compounds will generate a reactive organometallic-carbenoid catalyst which is able to undergo site-
specific insertion reactions with the target’s functional groups present in close proximity.  
This strategy was pursued by addressing the following aspects: 
(1) choosing a suitable conjugation method to build the organometallic-catalyst 
(2) synthesis of short peptide nucleic acid sequences equipped with modifiable functional groups 
(3) developing dirhodium catalysts with suitable functional groups for conjugation 
(4) assembling of the organometallic-catalyst and probing its ability in nucleic acid modification 
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1.1 Introducing the concept of bioconjugation 
 
Bioconjugation is a powerful chemical method used for the covalent derivatization of biomolecules to 
form stable conjugates comprising the combined properties of their individual components.
1
 Its 
development allows the direct access to a broad range of natural or synthetically valuable compounds 
(e.g., nucleic acids and proteins) exceeding the molecular complexity accessible by stepwise chemical 
synthesis.
2
 The ability to perform such conjugations through a selective and facile chemical 
transformation also has practical applications in therapeutics
3
 or diagnostics
4
. Applying bioconjugation 
in the field of chemical biology
5
 has helped scientists to understand biochemical pathways and 
mechanisms, and also enabled true structure-activity relationship (SAR) of biomolecular processes. 
Ideally a bioconjugation reaction should be chemoselective, robust and biocompatible (neutral pH in 
water, tolerant to other interfering functional groups) proceeding with high rate constants at low 
concentrations (e.g., nM-M regime) with substrate stoichiometries near unity (Figure 1.1).6,7 
Therefore it is necessary to develop and design new chemical methods which meet these challenging 
requirements to generate molecules with carefully engineered characteristics. Several techniques are 
reported in the literature and include labeling
8
, ligation
9
 as well as the use of heterobifunctional
10
 and 
trifunctional
11
 crosslinkers to study protein-protein interactions for example. The crosslinking of such 
monofunctional components to create multifunctional molecules can be accessed either by direct 
reaction of natural functional groups (FGs) or through bioorthogonal conjugation
12
 with unnatural FGs 
(vide infra).  
This clearly underlines the importance of exploring NEW STRATEGIES IN BIOCONJUGATION, 
an important component in today’s life science research. 
 
 
Figure 1.1: A bioconjugation reaction between two chemical species A and B bearing bioorthogonal functional groups. The 
reaction is biocompatible and proceeds in a complex environment of competing functionalities as found in living systems.  
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1.2 Direct reactions with natural functional groups 
 
Nature provides a sea of FGs which have a broad range of reactivity based on their chemical properties 
in different environments. Covalent and non-covalent interactions of FGs are the core of metabolism 
(e.g., ATP, NADH) and biological molecular recognition (e.g., DNA double helix, signalling 
proteins).
13
 If chemists are able to selectively target and modify these functional groups, then perhaps 
it would be possible to build on Nature’s designs and get access to new molecules applicable in the 
field of chemical biology. 
Since our research goal was to directly target and modify native FGs present in biopolymers, 
particularly nucleic acids, it is of importance to present an overview of selected and established 
methods covering this research area. Within the following section focus is laid on the use of natural 
FGs present in biomolecules for their modification through bioconjugation chemistry.  
 
1.2.1 Chemical modifications of DNA 
 
Targeting native DNA sequences with chemical probes is a challenging task which requires reagents 
that are reactive enough to form a covalent bond with one of the various functional groups present in 
the oligonucleotides. Of major interest are therefore activated electrophiles capable to react with 
nucleophilic phosphates or nucleobase heteroatoms in DNA. These reagents are mainly classified into 
two classes depending on their alkylation pathways; SN1 and SN2-type alkylation agents.
14
 Although 
the sites of DNA modification are the same for these reagents, they differ by their percental 
occurrence. The use of methyl methanesulfonate (MMS), a SN2-type reagent, was found to alkylate N-
1A and N-3C in ssDNA while N-methyl-N’-nitrosourea (NMU), a SN1-type reagent, alkylates the 
phosphodiester backbone of ssDNA (Figure 1.2).
15
 When tested with dsDNA both reagents perform 
similar with major preferences for the N-7G site which is located in the major groove of DNA, thus 
allowing for a greater accessibility.
16
 Guanine O-alkylations are less significant since the oxygen atom 
is involved in WATSON-CRICK base pairing and normally lacks reactivity to be modified efficiently. 
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Figure 1.2: DNA alkylating agents and their sites of modification on nucleobases and phosphodiester backbone. (A) Methyl 
methane sulfonate (MMS) alkylations of A/G in dsDNA and A/C in ssDNA. (B) N-methyl-N’-nitrosourea (NMU) alkylations 
of A/G in dsDNA and T/phosphodiester backbone in ssDNA. 
Another very similar alkylating agent, dimethyl sulfate (DMS), was investigated in the early sixties by 
LAWLEY and BROOKES as an efficient mutagen. Treatment of RNA with 
14
C-labeled DMS followed 
by acidic hydrolysis was found to deliver four isotopically labeled products, the major being N-7G.
17
 
Later GILBERT and MAXAM could exploit this finding by developing a new technique for DNA 
sequencing based on DMS-mediated guanine alkylation and subsequent depurination followed by 
alkaline cleavage at the abasic site (Scheme 1.1).
18,19
 A high resolution gel electrophoresis could 
reveal the cleaved fragments, resulting in a ladder with characteristic bands corresponding to each 
guanine present in the DNA. This reaction was part of one of the earliest sequencing technologies. 
 
Scheme 1.1: Dimethyl sulfate-initiated methylation pathway of the N-7G with subsequent depurination and piperidine-
mediated DNA cleavage used for sequencing. 
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Another important sequencing method relies on the principle of selective bisulfite-initiated conversion 
of intact cytidines to uracils (Scheme 1.2).
20,21
 This method is primarily used to reveal 5-
methylcytosine residues in individual DNA strands upon bisulfite treatment, polymerase chain 
reaction (PCR) amplification and sequencing.
22,23
 
 
Scheme 1.2: Selective bisulfite conversion pathway of cytidine to uracil used for the detection of 5-methylcytosines in DNA. 
 
In 1985, SEGAL and SOLOMON showed the potential of acrylonitrile (AN) as a direct mutagen in their 
alkylation studies with calf thymus DNA. Initial and separate treatment of AN with deoxynucleosides 
under physiological conditions resulted in site-specific cyanoethylation as confirmed by MS/MS 
studies. Probing the alkylating agent with calf thymus DNA showed various modifications of all 
nucleobases to different extents.
24
 In situ generated AN is also known to react with thymines during 
the deprotection step of oligonucleotide synthesis and results in cyanoethyl-alkylated N-3T species via 
MICHAEL addition.
25,26
  
ROKITA et al. developed an important method for direct nucleic acid modification which uses a 
reactive, in situ generated, ortho-quinone methide (QM) as alkylating agent.
27
 This species is quickly 
obtained through fluoride deprotection of an o-(bromomethyl)phenol derivative and susceptible to 
nucleophilic attack by the exocyclic amino groups of deoxynucleosides (Scheme 1.3).
28
 
 
Scheme 1.3: Representative o-quinone methide alkylation of the exocyclic amino group in deoxyadenine initiated by O-
deprotection with potassium fluoride. Further examples (dG and dC) are also reported.28 
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Later, in 2003 they could show that an acridine-functionalized QM is able to cross-link dsDNA as 
shown by denaturating gel electrophoresis. Monoalkylations were found to be rare and their presence 
explained by the ability of the QM to “walk” from unfavorable to favorable cross-links while 
generating this intermediate.
29
 Recently it was shown that the terminal attachment of a QM to an 
unnatural nucleic acid is effective in cross-linking a complementary DNA strand through a reversible 
process. Although self-adducts were found to be the kinetically dominating species, the system 
equilibrated to the thermodynamically favored interstrand product (Scheme 1.4).
30
 
 
Scheme 1.4: Pathway of interstrand cross-linkage using an unnatural nucleic acid equipped with a terminal QM. The reaction 
proceeds through a reversible self-adduct delivering the covalently linked product upon hybridization to a complementary 
ssDNA sequence. 
 
A variety of DNA cross-linking agents are known, some of which have even reached clinical 
application as cancer treatments.
31
 Among those, prominent examples are cis-platin and carboplatin
32
, 
nitrogen mustards like mustine, melphalan and chlorambucil
33
 as well as Mitomycin C
34
 and 
psoralens
35
, the latter which crosslinks DNA upon irradiation. For a full and detailed review on DNA 
interstrand cross-linking and potential cancer treatment the reader is redirected to DEANS and WEST.
31
 
A more recent approach for the structure-selective catalytic nucleic acid modification was described 
by our research group in 2012.
36
 DR. KIRIL TISHINOV could demonstrate that aqueous dirhodium-
carbenoid catalysis can be used as a direct method for the alkylation of native DNA. NMR 
experiments revealed that exocyclic amino groups are the only sites for modification while thymine 
and uracil were completely unreactive. Since dsDNA could not be targeted with this method, a single 
reactive adenine in a hairpin turn region or as a 3’ or 5’ overhang could be selectively alkylated as 
confirmed separately by MS/MS experiments (Scheme 1.5).  
7 
 
 
Scheme 1.5: Structure-selective catalytic nucleic acid modifications of the adenine nucleobase. (A) Reaction pathway for the 
alkylation of the exocyclic amino group using aqueous dirhodium-carbenoid catalysis. (B) Alkylation of a hairpin (i) turn 
region, (ii) 3’ overhang and (iii) 5’ overhang. 
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1.2.2 Modification of amino acids in proteins and peptides 
 
Since peptide modifications and their use in bioconjugation are presented at a later stage, I will 
introduce this concept now as a subsection of “Direct reactions with natural FGs”.  
Proteins and peptides are key components of life. These biomolecules are essential for the structure, 
function and regulation of the body’s tissues and organs. Composed by a unique sequence of short 
amino acid fragments, proteins and peptides play a key role in intra- and extracellular events. The 
activity and function of proteins are often regulated by specific chemical changes on amino acid side-
chains. These chemical modifications, termed post-translational modifications (PTMs), are natively 
introduced by enzymes or cofactors and include glycosylations, phosphorylations, acetylations or 
ubiquitinations, to mention only a few.
37
 These supremely complex and selective processes for the 
covalent modification of highly functional molecules is a key step in most biological processes. They 
are responsible for the generation of proteome complexity and thus great effort has been invested in 
understanding these processes in detail. Drawing inspiration from Nature, chemists and biologists have 
begun to develop methods for selective protein and peptide modifications. These bioconjugations are 
mainly based on the reactivity of particular amino acid residues within the biomolecule towards a 
specific chemical FG. Techniques that enable such artificial chemical modifications of amino acids are 
therefore of major interest in chemical biology.  
The following subsections will give the reader a brief overview of some selected and established 
methods available for the selective modification of reactive amino acids and their bioconjugation to 
other molecules. 
1.2.2.1 Cysteine modifications 
 
Reactions on cysteine are the most common chemical approach to direct protein modification due to 
its low natural abundance in proteins and the highly nucleophilic character of the sulfhydryl group 
compared to the side chains of other amino acids. Alkylation agents are widely used for covalent 
modifications, but sometimes off-target reactions with histidine, methionine, lysine as well as N-
terminal amino groups can be observed.
38
 Iodoacetic acid was early found to deliver selective cysteine 
modification in human hemoglobin as concluded by COLE et al.
39
 Similarly, papain was later shown to 
be modified at the sulfhydryl group of the active site cysteine residue (Cys
25
) using a -halocarbonyl-
containing flavin compound.
40
 Another alkylating reagent for the selective modification of cysteine is 
iodoacetamide which was first reported 1935 by GODDARD and MICHAELIS.
41
 The acetamide 
derivative of cysteine has found applications for peptide mapping of proteins containing cysteine 
residues.
42,43
 A schematic representation of the general mode of cysteine bioconjugation through 
alkylation is depicted in Scheme 1.6. 
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Scheme 1.6: Cysteine bioconjugation approach using -haloacetyl compounds forming a thioether linkage. 
 
Another important class of molecules for cysteine bioconjugation comprises maleimides
44,45
 and vinyl 
sulfones
46
 (Scheme 1.7). These MICHAEL acceptors undergo conjugate additions with sulfhydryl 
residues in proteins to give thioethers. A polyethylene glycol (PEG) equipped vinyl sulfone was 
shown to selectively modify reduced RNase at its cysteine residues depending on the pH. While this 
reaction with sulfhydryls was found to be fast and selective at pH 7-9, lysine residues were slowly 
modified at elevated pH values.
47
 This method is a suitable alternative to introduce a post-translational 
PEGylation into hydrophobic proteins which demand a water solubilizing agent. Similarly, BELL et al. 
reported that selective maleimide PEGylation of a -interferon based protein drug at its cysteine side 
chains resulted in enhanced circulating half-time and antitumor activity.
48
 Other maleimide-based 
bioconjugations comprise antibody affinity-labeling with biotin
49
 or with maleimide-activated 
enzymes
2
, the formation of mixed bis-thioethers
50,51
 and maleimide fluorophores for protein imaging.
52
 
However, maleimide and its conjugates were found to be hydrolytically unstable and ring opening 
with subsequent elimination of the cysteine residue is a problem at alkaline pH and should be 
considered when planning such a reaction.
53
 
 
 
Scheme 1.7: Conjugate additions of cysteine for bioconjugation. (A) Sulfhydryl addition to maleimides. (B) Sulfhydryl 
addition to vinylsulfones. 
 
When oxidized, cysteines are present as disulfides and play an important role in protein folding and 
stability. Interstrand disulfide bonds can be reduced by e.g., tris(2-carboxyethyl)phosphine (TCEP) or 
dithiothretiol (DTT) to unmask the cysteines and exploit their reactivities. In turn a suitable method for 
the covalent modification of reduced thiols is their conversion into mixed disulfides via disulfide 
exchange (Scheme 1.8). Reagents which can be used for these transformations comprise pyridyl 
disulfides
54
 and the more prominent ELLMAN’S reagent which was developed for the 
spectrophotometric quantification of protein thiols.
55,56
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Scheme 1.8: Disulfide exchange as a bioconjugation method for cysteine modification. 
 
1.2.2.2 Lysine modifications 
 
Lysines contribute to the overall net positive charge of proteins because they are protonated under 
physiological conditions. Above its pKa of 9.3-9.5 the -amino group becomes nucleophilic and a 
potential target for the modification with potent electrophilic reagents. Among those are e.g., N-
hydroxysuccinimide (NHS) activated esters for the formation of amide bonds, urea formation with 
isocyanates and thiourea formation with isothiocyanates (Scheme 1.9). 
 
Scheme 1.9: Selected bioconjugation strategies for lysine residues. (A) Amide bond formation through NHS esters. (B) Urea 
formation with isocyanates. (C) Thiourea formation with isothiocyanates. 
 
NHS esters are a widely used activation method for carboxylates in the formation of a stable amide 
bond and have been established as one of the most general bioconjugation techniques for lysine side 
chain modifications. Prior to the reaction, stable NHS esters have to be prepared synthetically through 
their carboxylates and a condensing agent such as N,N’-dicyclohexylcarbodiimid (DCC). Upon 
conjugation with the -amine of lysine the NHS acts as a leaving group while forming a stable amide 
conjugate. Prominent examples for this activation and lysine modification are the sulfo-NHS-mediated 
biotinylation
57,58
, the NHS-mediated introduction of fluorescent labels or the use as a 
heterobifunctional NHS ester-maleimide crosslinker (Scheme 1.10).
10
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Scheme 1.10: Heterobifunctional sulfo- and succinimidyl-4-(N-maleimidmethyl)cyclohexane-1-carboxylate (Sulfo-SMCC 
and SMCC) crosslinkers. A lysine-containing biomolecule can be connected to a cysteine target. 
 
Isocyanates have only limited applications for bioconjugation since these reagents were found to be 
too unstable and result in amines when exposed to moisture. Nevertheless some examples exist, one of 
them being the selective lysine side chain modification in horse cytochrome c with m-
trifluoromethylphenyl isocyanate as detected by 
19
F-NMR, trypsin digest and peptide mapping.
59,60
 
The less reactive isothiocyanates were found to deliver almost exclusively stable lysine conjugates but 
are also able to react with N-terminal -amines depending on the pH of the reaction media.2 TULS et 
al. demonstrated the selective labeling of Lys
338
 in cytochrome P-450 with fluorescein isothiocyanate
61
 
while NAKAMURA et al. used allyl isothiocyanate (AITC) which modifies lysines in bovine serum 
albumin through an intermediate AITC-cysteine adduct.
62
 This transfer was confirmed by synthetic 
probes which were subjected to detailed LC-MS analysis. The mechanism is not clarified yet and is 
proposed to happen through a fast but reversible AITC-cysteine intermediate delivering the 
thermodynamically favored AITC-lysine over time (Scheme 1.11). 
 
Scheme 1.11: Proposed mechanism by NAKAMURA for the reaction of AITC with a cys/lys-containing protein under 
physiological conditions.62 
 
1.2.2.3 Tyrosine modifications 
 
Tyrosine modifications are rather rare due to its low reactivity under physiological conditions. 
Nonetheless the resonance donation effect of the phenolic group allows tyrosine to be selectively 
modified at the ortho-position with suitable electrophiles. The most popular among tyrosine 
12 
 
modifications is the diazo bond formation with a diazonium reagent.
10
 Recently, a very elegant 
example was published for tyrosine-selective modification of proteins using formylbenzene diazonium 
hexafluorphosphate (FBDP) which introduces additionally a bioorthogonal aldehyde for further 
functionalization (Scheme 1.12).
63
 
 
Scheme 1.12: Selective tyrosine modification with FBDP under physiological conditions to give a functionalized, 
bioorthogonal conjugate. 
 
Modifications on tyrosine though were primarily chosen to obtain information on their binding 
properties within proteins and include also O-acetylations or nitrations of the phenyl ring.
10
 
 
1.2.2.4 Reactions of C- and N-termini 
 
The selective reaction of C- or N-terminal amino acids is also of great interest for PTM and strategies 
targeting one specific residue at the end of a peptide or protein have been successfully developed. 
Although direct methods for modification exist, some amino acids have to be converted first into 
different, reactive groups which are then able to be used in further bioconjugation reactions. N-
terminal serine
64
 or threonine
65
 can be oxidized with NaIO4 to glyoxal groups which can be further 
reacted to form a stable bioconjugate as shown by KAWAKAMI or CHELIUS (Scheme 1.13). Similarly 
FRANCIS et al. could show that pyridoxal 5’-phosphate is able to oxidize the -amino group into a 
ketone or an aldehyde which can then be condensed with a hydroxylamine-bearing dye.
66
 Other 
chemoselective strategies comprise oxazolidine (serine) and thiazolidine (cysteine) formation with 
aldehydes as well as N-terminal tryptophan modification through PICTET-SPENGLER reaction.
67,68
  
 
Scheme 1.13: N-terminal serine and threonine oxidation with subsequent bioconjugation to a hydrazide derivative. 
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Certainly the most prominent example which exploits various reactivities in a stepwise fashion for 
selective protein modification is native chemical ligation (NCL). In 1993, DAWSON et al. applied this 
ligation method to peptide fragments containing a C-terminal -thioester whereas the second one was 
equipped with an unprotected N-terminal cysteine residue.
69
 The reaction is initiated by nucleophilic 
attack of the cysteine thiol (Scheme 1.14, peptide2) on the -thioester (peptide1) to give the kinetic 
transthioesterification intermediate. The final thermodynamic and enlarged peptide product is obtained 
by subsequent S → N acyl shift and connected through a robust amide bond, providing a powerful 
method for the chemoselective ligation of peptide fragments in a smart way. 
 
Scheme 1.14: Native chemical ligation strategy used for the formation of larger peptides from smaller peptide fragments 
containing a C-terminal -thioester and an unprotected N-terminal cysteine. The ligated product is connected via native 
(amide) bond next to the cysteine. 
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1.3 “Bioorthogonal” bioconjugation using unnatural functional groups 
 
Nature provides a defined but limited toolbox of FGs (e.g., hydroxyls, acids, amines, thiols, 
phosphates, phenols etc.) which can be used for molecular conjugation. Amide bonds in peptides can 
be formed by condensing amines with carboxylic acids and are amongst the most important bonds 
found in biology (vide supra). Scientists however have extended this toolbox by developing unnatural 
but highly useful FGs (e.g., alkyl halides, azides, alkynes, boronic acids, phosphorous(III), diazo 
compounds etc.) which can be used for bioorthogonal bioconjugation reactions. In general, a 
bioorthogonal transformation is a reaction that does not interfere with biological processes but 
displays chemoselectivity and high reactivities under physiological conditions.
6
 The development of 
such reactions remains important not only to study natural processes, but to potentially expand on 
them. 
Because the bioconjugation strategies used for the presented work relied on unnatural FGs the reader 
is given a brief overview of selected and important methods developed in the past and applied in this 
field. 
 
1.3.1 Staudinger Ligation 
 
Almost 100 years ago, in 1919 STAUDINGER and MEYER discovered the irreversible reaction of a 
phosphine with an azide to yield an amine under aqueous conditions (Scheme 1.15, panel A).
70
 In 
2000, BERTOZZI et al. could further develop the STAUDINGER reaction by a modification using a 
phosphine reagent containing an internal electrophilic trap (Scheme 1.15, panel B).
71
 This method 
termed “STAUDINGER ligation” enables the covalent coupling reaction between complex reaction 
partners and is the artificial counterpart of the NCL for bioconjugation using unnatural FGs. Shortly 
after, BERTOZZI and RAINES independently turned this reaction into a “traceless” STAUDINGER ligation 
by the use of phosphinothiols.
72,73
 The latter being first reacted with a peptide containing a C-terminal 
thioester reacts afterwards with an azide to give an aza-ylide intermediate. Upon reaction with the 
activated thioester a stable peptide bond is formed, with the phosphinoxide released as the sole by-
product (Scheme 1.15, panel C). Compared to NCL where an N-terminal cysteine residue is essential 
for a successful connection, this method allows the synthesis of long peptides which may contain any 
amino acid at the ligation junction. Unfortunately this method is of limited applicability due to its 
rather slow kinetics and the use of easily oxidized phosphines under aerobic conditions. For a detailed 
overview on the bioconjugation via azide-STAUDINGER ligation the reader is referred to the reviews of 
VAN HEST and BRÄSE.
74,75
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Scheme 1.15: (A) STAUDINGER reduction of azides with triphenylphosphine to yield primary amines. (B) Staudinger ligation 
using an electrophilic trap for the conjugation of the azide moiety to the phosphine. (C) Traceless STAUDINGER ligation using 
a phosphinothiol as the ligating mediator. 
 
1.3.2 “Click” Chemistry 
 
The origin of “click” chemistry goes back to the mid sixties where HUISGEN et al. presented the 
concept of 1,3-dipolar cycloaddition reactions between a dipolarophile (e.g., alkene, alkyne) and a 
dipolar species (e.g., nitrile, azide) to give five-membered heterocycles.
76
 In particular, the addition of 
azides to alkynes or olefins is nowadays known as the HUISGEN 1,3-dipolar cycloaddition and still one 
of the classic reactions in organic chemistry. Although the reaction connects two substrates with 
excellent atom economy, it was found to be slow and elevated temperatures were essential for 
acceptable product yields (Scheme 1.16, panel A). In addition, the concerted mechanism usually 
results in mixtures of 1,4 and 1,5-regioisomers and is difficult to control. In 2001, US scientists KOLB, 
FINN and SHARPLESS introduced the term “click” chemistry which relies on the use of a Cu(I) catalyst 
for the efficient synthesis of such triazoles.
77
 This method turned out to be very powerful, selective and 
modular delivering the products in high yields under mild reaction conditions and with broad FG 
tolerance. Using a Cu(I) catalyst was found not only to accelerate the reaction, but also to deliver 
16 
 
regiospecifically the 1,4-disubstituted 1,2,3-triazoles (Scheme 1.16, panel B). These observations were 
independently reported in 2002 by FOKIN and SHARPLESS, and MELDAL as separate publications.
78,79
 
The proposed mechanism of the Cu(I)-catalyzed azide-alkyne cycloaddition (CuAAC) was recently 
revisted by FOKIN and describes the involvement of a dinuclear Cu(I) species which was supported by 
isotopic crossover experiments (Scheme 1.16, panel C).
80
 
 
Scheme 1.16: (A) HUISGEN 1,3-dipolar cycloaddition delivering mixtures of 1,4 and 1,5 regioisomers upon heating. (B) 
General Cu(I)-catalyzed azide-alkyne cycloaddition; “click” reaction. (C) Revisted mechanistic cycle of CuAAC involving 
two copper atoms. 
The revised mechanism of CuAAC involves initial formation of a π-coordinated copper/acetylene 
species which is transformed into a copper acetylide upon addition of a second copper atom. The 
added azide is able to coordinate the dinuclear copper acetylide species in a reversible fashion. Upon 
cycloaddition and C-N bond formation with subsequent elimination of one copper atom from the 
catalytic cycle, a five-membered copper triazolide is formed delivering the 1,4-disubstituted 1,2,3-
triazole after protonation.  
Since its discovery, the CuAAC reaction has found considerable applications in organic synthesis, 
materials chemistry and for bioconjugation of larger constructs.
81
 The main advantage of this method 
is the bioorthogonal nature of these two synthetic FGs and the tolerance of aqueous and oxygen rich 
conditions when Cu(I) is formed in situ by reduction of copper(II) salts (e.g., CuSO4 · 5 H2O).
82
 Its 
major limit for in vivo applications is the need for a catalyst (which is often toxic) and the rather slow 
kinetics. For a detailed overview on click bioconjugation the reader is referred to the reviews of BEST 
and FINN.
83,84
 
17 
 
1.3.3 Inverse electron demand Diels-Alder reaction 
 
Originally designed as a “Click” substitution avoiding a toxic copper catalyst, inverse electron demand 
DIELS-ALDER (IEDDA) reactions have shown to display unusually fast reactions kinetics. First 
reported in the sixties
85
, FOX and HILDERBRAND introduced this reaction separately in 2008 as an 
efficient method for the bioconjugation of tetrazines and olefins, and has attracted high attention in the 
field of chemical biology ever since.
86,87
 FOX et al. demonstrated later an unusually fast tetrazine-
trans-cyclooctene ligation, also known as strain-promoted inverse electron demand DIELS-ALDER 
cycloaddition (SPIEDAC).
88
 Through a smart design of a highly strained alkene dieneophile, they 
report initial reaction rates of >20,000 M
-1
 s
-1
 (Scheme 1.17). 
 
Scheme 1.17: Representative SPIEDAC bioconjugation with fast reaction kinetics between a tetrazine and a trans-
cyclooctene. The intermediate undergoes a retro DIELS-ALDER reaction upon release of nitrogen and delivers the re-
aromatized product after a separate oxidation step. 
 
Recently a number of researchers have introduced genetically encoded tetrazine amino acids into 
proteins. In one case green fluorescent protein was expressed in bacteria and then rapidly conjugated 
to a strained olefin for fluorogenic labeling. In the same study they also identified a water soluble 
substrate pair for SPIEDAC which displays second order rate constants of >3,000,000 M
-1
 s
-1
, the 
fastest rate known for a bioconjugation reaction to date.
89
 These remarkable findings display again the 
potential of bioorthogonal FGs in chemical biology as useful tools for the selective and fast connection 
of large biomolecules. However IEDDA reactions have the obvious drawback of relatively complex 
starting materials which limits their use for quick assembly. Nonetheless, if high reaction rates are key 
criteria, this technique is certainly the most interesting one and further examples as well as their 
biomedical applications have been reviewed in several scientific publications.
90,91
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1.3.4 Hydrazone and Oxime condensations 
 
Probably one of the oldest class of FGs used for bioorthogonal bioconjugations are aldehydes and 
ketones.
92
 If condensed with hydrazines they deliver hydrazones whereas their reaction with O-
alkylhydroxylamines results in the formation of oximes (Scheme 1.18). Compared to the rather labile 
Schiff bases obtained from carbonyls and primary or secondary amines, these strong -effect amines 
form significantly more stable conjugates under physiological conditions.
1
 Both, hydrazones and 
oximes have found broad applications in the field of chemical biology as bioconjugation strategies. 
Oximes have been used for the fluorescent labeling of proteins
93
, synthesis of antibody-drug 
conjugates
94
, surface-functionalization of nanoparticles
95
 or as fluorescence quenchers
96
 to mention a 
few examples. In industry oximes are used as intermediates in the production of -caprolactam which 
can be polymerized for the large scale synthesis of polycaprolactam (Nylon 6), a material with high 
tensile strength and elasticity.
97
 The hydrazone formation has also been exploited for the modification 
of cell surfaces with affinity tags
98
, for immobilizing protein capture agents
99
 or for the construction of 
biocompatible and exchangeable linkers
100
. Although widely applied, the kinetics of these 
condensations are generally slow and require fine tuning of the reaction conditions.
92
 Nonetheless the 
readily available starting materials and the bioorthogonal nature of these transformations has made 
hydrazone and oxime condensations a mainstay in chemical biology.  
 
Scheme 1.18: Condensation of carbonyl compounds with -effect nucleophiles like hydrazines and O-alkylhydroxylamines 
to form hydrazones and oximes, respectively. 
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1.4 Challenges and remaining problems 
 
As described in the previous sections, many methods have been successfully developed for the 
selective modification of nucleic acids, peptides, proteins and other large biomolecules. Many of them 
have found broad applications in research laboratories, medical clinics and industrial facilities but are 
still rare and call for further development.
1
 Each of the individual methods have their limitations like 
slow reaction kinetics, water incompatibility, the use of toxic or easily oxidized reagents, complex 
starting material syntheses, additional catalysts or high substrate concentrations. Therefore research is 
a necessary task to circumvent, minimize, or even exclude those limits. An extended overview of 
various established bioorthogonal reactions for bioconjugation classified by their reaction kinetics, 
which spans almost 10 orders of magnitude, is shown in Figure 1.3. Their general limitations are 
indicated below the respective reaction schemes.
92
 
 
Figure 1.3: A collection of bioorthogonal reactions used in the field of bioconjugation and their limitations assorted by their 
rate constants.92 With personal permission of Prof. Dr. Jason W. Chin. 
 
Taken together, the existing tools for the chemical modification of biomolecules (vide supra) have 
proven fruitful, combining chemical reactivity with natural or artificial functionalities and has 
delivered methods to explore Nature’s secrets. Nonetheless these techniques require further 
development or even new innovations. 
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2 Guided catalyst to selectively target nucleic acids 
 
To achieve our research goal for the catalytic, structure-selective nucleic acid modification using 
guided organometallic-catalysts, a short peptide nucleic acid (PNA) sequence was envisioned as 
template linked to a dirhodium catalyst. PNA has been widely used as a DNA counterpart for many 
applications based on its superior properties whereas dirhodium catalysis has been commonly used for 
carbenoid-based chemistry. Within the following sections focus is laid first on the introduction of 
PNA, its applications in templated chemistry and assembly through PNA monomers followed by a 
brief overview of dirhodium catalysis in chemical biology.  
2.1 Peptide Nucleic Acids 
2.1.1 Peptide Nucleic Acids and their properties 
 
Peptide Nucleic Acids are an artificial DNA mimic which specifically recognizes complementary 
ssDNA, dsDNA as well as mRNA through WATSON-CRICK base pairing.
101
 PNA, first termed 
polyamide nucleic acid, was introduced by the Danish scientist PETER EGIL NIELSEN and co-workers 
in 1991.
102
 These unnatural nucleic acids were originally designed as potential ligands which should 
be able to recognize dsDNA in a sequence specific manner. It was first built by using computer-
assisted models to determine proper bond distances and structural similarities (e.g., hydrogen donor-
acceptor properties) to the natural archetype. In addition, the inspiration for a synthetic analog came 
from earlier work by MOSER and DERVAN in which they investigated the possibility of triplex 
formation of dsDNA with a homopyrimidine-containing ssDNA.
103
 Unlike dsDNA they found that the 
third ssDNA binds to the major groove of the pre-formed double helix through HOOGSTEEN base 
pairing thus forming a stable triple helical structure (Figure 2.1).
104,105
 
 
Figure 2.1: (A) Schematic front view of a dsDNA containing a major and minor groove. Both twist around their common 
helix axis and are opposite to each other. (B) Major groove binding modes of an isomorphous C+GC (i) and a TAT (ii) DNA 
triplex (helical top view). HOOGSTEEN base pairing of C+GC and TAT is indicated through hydrogen bonds (blue) whereas 
the WATSON-CRICK duplex is highlighted in red. 
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This observation was the driving force for the development of a concept in which an oligonucleotide 
mimic is able to bind to dsDNA through this alternative hydrogen-bonding pattern within the major 
groove. Replacement of the deoxyribose phosphodiester backbone of DNA with repeating units of N-
(2-aminoethyl)glycine (aeg) to which the nucleobases are attached via a methylenecarbonyl group 
were found to fit best to the structural requirements needed (Figure 2.2).
106
 
 
Figure 2.2: Schematic structural comparison of the deoxyribose phosphodiester backbone in DNA (i) and (ii) and the N-(2-
aminoethyl)glycine backbone of its PNA analog (iii) and (iv). Both structures contain a six bond distance between the 
nucleobase and their respective repeating unit as well as a three bond distance to their backbone (indicated through bond 
numbering 1, 3 and 6 in (i) and (iv)). 
 
While the structural differences of PNA compared to DNA were obvious (achiral, acyclic, more 
flexible, uncharged) and considered as potential drawbacks its synthetic challenge was less of a 
problem. Once a suitable monomer synthesis was established the pseudo-peptides were readily 
accessible through MERRIFIELD’S SPPS approach established in the early sixties.107 Due to its 
synthetic nature PNA was found to be chemically stable and resistant to enzymatic degradation, which 
makes it attractive for in vivo applications as a nucleic acid analog.
108
 Many studies on PNA/DNA or 
RNA systems revealed that PNA had superior helical binding properties at low to medium ionic 
strength compared to DNA that set them apart from traditional nucleic acid analogues (e.g., LNA, 
TNA or GNA).
109
 These findings are mainly attributed to the uncharged nature of PNA which allows 
short sequences to bind complementary DNA in a quick and sequence selective fashion. In particular, 
thermal denaturation studies demonstrated that antiparallel PNA/DNA and PNA/RNA duplexes were 
more stable than the corresponding dsDNA and dsRNA duplexes.
101
 In addition the stability of PNA 
was also found to be highly affected by the presence of base pair mismatches compared to DNA or 
RNA as reported by JENSEN et al.
110
 Besides the ability of PNA to form stable PNA/DNA or RNA 
duplexes
111
, NIELSEN and others revealed the existence of several dsDNA-PNA systems like triplex-
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invasion
112
, duplex-invasion
113
, double duplex-invasion
114
 or tail-clamp complexes which could be 
used for various applications.
115,116
 In summary, the ability of PNA to sequence-specifically bind to 
complementary DNA/RNA forming highly stable helical structures has attracted many scientist’s 
attentions to exploit these systems for a particular research problem in e.g., chemical biology, material 
science, diagnostics and therapeutics. Some of these examples will be discussed in more detail in the 
following sections. 
 
2.1.2 Peptide Nucleic Acids in templated chemistry 
 
In 1995 BÖHLER, NIELSEN and ORGEL reported the first example of a PNA-templated reaction. They 
demonstrated that a PNA C10 oligomer could either act itself as a template for the synthesis of a RNA-
containing oligomer using a primer for extension, or it can be assembled from its PNA G2 dimers by 
template-directed synthesis on a d(C)10 template (Scheme 2.1).
117
  
 
Scheme 2.1: PNA template-directed synthesis of a PNA-G10 oligomer by the assembly of five PNA-G2 units using an 
EDC/2-methyl imidazole coupling protocol at neutral pH. 
 
Later LIU et al. used a hairpin DNA template for the oligomerization of PNA aldehydes up to 20 base-
pairs and showed additionally high discrimination when base pair mismatches were present.
118
 A 
homothymine PNA decamer was used by JANSSEN and co-workers for the size-controlled templated 
assembly of chiral p-phenylenevinylene oligomers into functional nanostructures.
119
 As mentioned in 
section 1.2.1 (vide supra), the ROKITA group was able to use an ortho-quinone methide (QM) strategy 
for templated nucleic acid crosslinking (see Scheme 1.3 in section 1.2.1). For this purpose they used a 
QM-containing PNA template which upon hybridization to ssDNA was able to deliver the quinone 
methide alkylating agent forming a stable PNA-DNA conjugate.
30
 Until today several methods were 
published which show the potential of PNA-templated reactions for e.g., chimeric DNA/PNA 
ligation
120
, carbodiimide-mediated ligation of short PNA fragments
121
 or more recently the self-
assembly of Fab (fragment antigen binding) antibody fragments.
122
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2.1.3 Applications of Peptide Nucleic Acids in chemical biology 
 
As described before, PNA was initially created as potential sequence-specific DNA analog which can 
be used as gene silencing agent at the level of transcription or translation. Preventing gene modulation 
is essential if an organism (in particular a human being) comprises a genetic defect and a regulatory 
system for the over expression of specific proteins is needed. Due to its property to break up DNA 
duplexes PNAs are considered as potential antigene and antisense agents for blocking either 
translation or transcription (Figure 2.3).
123
 
 
Figure 2.3: (A) The central dogma of molecular biology124: cellular dsDNA is transcribed into mRNA which is translated 
into proteins. (B) Treatment of the cell with a complementary antisense oligonucleotide inhibits protein expression at the 
level of mRNA translation. (C) Treatment of the cell with a complementary antigene oligonucleotide inhibits gene 
expression. 
 
A more recent in vivo study which also relies on the principle of RNA interference through antisense 
PNA showed promising results on the basis of reactivating proteins needed for a specific function. In 
particular WOOD and LU could demonstrate that muscular dystrophy, which is a genetic disease 
caused by point mutations, can be treated by applying a PNA-based drug. The PNA is delivered into 
the cell of a mouse where it binds to the defect pre-mRNA intron22/exon23 junction containing a stop 
codon, thereby skipping exon23 during the process of splicing. The shortened dystrophin protein 
generated was found to have sufficient activity and restored its muscular functionality (Figure 2.4).
125
 
This shows the potential of RNA interfering PNAs to be used in drug discovery by fine-tuning 
conditions and the structural characteristics. 
Compared to DNA and RNA, PNAs in general have poor penetration properties that limit their 
application for in vivo studies. To enhance the cellular uptake of uncharged PNA it is typically 
conjugated to cationic cell-penetrating peptides (CPPs) like TAT or penetratin which are additionally 
equipped with oligo-arginine residues.
126
 Using phosphonate-peptide PNA conjugates were found to 
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show enhanced cellular delivery through cationic lipids and exhibit antisense activity in a luciferase 
splicing redirection system in the low nanomolar concentration range.
127
   
 
Figure 2.4: Schematic representation of the antisense PNA blocking the intron22/exon23 junction in pre-mRNA. The 
splicing process generates mRNA lacking exon23 but can be transcribed into a protein which restores muscular function. 
 
Other examples where PNA has been successfully applied so far comprise PCR clamping
128
 for the 
selective amplification of a mutated sequence for early stage genetic diagnostics (e.g., detection of a 
few cancer cells in a tissue), as fluorescent in situ hybridization probes (FISH) for the detection and 
visualization of infective agents in clinical microbiology
129
 or as an antibacterial agent against multi-
resistant microbes.
130
 
These applications demonstrate the power of chemical modification in enabling life science research. 
It is at the stage of synthesis where functionality and compatibility can be introduced and many 
methods have been developed over the past years introducing chemical modifications into PNAs to 
enhance their SAR. It is clear however that prior to the modification of a PNA, monomers have to be 
synthesized in a simple and effective way which can be scaled up easily. The following section will 
focus on the synthesis of standard PNA monomers which are generally used for assembling the PNA 
oligomers. 
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2.1.4 PNA monomers and their chemical assembly 
 
The routinely used PNA monomers for SPPS are the products of multistep synthesis and scalable up to 
several grams. Although the Fmoc/Bhoc-protected monomers are available from several suppliers 
(e.g., Link, Panagene or PolyOrg, Inc.; starting at ± 200$/g) the synthetic pathway commonly used for 
academic research is presented in this section. If affordable in terms of time, the synthesis of 
multigram quantities of PNA monomers is easily achieved through robust and easy chemistry starting 
from very cheap starting materials (e.g., adenine, thymine, cytosine; 0.05-0.18 $/g). An overview of 
the synthetic steps for the synthesis of Fmoc-B(PG)-OH PNA monomers is presented in Scheme 2.2.  
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Scheme 2.2: (A) Synthesis of the PNA backbone Fmoc-(aeg)-OH; (a) neat ethylenediamine; (b) TMS-Cl, Fmoc-OSu, NMM. 
(B) Synthesis of the final PNA monomers starting from their nucleobases T/A/C and G precursor; (c) KOH, bromoacetic 
acid; (d) Fmoc-(aeg)-OH, TSTU, DIPEA (this procedure is used for the monomers containing Boc protecting groups – the 
yields for step d in all cases are also related to Boc protected monomers); (e) KOtBu, benzyl bromoacetate followed by CDI, 
benzhydrol followed by LiOH; (f) K2CO3, benzyl bromoacetate followed by triphosgene, DIPEA, benzhydrol followed by 
NaH, 3-hydroxypropionitrile. (C) Chemical structures of the four Fmoc-PNA-B(PG)-OH monomers. 
 
The monomer synthesis is divided into two parts which are the synthesis of the PNA backbone and the 
synthesis of the four protected nucleobases containing a free carboxylic acid. The backbone is 
constructed starting from chloroacetic acid reacting with neat ethylenediamine to give the amine salt 
(i) which is then Fmoc protected at its N-terminus affording the PNA backbone scaffold (Fmoc-aeg-
OH) in 34% overall yield (Scheme 2.2, panel A).
131,132
 In the second synthetic part the carboxylic acid 
moiety at N-1 (T/C) and N-9 (A/G) is first introduced, followed by protection of the exocyclic amino 
groups of the nucleobases A/C and G-precursor with N-benzhydryloxycarbonyl (Bhoc) to give the 
acids (ii-v) ready to be coupled.
133,134
 The final PNA monomers are obtained by an amide coupling 
between the backbone and the protected nucleobases in yields ranging from 62-74% (Scheme 2.2, 
panel B and C).
135
  
The monomers, once successfully synthesized or obtained from commercial sources, can be used 
either for automated or manual SPPS on the same resins employed for the coupling of amino acids. 
Depending on the final functionality of the oligonucleotide suitable resins have to be selected which 
allow either a C-terminal amide (e.g., MBHA, rink amide resin) or carboxylic acid (e.g., Wang, 2-
Chlorotrityl resin). A general protocol for the manual assembly of short PNA sequences is outlined in 
Scheme 2.3 and follows a published procedure by GOODWIN et al.
136
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Scheme 2.3: General synthetic cycle for the SPPS of short PNA sequences containing a C-terminal amide. 
To allow a high degree of FG accessibility the polystyrene-based solid phase needs to be swollen in a 
suitable solvent for one to several hours.
137,138
 This is followed by a repetitive piperidine deprotection 
step if a Fmoc protected amine-based resin is used. After each step a washing cycle is included which 
uses CH2Cl2/NMP (1:1, 1 min, 3 x) to remove excess reagents. A pre-activated reaction cocktail 
containing 4 eq. of each Fmoc-PNA(PG)-OH, HATU, DIPEA and 2,4,6-collidine is then reacted with 
the free amine for 20 min at room temperature followed by a washing cycle. From this stage on the 
deprotection/coupling cycles are repeated until the desired PNA sequence is assembled and is ready 
for a final Fmoc removal. Treating the resin with high TFA concentrations and a thiol-based cation 
scavenger removes all Bhoc protecting groups and liberates the crude PNA which is then precipitated 
from cold ether and purified preparatively employing acidic RP-HPLC. After lyophilizing the pure 
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PNA oligonucleotide aqueous stock solutions are prepared and quantified by UV spectrophotometry at 
260 nm using molar extinction coefficients 260 for the bases reported in the literature or supplied from 
companies.
139,140
  
Although the above described conditions are well-established, they require harsh conditions during the 
oligomer synthesis and possible side reactions can lead to undesired products hampering the 
purification. An alternative to the Fmoc/Bhoc strategy was reported in 2007 by co-workers of 
Panagene Inc. which uses self-activating PNA monomers and the Bts (benzothiazole-2-sulfonyl) 
strategy (Scheme 2.4).
141
 The process was found to deliver excellent purities of PNA products without 
the need for additional coupling reagents and a straightforward monomer synthesis with high yields. 
 
Scheme 2.4: Synthesis of self-activating PNA monomers using the Bts strategy and their assembly by SPPS through 
repetitive coupling, capping and deprotection cycles. (a) NEt3; (b) DCC, HOBt, nucleobase acetic acid followed by LiOH; 
(c) EDC. 
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2.2 Dirhodium catalysis and its applications in chemical biology 
 
Many of the reactions used to introduce new functionality into biomolecules are slow and unspecific. 
To improve these potential drawbacks, catalysts are commonly implied which can overcome these 
limits. Within this section focus is laid on the use of dirhodium catalysis (acronym: Rh(II)) for the 
transformation of specific FGs and the formation of new bonds connecting the reaction partners. 
In the early 1970s, TEYSSIÉ et al. could demonstrate the first documented example of a dirhodium-
catalyzed carbenoid O-H insertion reaction of ethyldiazoacetate using substoichiometric amounts of 
dirhodium tetracarboxylate [Rh2(OAc)4] achieving ~600 turnovers in 4 h (Figure 2.5, panel A).
142
 This 
finding was the basic principle for transition-metal catalyzed carbene chemistry using Rh(II) species. 
In general the two axial d
7
 Rh(II) centers are bridged by four equatorial ligands to give a stable, 
paddlewheel-like 18e
-
 complex (Figure 2.5, panel B). The two vacant axial positions are used for the 
formation of electrophilic dirhodium(II)-stabilized carbenoids with e.g., -diazocarbonyl compounds 
which readily insert into polar X-H bonds (X = O, N, C, S). 
 
Figure 2.5: (A) Rh2(OAc)4 catalyzed O-H insertion reaction of ethyldiazoacetate with various alcohols. (B) Three-
dimensional “paddlewheel”  structure of Rh2(OAc)4 containing four equatorial acetate ligands bridging the two central Rh 
atoms while two vacant axial positions are available for catalysis. 
 
A mechanistic model proposed by YATES for the copper-catalyzed decomposition of diazoketones is 
generally accepted for the formation of dirhodium carbenoids (Scheme 2.5, panel A).
143
 It is initiated 
by the complexation of the negatively-polarized carbon atom of the -diazocarbonyl compound to one 
of the axial positions forming a Rh-C -bond with negative charge transfer to the Rh atom. 
Subsequent release of N2 forms the final electrophilic dirhodium(II) carbenoid species. Several 
decades later, MOREHEAD was able to show that the addition step is in a pre-equilibrium whereas the 
carbenoid forming step is rate-determining.
144
 A general pathway for X-H insertions using metal-
carbenoids and its concerted mechanistic steps using a Rh(II) catalyst and -diazocarbonyl compounds 
is presented in Scheme 2.5, panel B and C.
145
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Scheme 2.5: (A) Generally accepted mechanism of Rh(II) carbenoid formation illustrated with an example: Rh2(OAc)4 reacts 
reversibly with an -diazocarbonyl compound to give the covalent Rh-C species (i) which after irreversible loss of one 
equivalent N2 results in the catalytically active Rh2(OAc)4 carbenoid species (ii). (B) General schematic representation of X-
H insertion reactions involving transition-metal catalysts equipped with ligands. (C) Concerted mechanistic pathway of an X-
H insertion reaction using Rh2(L)4 as catalyst. 
 
Rhodium(II) carbenoid chemistry can be exploited in a variety of bond-forming methods to generate 
molecular diversity, expand substrate scopes and simplify or allow new key transformations in natural 
product synthesis (e.g., total synthesis of (-)-serotobenine).
146
 Until today many useful reactions were 
published on the basis of rhodium(II) carbenoids from -diazocarbonyl substrates and comprise S-H 
insertions
147
, N-H insertions used for example in Merck’s synthesis of (+)-Thienamycin148, O- and N-
ylide formations with appropriate carbonyls and imines
149
, [3+2]
150
 and [4+3]
151
 cyclizations of 
alkenes and dienes, cyclopropanation of alkenes
152
 or alkynes
153
 and C-H insertions on a variety of 
substrates (e.g., intramolecular cyclization)
154
. A collective overview of Rh(II) carbenoid chemistries 
is presented in Scheme 2.6.  
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Scheme 2.6: Overview of Rh(II) carbenoid reactions from -diazo carbonyl precursors with different substrates delivering a 
variety of products. R1 and R2 are general placeholders and unrelated to the products illustrated. 
 
Almost a decade ago, FRANCIS et al. reported the first example of using Rh(II) carbenoid chemistry in 
aqueous solution for potential applications in chemical biology. They demonstrated a method for the 
selective modification of tryptophan residues using -diazocarbonyl compounds on various protein 
substrates (e.g., myoglobin and subtilisin) which was expanded a few years later to include lysozyme, 
melittin and human FKBP (Scheme 2.7).
155,156
  
 
Scheme 2.7: Selective tryptophan modification on proteins in aqueous media using Rh(II) carbenoid chemistry. 
Modifications were found to occur at the indole nitrogen and C-2 position in a 1:1.4 ratio in 51% overall yield using a 
catalyst loading as low as 0.1 mol%.155 
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These findings established the possibility of using biocompatible and chemoselective metallocarbene-
based reactions on large biomolecules. In 2010, BALL and POPP extended the target of amino acid side 
chains to other aromatic residues (e.g., phenylalanine and tyrosine) using dirhodium metallopeptide 
catalysis (Scheme 2.8).
157
 A year later they expanded the scope and utility of the method while several 
buffer systems at physiological pH were tested along with a biotin-diazo conjugate allowing affinity 
tagging of target proteins.
158
 
 
Scheme 2.8: Dirhodium metallopeptide catalysis illustrated on a tryptophan-containing peptide. The reaction is enabled by 
an intermediate coiled-coil interaction of the peptide and carbenoid metallopeptide strands only when a perfect facial match 
(i) is present promoted by electrostatic attraction between opposing glutamate/lysine residues. The rate of modification drops 
when electrostatic repulsions (both lys-lys) of opposing strands are introduced (ii) or if a facial mis-matched pair is present 
(iii). 
 
In 2012, BALL demonstrated a chemoselective cysteine modification in CALP protein using the same 
Rh(II) carbenoid chemistry based on a biotin-diazo compound but without using a protein template 
(Scheme 2.9).
159
 They confirmed the site of protein modification by trypsin digest followed by 
MS/MS fragmentation studies and verified these results separately by modifying a series of peptides 
derived from that particular CALP sequence. The covalent linkage was additionally found to be stable 
in human serum over several hours thus promising potential for applications under biological 
conditions. 
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Scheme 2.9: Chemoselective cysteine modification using Rh(II) carbenoid chemistry using a biotin-diazo compound at near 
neutral pH in aqueous media. Tryptophan or other amino acid side chains were found to be untouched under these reaction 
conditions. 
 
For a detailed summary on dirhodium metallopeptides described by BALL, the reader is referred to the 
publication entitled “Designing Enzyme-like Catalysts: A Rhodium(II) Metallopeptide Case Study”.160 
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2.3 Results and discussion 
 
Note: For clarity many molecular structures are represented only schematically; their entire skeletal 
formulas are illustrated in the experimental section 4.2.1.3. 
2.3.1 Nucleic acid alkylation using template PNA-dirhodium conjugates 
 
The aim of the work discussed in this chapter was to develop a short PNA-based self-assembling 
catalyst for the direct, sequence-specific alkylation of ssDNA using Rh(II)-stabilized carbenoids in 
aqueous media under neutral conditions. The catalytic system was envisioned to contain a templating 
PNA sequence which is covalently linked to a Rh(II) catalyst through a rapid bioconjugation reaction. 
Once the organometallic catalyst is assembled, substrate selectivity is achieved through dynamic 
WATSON-CRICK base-pairing (annealing) with the complementary ssDNA target. Reaction with a -
diazocarbonyl compound forms a Rh(II)-stabilized PNA carbenoid in situ which is able to alkylate the 
nucleobases of DNA by subsequent N-H insertion as previously shown by TISHINOV et al.
36
 Once 
modification is achieved and after denaturation of the hybrid duplex, the Rh(II)-containing PNA is 
envisioned to re-enter the catalytic cycle achieving high turnovers (Scheme 2.10).  
 
Scheme 2.10: Proposed catalytic cycle for nucleic acid modification using a pre-formed templating PNA catalyst. Step A: 
PNA catalyst and complementary ssDNA anneal through WATSON-CRICK base-pairing to form a dymanic DNA/PNA hybrid. 
Step B: Addition of a -diazocarbonyl compound generates a reactive DNA/PNA carbenoid species which is able to undergo 
an insertion reaction on the DNA complement. Step C: Denaturation of the product liberating the active and unmodified 
PNA catalyst ready for the next cycle. 
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2.3.1.1 Design of the PNA catalyst template – a retrosynthetic analysis 
 
For a successful design of the envisioned PNA sequence it was essential to consider some general 
rules reported in the literature or directly supplied from companies and their webpages.
161,162
 It is 
known that longer PNA oligomers tend to aggregate in solution, are difficult to purify and characterize 
and participate in non-specific binding of other nucleic acids.
163,164
 It was therefore essential to answer 
two major questions which come along with the proposed catalytic system shown in section 2.3.1: 
(1) what is a reasonable PNA length to allow a dynamic hybridization to ssDNA? 
(2) which PNA sequence should be chosen? 
A detailed literature search could quickly give information on the required PNA length allowing a 
dynamic system. In their early studies on PNA, NIELSEN et al. determined the thermal stability of 
PNA/DNA hybrid duplexes of varying lengths.
106
 An oligothymine PNA hexamer was found to have a 
melting temperature (Tm) of 31°C whereas its octamer is significantly more stable (Tm = 52°C). For 
comparison, an oligothymine DNA hexamer was shown to have a Tm below 10°C.
165
 Therefore it 
seemed reasonable to choose a hexameric sequence based on these findings since a Tm close to room 
temperature would be ideal for the required abilities of the final system. 
Next, the sequence of the PNA template had to be selected which was done according to a 
complementary commercial ssDNA d(GCG TAT CCG GCA CGT CGA) (BioTeZ, Berlin-Buch) in 
the strongly preferred antiparallel orientation (amino terminus of the PNA facing the 3’-end of the 
ssDNA) (Figure 2.6).  
Thus the desired PNA hexamer contained the following base sequence: pna(CGC ATA)  
 
Figure 2.6: Antiparallel PNA sequence pna(CGC ATA) designed on the basis of a ssDNA d(GCG TAT CCG GCA CGA). 
 
Inspired by previous work of BALL et al., the covalent linkage of a Rh(II) species was envisioned to be 
achieved through simple carboxylate ligand exchange in water using an appropriate dicarboxylate 
linker installed at the PNA N-terminus and cis-Rh2(OAc)2(TFA)2. This strategy was imagined to be 
highly efficient since peptide couplings on PNA are achieved with ease and final dirhoidum ligations 
have been shown to be readily achieved in good yields with short reaction times.
166
 A retrosynthetic 
analysis of the hexameric PNA catalyst 1.1 is outlined in Figure 2.7.  
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Figure 2.7: Retrosynthetic analysis of hexameric PNA catalyst 1.1. The Bhoc-protected PNA monomers are assembled on an 
amino functionalized solid support using SPPS conditions. Synthetic acid 1.2 is attached to the PNA N-terminus followed by 
dicarboxylate ligand exchange with cis-Rh2(OAc)2(TFA)2 (1.3). 
 
Note: By convention, PNAs are depicted like peptides starting with the N-terminus (left) and ending 
with the C-terminus (right).
109
 Throughout this thesis the synthesized PNA sequences are noted in the 
C to N-terminal form and displayed in a rectangular box for graphical simplicity. 
 
2.3.2 Synthesis of 1st generation PNA and its conjugation to dirhodium 
 
The synthesis of the desired PNA sequence 1.4 was envisioned employing manual SPPS and 
Fmoc/
t
Bu strategy on a 4-methylbenzhydrylamine resin (MBHA). A simple procedure was followed 
using the coupling protocol described by GOODWIN et al. for the assembly of PNA monomers or for 
introduction of amino acids and other carboxylic acid derivatives (Scheme 2.11).
136
 In a first synthetic 
attempt the desired PNA 1.4 couldn’t be identified by mass spectrometry (ESI-MS and MALDI-TOF-
MS) after semi-preparative HPLC purification. It was not clear at that time why the desired product 
was not obtained but several factors could have handicapped the synthesis: high initial resin loadings 
inhibit PNA couplings
167
, false positive on bead tests after deprotection/coupling
168
 or partial 
decomposition of the Fmoc deblock solution containing 20% piperidine/DMF.
169
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Scheme 2.11: (A) Synthetic sequence for the preparation of pna(CGC ATA)-diacid  1.4: (a) Fmoc-PNA-C(Bhoc)-OH, 
HATU, DIPEA; (b) repetitive cycles of (i) 20% piperidine/DMF, (ii) Fmoc-PNA-B(PG)-OH, HATU, DIPEA - all PNA 
nucleobases except for T contained Bhoc protection groups - order of PNA nucleobases introduced: GCATA; (c) (i) 20% 
piperidine/DMF, (ii) Fmoc-Glu(OtBu)-OH, HCTU, 2,6-lutidine, DIPEA; (d) (i) 20% piperidine/DMF, (ii) 1.6, HCTU, 2,6-
lutidine, DIPEA; (e) TFA/m-cresol/thioanisole/TFMSA (6:1:1:2). (B) Synthesis of 5-(tert-butoxy)-5-oxopentanoic acid (1.6): 
(a) tBuOH, N-hydroxysuccinimide, DMAP, NEt3. 
 
A second attempt using rink amide resin (Novbiochem) containing a lower initial loading proved to be 
more suitable. A test cleavage of hexameric PNA 1.7 and MALDI-TOF-MS analysis revealed the 
correct mass for the pna(CGC ATA) intermediate. After sequential coupling of Fmoc-Glu(O
t
Bu)-OH 
and carboxylic acid 1.6 the resulting PNA analysis indicated a mass corresponding to the N-acetyl 
derivative 1.8 which lacked the N-terminal carboxylate (Scheme 2.12). Although both “peptide” 
couplings were performed identical, it was obvious from this result that the second one failed 
completely for unknown reasons and the final capping with Ac2O prevented further on-resin 
manipulation. While the PNA assembly seemed to be straightforward, the sequential coupling of the 
two carboxylic acids caused unexpected problems. It was assumed that a more facile introduction of 
the acid building block 1.2, which was obtained in a two-step synthesis from 5-(tert-butoxy)-5-
oxopentanoic acid (1.6), could circumvent this issue. We were pleased to find that this strategy turned 
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out to be successful delivering the desired PNA diacid 1.4 which was then subjected to several ligand 
exchange reactions with synthetic cis-Rh2(OAc)2(TFA)2 (1.3) in pure water at millimolar 
concentrations. The use of this electron deficient dirhodium catalyst should facilitate double TFA 
ligand substitution at ambient to slightly elevated temperatures in a few hours as reported by BALL et 
al.
157,166
 Unfortunately none of the ligand exchange attempts were successful and even after days, 
increased temperature (40°C) and various concentrations unreacted starting materials were detected by 
HPLC/ESI-MS. It is assumed that higher temperatures could have been beneficial in terms of ligand 
exchange but inappropriate with respect to the low thermal stability of short PNAs. In retrospect fine 
tuning of the pH (towards alkaline pH) could have helped too, although both carboxylic acids residues 
have pKa values below 5 and should be deprotonated under the conditions employed.  
  
Scheme 2.12: (A) Synthetic pathways for the preparation of hexameric PNA catalyst 1.1: (a) (i) Fmoc-Glu(OtBu)-OH, 
HCTU, 2,6-lutidine, DIPEA; (ii) 1.6, HCTU, 2,6-lutidine, DIPEA; (iii) 5% Ac2O, 6% 2,4,6-collidine, NMP; (iv) 
TFA/TIS/H2O (95:2.5:2.5). (b) (i) 1.2, HATU, 2,4,6-collidine, DIPEA; (ii) 5% Ac2O, 6% 2,4,6-collidine, NMP; (iii) 
TFA/TIS/H2O (95:2.5:2.5); (c) cis-Rh2(OAc)2(TFA)2 (1.3). (B) Synthetic pathway for the preparation of acid building block 
1.2: (a) (i) 4-Nitrophenol, DCC; (ii) H2N-Glu(O
tBu)-OH, NEt3. 
 
These results clearly emphasized the need for a different conjugation method since the covalent 
attachment to a Rh(II) pre-catalyst by simple ligand exchange was found to be the critical step. At this 
point re-evaluation of the linkage was the next logical step since the PNA synthesis was 
unproblematic. 
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2.3.3 Retrosynthesis of 2nd generation PNA catalyst 
 
The strategic change for placing the Rh(II) species to the PNA N-terminus directed us towards the 
principle of bioconjugation. The major criteria which had to be fulfilled was the facile formation of a 
stable linkage which can be performed in water without generating interfering by-products. It was 
clear that both components, PNA and Rh(II) pre-catalyst, had to be modified with bioorthogonal FGs 
that are able to participate in a final bioconjugation reaction to give the desired PNA catalyst. Ideally 
the chemical modifications should be introduced with little synthetic effort to allow a prompt proof of 
the envisioned concept. We found that an oxime condensation between a ketone/aldehyde and an O-
alkylhydroxylamine seemed to be most suitable for the following reasons: 1) high hydrolytic stability 
of the oxime linkage in aqueous media due to the oxygen -effect170 2) oxime formation is reported 
for PNA-peptide conjugates
171
 and peptide dendrimers
172
 3) oxime condensation generates solely 
water as by-product.  
A schematic retrosynthetic analysis of the 2
nd
 generation PNA catalyst is shown in Figure 2.8. It is 
assembled through a peptide coupling of the PNA N-terminus with commercial 2-(Boc-aminooxy)-
acetic acid (Boc-AOAc-OH, 1.9) which is then able to form an oxime linkage with a respective 
dirhodium carbonyl compound after N-Boc deprotection. 
 
Figure 2.8: Schematic retrosynthesis of oxime-linked PNA catalyst via Boc-AOAc-OH 1.9. 
 
Since the PNA assembly and final peptide coupling were considered unproblematic, focus was laid on 
the design and synthesis of the desired functionalized dirhodium species. In particular we had to come 
up with a creative and simple synthetic route for the generation of functionalized and modular ligands 
which can be installed into the transition metal framework. 
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2.3.4 Synthesis of modular dicarboxylate ligands and dirhodium catalysts 
 
The results discussed within this section are the cumulative work of the author Pascal Schmidt, Daniel 
Bachmann, Stefanie Geigle, Wolf-Dietrich Woggon, Antoinette Chougnet, Dennis Gillingham and 
have been published in 2015.
173
 The material is used with a personal permission of the publisher John 
Wiley and Sons and the corresponding license details can be found in the appendix (section 4.3.2). 
The new Rh(II) pre-catalyst design was inspired by seminal work from DU BOIS and BONAR-
LAW.
174,175
 These groups described the synthesis of dicarboxylate ligands which function as a 
dirhodium tether thus increasing the stability of the respective mono- or bis-chelates (Scheme 2.13). In 
addition these complexes were found to perform outstanding in nitrene and C-H insertions compared 
to their untethered analogs. 
 
Scheme 2.13: The DU BOIS and BONAR-LAW dicarboxylate ligands and a corresponding tethered dirhodium catalyst: 
Rh2(esp)2 when X = CH2. The acronym esp stands for ESPINO, a PhD student of DU BOIS which accomplished the first 
synthesis of the esp ligand and corresponding dirhodium complex.  
 
We also became interested in such tethered bis-dicarboxylate dirhodium complexes in the context of 
our recent studies on metal-carbenoid based nucleic acid alkylation.
36
 To further develop this 
technology and in order to meet the requirements for the envisioned PNA catalyst (vide supra) we 
needed a set of dirhodium complexes with stable and modular ligands that still performed well in 
synthetic processes. Most rhodium or metal complexes are highly insoluble in water and not readily 
amenable to modification.
176-180
 We settled on the tethered bis-carboxylate structure because we 
thought its increased stability
181
, as well as its potential to intercalate DNA
182
, could deliver 
performance improvements in comparison with simple dirhodium carboxylates (e.g., cis-
Rh2(OAc)2(TFA)2 or Rh2(OAc)4). The ligand introduced by DU BOIS and co-workers
174
 was chosen as 
a starting scaffold but two major problems prompted us to change tack: first, creating a library of 
ligands proved synthetically cumbersome and second, controlling mono- versus double-substitution in 
the rhodium carboxylates was unpredictable. Inspired by previous work from BONAR-LAW in creating 
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dirhodium-based metal-organic architectures
175,183-185
, we examined dicarboxylate ligands derived 
from 1,3-benzenediols. This construct maintains the essential structural features of the ESPINO ligand, 
but has the advantage of modularity since numerous 1,3-benzenediol derivatives are commercially 
available. Moreover, since BONAR-LAW used these dicarboxylates to create well-defined 
supramolecular objects the coordination of each ligand needed to be precisely controlled, providing 
valuable information for our own studies. Shown in Scheme 2.14 is the full collection of dicarboxylate 
ligands 1.12a-f we have synthesized thus far starting from commercial C5-substituted 1,3-
benzenediols 1.10a-f. Diesters 1.11a-f were obtained by double O-alkylation with ethyl-2-
bromoisobutyrate and a mixture of K2CO3 and Cs2CO3 in yields ranging from 48-94%. Final 
hydrolysis was accomplished with LiOH to afford the desired dicarboxylate ligands 1.12a-f in 
excellent yields, bearing a variety of functional groups poised for further modification such as amide 
bond formation (triacid 1.12b), Pd-catalyzed cross coupling (bromide 1.12e), click chemistry (alkyne 
1.12f) or condensation reactions (ketone 1.12c or aldehyde 1.12d).
173
 
 
Scheme 2.14: Synthetic pathway for the preparation of various modular dicarboxylate ligands 1.12a-f: (a) ethyl-2-
bromoisobutyrate, K2CO3, Cs2CO3; (b) LiOH · H2O. 
 
Some of these ligands were subjected to ligand exchange reactions with either cis-Rh2(OAc)2(TFA)2 
or Rh2(OAc)4. The syntheses of the various homo- and heteroleptic dirhodium complexes we have 
prepared are shown in Scheme 2.15. Using the conditions developed by BONAR-LAW the 
monobiscarboxylate complex 1.13 is obtained in 60% yield after three hours in N,N-dimethylaniline at 
140°C. However, for ligands with electron withdrawing groups at C5 (12b, d and e) milder conditions 
were necessary: cis-Rh2(OAc)2(TFA)2 in 1,2-dichloroethane at 60-70°C with small amounts of EtOAc 
as co-solvent led to acceptable yields (31% for 1.14, 27% for 1.15, and 35% for 1.16). Unfortunately, 
attempts to perform a second substitution to access the heteroleptic complexes using BONAR-LAW’S 
conditions led to low yields and mixtures of products. We therefore turned to TABER’S original 
procedure involving a portion-wise addition of the ligand.
186
 Through the combination of these 
protocols we have been able to synthesize new dirhodium complexes containing a variety of functional 
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groups (Scheme 2.15). In general the isolated yields were rather moderate to low which is a typical 
feature of dirhodium complex syntheses. However in many cases unreacted starting material could be 
recovered chromatographically.  
 
Scheme 2.15: Synthetic pathway for the preparation of various homo- 1.13-1.16 and heteroleptic dirhodium complexes 1.17-
1.19. 
 
2.3.5 Dirhodium catalyzed nitrene-, C-H and O-H insertion 
 
The use of dirhodium catalysts for the bioconjugation to PNA is discussed in section 2.3.6. The 
present section should give the reader a quick overview of the catalytic potential of newly synthesized 
dirhodium catalysts we have developed. For a detailed discussion of the following summarized results 
the reader is referred to our publication.
173
 
  
To probe the impact of the ligand on catalysis dirhodium catalysts 1.17, 1.18, and 1.19 were tested in 
several benchmarking nitrene- and C-H insertion reactions using organic solvents or pure water 
(Scheme 2.16). A typical intramolecular nitrene insertion reaction of sulfamate ester 1.20 with 2 
mol% of catalyst 1.17 was found to be as effective as the DU BOIS system Rh2(esp)2 delivering 
oxathiazinane 1.21 in excellent isolated yield.
174
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Scheme 2.16: Benchmarking nitrene insertion of sulfamate ester 1.20. 
 
In a second set of benchmarking experiments catalysts 1.17 and 1.19 were tested in C-H insertion 
reactions to form - 1.23 or -lactams 1.24 and performed superior compared to Rh2(OAc)4 delivering 
the products in 10 min with a 9:1 ratio in favor of the -lactam 1.23 (Scheme 2.17).  
 
Scheme 2.17: Benchmarking C-H insertion for the synthesis of - 1.23 and -lactams 1.24. 
 
 
The heteroleptic dirhodium complex 1.18 bearing a ketone functionalized ligand (1.12c) and a 
carboxylate functionalized ligand (1.12b) was found to be completely water soluble above the pKa 
(~4.2) of the carboxylate. As a proof of concept for the potential of 1.18 in aqueous catalysis we 
carried out two different types of reactions using pure water as the reaction media. The first was an 
intramolecular C-H insertion reaction of -diazoacetamide 1.25 which required lower loading (0.5 vs. 
1-2 mol%) and less time (10 min vs. 0.5-24 h) than the previous best catalyst (Scheme 2.18).
187
 
 
Scheme 2.18: Intramolecular C-H insertion in water for the formation of diastereomeric -lactams 1.26 and 1.27. 
 
Next we tested a simple O-H insertion of -diazoester 1.28 with water and compared the catalytic 
activity of 1.18 with Rh2(OAc)4 (Figure 2.8). Catalyst 1.18 reaches the first half-life approximately 
twofold faster than Rh2(OAc)4 and converts 90% of the starting material in 100 min whereas the latter 
required 160 min. 
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Figure 2.8: Catalytic comparison of dirhodium catalyst 1.18 with Rh2(OAc)4 in an O-H insertion reaction performed in 
water. 
 
2.3.6 Synthesis of 2nd generation PNA and its bioconjugation to dirhodium 
 
The envisioned hydroxylamine terminated PNA 1.30 was manually synthesized on rink amide resin 
according to the previously used SPPS protocol for PNA 1.4. The final peptide coupling was 
performed for 90 min with five equivalents of Boc-AOAc-OH 1.9 (Bachem) to ensure full conversion 
(Scheme 2.19). To achieve high yields, the respective PNA-hydroxylamine 1.30 cleavage was 
performed for a prolonged time of 2 h. Subsequent HPLC purification and analysis by mass 
spectrometry confirmed the PNA-hydroxylamine 1.30. 
 
Scheme 2.19: Shortened synthetic sequence for the preparation of pna(CGC ATA)-hydroxylamine 1.30: (a) (i) Fmoc-PNA-
B(Bhoc)-OH, HATU, DIPEA; (ii) repetitive cycles of 20% piperidine/DMF then Fmoc-PNA-B(Bhoc)-OH, HATU, DIPEA 
with a final Fmoc cleavage; (b) (i) Boc-AOAc-OH 1.9, HATU, 2,4,6-collidine, DIPEA; (ii) TFA/TIS/H2O (95:2.5:2.5). 
After a test oxime formation with the ketone functionalized dicarboxylate ligand 1.12c resulted in full 
conversion of PNA-hydroxylamine 1.30, as concluded by MALDI-TOF-MS, we tested the aqueous 
bioconjugation with the ketone functionalized dirhodium catalyst 1.19. The reaction setup turned out 
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to be challenging since the hydrophobic dirhodium catalyst 1.19 was found to be only partially soluble 
even when adding high amounts of organic co-solvents (e.g., CH2Cl2 and MeOH) while the PNA-
hydroxylamine showed decent water solubility. Nonetheless the system was tested on its ability for 
bioconjugation and the dirhodium catalyst 1.19 was mixed with the PNA in an approximate 3:1 ratio 
(Scheme 2.20). Upon mixing a color change from light blue to pink was noticed in the heterogeneous 
reaction which was analyzed over a period of 22 h by MALDI-TOF-MS and LC/MS. While the 
desired oxime mass of 1.31 could be identified, the PNA conversion didn’t exceed ~20%. At that point 
we decided to reconsider this “heterogenic” system which seemed far from perfect for the envisioned 
catalysis in water. Obviously the highly hydrophobic nature of catalyst 1.19 had to be replaced with a 
more soluble variant. 
 
Scheme 2.20: Synthetic pathway for the oxime condensation of PNA-hydroxylamine 1.30 and dirhodium catalyst 1.19: (a) 
H2O/MeOH/CH2Cl2 (3:1:0.5). 
 
The next logical step was to test the keto/acid functionalized heteroleptic dirhodium catalyst 1.18 
which already performed outstanding under aqueous conditions (vide supra) but was not accessible at 
the time we tested our first bioconjugation to PNA. Once the catalyst 1.18 could be dissolved in a 
mixture of water/500 mM MES buffer containing a marginal volume of concentrated 1M NaOH it was 
also tested in an oxime condensation with PNA-hydroxylamine 1.30. To our disappointment we 
noticed the immediate precipitation of a pink solid directly after mixing the components which was 
identified as the PNA-Rh2 conjugate by ESI-MS but again rendered the system inappropriate for our 
needs. After having established a perfectly water soluble dirhodium catalyst and a moderately soluble 
PNA-hydroxylamine we had to fix the solubility of its conjugate in an aqueous environment. It was 
therefore clear to us that the solubilizing property of the PNA had to be improved which in turn should 
have a positive impact on the solubility of the oxime. We got inspired by seminal work of the LY 
research group which reported that (R)-diethylene glycol (“miniPEG”, R-MP) containing -PNAs 
showed not only superior hybridization properties, but also were highly water soluble (Figure 2.9).
188
 
They demonstrated that the incorporation of a single 
R-MP-PNA monomer into a decameric sequence 
transforms its randomly folded structure into a highly preorganized right-handed-helix. In addition a 
hexadecameric PNA sequence containing one 
R-MP-PNA unit enhanced the water solubility by a factor 
of two as determined by saturation experiments.  
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Figure 2.9: (i) Schematic representation of the -,- and -positions on the PNA backbone available for chemical 
modifications. (ii) -backbone modification with a R-MP unit as described by LY et al.188 
 
Encouraged by these findings we decided to synthesize such a monomer which we planned to 
introduce later into the PNA sequence at the C-terminus. For a reason of synthetic simplicity we 
envisioned the thymine monomer (
R-MPT-PNA) 1.38 which requires no additional protecting groups 
thus shortens the synthesis to six linear steps (Scheme 2.21, panel A). We adapted the route of LY et 
al. to our needs starting from commercial Boc-Ser-OH (1.32) which was O-alkylated with the 
miniPeg-containing 1-Bromo-2-(2-methoxyethoxy)ethane to give methylether 1.33. Formation of a 
mixed anhydride with subsequent NaBH4 reduction afforded the primary alcohol 1.34 in good yield. It 
was then reacted with separately synthesized nosyl sulfonamide derivative 1.40 in a MITSUNOBU 
reaction to give the N-protected PNA backbone species 1.35. Quantitative deprotection with 
thiophenol was followed by PyBrop-mediated coupling with separately synthesized thymine-1-acetic 
acid (1.42) to yield amide 1.37. After final alkaline ester hydrolysis the desired 
R-MPT-PNA monomer 
1.38 was obtained in an overall yield of 7.3%.  
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Scheme 2.21: Synthetic pathway for the preparation of R-MPT-PNA 1.38 and reagents needed throughout this route: (A) 
Linear six step sequence for the synthesis of R-MPT-PNA 1.38; (a) NaH, 1-Bromo-2-(2-methoxyethoxy)ethane; (b) isobutyl 
chloroformate, NaBH4; (c) DEAD, PPh3, 1.40; (d) thiophenol, KOH (aq.); (e) PyBrop, DIPEA, 1.42; (f) 2M Cs2CO3. (B) 
Synthesis of nosyl sulfonamide derivative 1.40; (a) H-Gly-OMe · HCl, NEt3. (C) Synthesis of thymine-1-acetic acid (1.42); 
(a) bromoacetic acid, KOH (aq.). 
As mentioned before this monomer was envisioned to be introduced as the first unit into the new PNA 
sequence pna(T CGC ATA) to minimize possible interference with the complementary ssDNA strand 
within our alkylation system (vide supra). While the LY group used exclusively Boc protected PNA 
monomers for their oligomer synthesis we wanted to combine this monomer into our Fmoc/Bhoc 
strategy for SPPS which seemed challenging using an acid labile solid support. An extensive literature 
search directed our attention to a tailor-made protocol by ZHANG et al. for the selective removal of N-
Boc protecting groups on acid labile resins.
189
 In their studies they used a mixture of TMSOTf/2,6-
lutidine in CH2Cl2 to remove the N-terminal protecting group of peptides on rink amide resin with 
relative yields up to 93%. This strategy seemed to fit best to our requirement and turned out to be 
applicable to PNA synthesis. The synthetic multistep sequence of T-containing PNA-hydroxylamine 
1.45 is outlined in Scheme 2.22. First, rink amide resin was loaded with 
R-MPT-PNA 1.38 followed by 
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a mild N-Boc deprotection with TMSOTf/2,6-lutidine in CH2Cl2 to afford the solid phase bound 
R-
MPT-PNA monomer 1.44 which was confirmed by UPLC-MS analysis after a test cleavage. The final 
PNA sequence 1.45 was assembled with ease using the standard Fmoc/Bhoc SPPS strategy including a 
final peptide coupling with Boc-AOAc-OH 1.9 followed by TFA cleavage. 
 
Scheme 2.22: Synthetic pathway for the preparation of T-containing PNA-hydroxylamine 1.45: (a) (i) R-MPT-PNA 1.38, 
HATU, DIPEA, 2,4,6-collidine; (ii) 5% Ac2O, 6% 2,4,6-collidine, NMP; (b) 1M TMSOTf, 1.5M 2,6-lutidine; (c) repetitive 
cycles of (i) Fmoc-PNA-B(Bhoc)-OH or Boc-AOAc-OH 1.9, HATU, DIPEA; (ii) 20% piperidine/DMF and final cleavage 
(iii) TFA/TIS/H2O (95:2.5:2.5). 
 
The HPLC purified T-containing PNA-hydroxylamine 1.45 was found to be freely soluble in pure 
water at millimolar concentrations and ready for its oxime bioconjugation to the water soluble 
dirhodium catalyst 1.18 containing a ketone. A preliminary test reaction indicated that oxime 
formation was rather slow and PNA conversions at 15 min and 18 h were similar without exceeding 
~30%. In a more preparative attempt both components were mixed in water, with the PNA being in a 
slight excess (1.5:1), whereupon a heterogeneous pink solution formed immediately (Scheme 2.23). 
After centrifugation of the reaction mixture a pink solid separated from the clear supernatant. UPLC-
MS analysis of the solution confirmed exclusively unreacted PNA while the pink solid (dissolved in 
DMSO) contained a mixture of unreacted PNA and dirhodium catalyst along with the desired PNA-
Rh2 oxime 1.46 which could be isolated after semipreparative HPLC. A solubility test with various 
organic solvents indicated that the oxime conjugate was most soluble in DMSO which is known to be 
a potential axial ligand in dirhodium complexes.
190-193
 Although these coordinating ligands were found 
to form a much weaker bond to the reactive rhodium atom than the equatorial ones, they may partially 
influence the reactivity of the carbenoid catalyst.
194,195
 Nonetheless, after tedious accomplishment of 
the PNA-dirhodium oxime template 1.46 its catalytic ability was tested in an initial alkylation 
experiment of ssDNA.  
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Scheme 2.23: (A) Synthetic pathway for the oxime condensation of T-containing PNA-hydroxylamine 1.45 and heteroleptic 
dirhodium catalyst 1.18: (a) H2O; ratio of PNA:Rh2 catalyst (1.5:1). (B) Homogenous stock solutions of PNA 1.45 (light 
yellow) and dirhodium catalyst 1.18 (blue) in water which upon mixing result in a heterogeneous pink solution of the 
precipitated oxime 1.46. 
 
2.3.7 Initial alkylation of ssDNA using template PNA-dirhodium 
carbenoids 
 
Since the commercial ssDNA sequence d(GCG TAT CCG GCA CGA) was used up at that time in the 
context of our separate studies on catalytic alkylation of nucleic acids, we synthesized a shorter analog 
employing oligonucleotide solid-phase synthesis. The new sequence d(GCG TAT ACG) (see section 
4.2.1.3 for the full skeletal structure) contained the same hexameric hybridizing region to the PNA 
complement with an additional three base overhang lacking unreactive thymine (see section 1.2.1). 
We chose a shorter oligonucleotide to limit the possibilities of alkylation sites and for analytical 
simplicity of potential products.  
After successful synthesis of T-containing PNA-hydroxylamine 1.45 we began our investigations in a 
proof of concept experiment series for PNA-dirhodium templated alkylation of d(GCG TAT ACG) 
using -diazoester 1.28 in water. First we envisioned the self-assembling of the catalytic system by 
sequential addition of the guiding PNA sequence, dirhodium catalyst, and substrate to a solution of the 
target ssDNA. Ideally the oxime bioconjugation of the guiding PNA with the catalyst is followed by 
duplex formation with the target oligonucleotide and subsequent site-selective alkylation through 
reaction with the diazo substrate. The results obtained are summarized in Table 2.1 and show that 
although oligonucleotide conversions are low using dirhodium catalyst 1.18 (entries 1-5), 
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monoalkylated species could be detected by MALDI-TOF-MS analysis in most cases (Figure 2.10). 
Throughout these experiments it was noted that upon mixing T-containing PNA-hydroxylamine 1.45 
with the heteroleptic catalyst a pink solid precipitated inside the reaction vial. It is very likely that the 
active but insoluble oxime species 1.46 (vide supra) inhibits efficient homogeneous catalysis and once 
omitted, oligonucleotide conversions almost doubles (compare entries 4 and 5). High PNA 
concentrations though are detrimental and assumed to result in unreactive aggregates (entry 1) while 
low concentrations couldn’t be effectively detected under the HPLC conditions employed (entries 2 
and 3). Control reactions with Rh2(OAc)4 (entries 6 and 7) indicated higher oligonucleotide 
conversions up to 70% (at equimolar ratios) but resulted in the same monoalkylated species as 
concluded from the corresponding HPLC traces.  
 
Table 2.1: Proof of concept experiment for PNA-dirhodium templated alkylation of ssDNA. 
 
 
Entry [PNA] [Rh2 cat.] [oligo] conv. [%] 
[b]
 monoalkylation 
[c]
 
      
      
1 1 mM 1 mM 1.18 5 mM 3 1 
2 0.1 mM 0.1 mM 1.18 0.1 mM n.d. 1 
3 0.1 mM - 0.1 mM n.d.     0 
[d]
 
4 0.5 mM 0.5 mM 1.18 2.5 mM 15 1 
5 - 0.5 mM 1.18 2.5 mM 28 1 
6 0.5 mM 0.5 mM Rh2(OAc)4 0.5 mM 70    1
[e]
 
7 - 0.5 mM Rh2(OAc)4 0.5 mM 61    1
[e]
 
      
Order of addition: 1. T-PNA-ONH2 1.45, 2. Rh2 cat., 3. d(GCG TAT ACG), 4. -diazoester 1.28. Analyzed by RP-HPLC 
using 100 mM triethylammonium acetate (pH 7.0)/MeCN. [a]  >99% conversion after 14 h. [b] Oligonucleotide conversion - 
reported after 14 h by integration of the respective HPLC peak area at 254 nm. [c] Identified by collection of the HPLC peak 
and subsequent MALDI-TOF-MS analysis. [d] No conversion of the diazo substrate was observed after 14 h; upon addition 
of 1 eq. Rh2 cat 1.18, -diazoester 1.28 was converted by 83% within 3 h but didn’t result in an oligonucleotide alkylation. 
[e] Alkylation product could only be identified through comparison of the respective tR with previous HPLC traces; MALDI-
TOF-MS analysis of the collected peaks were non-informative. n.d. = not determined. 
51 
 
 
Figure 2.10: Representative HPLC trace after 14 h. The singly modified species (tR = 7.64 min) was characterized by 
MALDI-TOF-MS (inset). 
 
In summary, these initial results using self-assembling catalysts indicate that although a templating 
PNA effect was not observed, monoalkylations can be achieved with the novel dirhodium catalyst 1.18 
in aqueous media. In addition oligonucleotide conversions are low to moderate using catalyst loadings 
of 20 mol% while the diazo substrate is completely consumed after 14 h.  
Next, we tested the guiding catalyst 1.46 in a direct PNA-dirhodium templated alkylation of d(GCG 
TAT ACG) using -diazoester 1.28 in water (Scheme 2.24). We chose to use an equimolar ratio of the 
template and the target strand to achieve higher conversions and force the templating ability of the 
PNA catalyst. 
 
Scheme 2.24: Attempt for PNA-dirhodium templated alkylation of ssDNA. 
 
Again, upon addition of the aqueous oligonucleotide solution to the oxime in DMSO a pink precipitate 
was noticed in the reaction vial which was most likely the water-insoluble PNA catalyst 1.46. HPLC 
and MALDI-TOF-MS analysis of the reaction mixture after 17 h revealed that <5% of the starting 
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oligonucleotide has been converted to one singly modified product while -diazoester 1.28 was 
completely consumed. From this result, we hypothesized that the PNA-dirhodium catalyst 1.46 is 
likely to have poor hybridization properties with its ssDNA complement which strongly diminishes 
catalytic turnovers. This assumption was directly tested by circular dichroism (CD) spectroscopy of 
the hybrids between d(GCG TAT ACG) and PNA-dirhodium catalyst 1.46 or T-containing PNA-
hydroxylamine 1.45 (Figure 2.11). The PNAONH2-DNA duplex was found to have distinct minima at 
242 and 271 nm and maxima at 220 and 297 nm, characteristic of a right-handed helix.
188
 In contrast 
the respective PNARh2oxime-DNA duplex completely lacked spectral transitions suggesting that this 
randomly organized species is not pre-organized through WATSON-CRICK base-pairing. This finding 
may explain the marginal oligonucleotide conversion described above when using the templating 
PNA-dirhodium catalyst 1.46.  
 
Figure 2.11: CD spectra of the PNA-DNA hybrid duplexes at 8 M strand concentrations in 10 mM KPi buffer pH 7.6 
recorded at room temperature. KPi = potassium phosphate buffer. 
 
We reasoned that maybe the rigidity of the dirhodium directly attached to the PNA N-terminus could 
be problematic and suppress catalytic activity. Moreover the water solubility of the system was still an 
issue we had to fix which may allow for homogeneous catalysis. The combination of these particular 
needs is reflected in the ethylene glycol based linker 1.50 (Scheme 2.25). While its length allows for a 
more flexible junction to the dirhodium, the additional ethylene glycol unit improves solubility in 
aqueous media. The linker 1.50 was prepared in a straightforward two-step synthesis with an 
acceptable overall yield of 30%. Commercial 2-bromoethanol (1.47) was first substituted with tert-
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butyl N-hydroxycarbamate (1.48) to give the alcohol 1.49 which was then reacted with bromoacetic 
acid to deliver the desired carboxylic acid 1.50 containing a protected O-alkylhydroxylamine. 
 
Scheme 2.25: Synthetic pathway for the preparation of ethylene glycol based linker 1.50: (a) DBU; (b) NaH, bromoacetic 
acid. 
 
Once established, linker 1.50 was incorporated into the synthetic cycle of PNA 1.51 which was 
unproblematic for the assembly of the PNA monomers and an initial test coupling of the N-Boc 
protected O-alkylhydroxylamine 1.50 (Scheme 2.26, panel A). Unfortunately the attempt to synthesize 
PNA 1.51 in larger scale failed as indicated by MALDI-TOF-MS and UPLC-MS analysis which both 
revealed the product mass minus 18 Da after cleavage. This particular mass difference most likely 
corresponds to the loss of one water molecule thus indicating an intramolecular oxime formation 
which renders it inappropriate to be further used for the condensation to dirhodium catalyst 1.18.  
 
Scheme 2.26: (A) Synthetic attempt for the preparation of ethylene glycol based hydroxylamine PNA 1.51: (a) (i) R-MPT-
PNA 1.38, HATU, DIPEA, 2,4,6-collidine; (ii) 5% Ac2O, 6% 2,4,6-collidine, NMP; (iii) 1M TMSOTf, 1.5M 2,6-lutidine; (b) 
repetitive cycles of (i) Fmoc-PNA-B(Bhoc)-OH or O-alkylhydroxylamine 1.50, HATU, DIPEA; (ii) 20% piperidine/DMF 
and final cleavage (iii) TFA/TIS/H2O (95:2.5:2.5). (B) Possible cyclic products obtained after full cleavage of the PNA from 
the solid support. Formation of cytosine oxime 1.52 is less probable compared to thymine oxime 1.53 as suggested by 
literature examples.196 
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It is known that cytosine residues in DNA can react selectively with hydroxylamines in aqueous 
solutions
197,198
 but also can be transformed to uracil via their oxime sulfonates.
199
 Although these 
reaction pathways were found to proceed through modification of the exocyclic amino group in 
cytosine it could be possible that intramolecular hydroxylamine condensation proceeds at its carbonyl 
function which to the best of our knowledge has not yet been reported in the literature (Scheme 2.26, 
panel B). A more probable target for condensation is one of the two thymines from the sequence to 
give cyclic PNA 1.53. In 2000 the research groups of RODE and KULIKOWSKI showed that a triazole 
activated deoxythymidine derivative can be modified at O-4 by simple hydroxylamine treatment.
196
 
While in our case the flexible N-terminal hydroxylamine is in a high effective concentration the 
additional activation of the nucleobase may be irrelevant to achieve successful intramolecular 
condensation. This however is only a hypothesis based on the obtained results and was not further 
investigated since the priority of our studies was the final bioconjugation of the PNA to the dirhodium 
catalyst 1.18. At that point we decided to examine the rather slow oxime condensation reaction in 
more detail which is also a key criterion for successful assembly of the catalytic system. 
 
2.3.8 Conclusion and outlook 
 
The concept of guided catalysts for the sequence-specific alkylation of ssDNA using Rh(II)-stabilized 
carbenoids in aqueous media described above was successfully implemented from a synthetic point of 
view. Although second generation PNA could be connected to a dirhodium catalyst via oxime 
condensation this reaction was found to be slow and water incompatible. A new set of modular ligands 
for dirhodium complexes gave access to a water soluble candidate which was used for bioconjugation. 
Even though the separate introduction of a solubilizing T monomer gave access to freely soluble 
PNA the final condensation rate is slow and calls for improvement. The results obtained from initial 
alkylation studies of ssDNA in water show that the PNA-dirhodium catalyst is active to a certain 
extent and results in a single modification despite marginal turnovers. Templation seems to be 
hindered when dirhodium is covalently attached to PNA as concluded from CD spectroscopy 
experiments. Attempts to allow for a more soluble and flexible handle on the oxime junction were 
unsuccessful so far but should be reconsidered in future investigations.  
A possible option could be the attachment of the linking unit to the dirhodium precatalyst prior to the 
connection to the PNA (Scheme 2.27). This may be achieved by a simple peptide coupling or an 
oxime condensation of an O-alkylhydroxylamine bearing dirhodium catalyst. 
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Scheme 2.27: Possible pathways for the preparation of flexible, ethylene glycol based PNA-dirhodium oxime conjugates. 
Pathway A: The linking unit may be attached through an oxime condensation to the dirhodium while a carboxylic acid or an 
activated derivative is used for the attachment to PNA. Pathway B: The free N-terminus of the PNA is first reacted with a 
carboxylic acid containing a terminal ketone which can then form an oxime linkage with the corresponding dirhodium O-
alkylhydroxylamine to give a highly flexible bisoxime catalyst. 
 
In addition an oligonucleotide target strand with a longer overhang would allow for a higher alkylation 
probability and needs to be chosen according to the linker length. Computational studies could further 
help to get more detailed insights on the interaction of the PNA-dirhodium catalyst with the 
complementary strand in a three-dimensional fashion. Furthermore, it could serve as an early 
diagnostic tool for locating potential structural incompatibilities and prove beneficial when planning a 
synthesis. Once a more efficient system is established, in-depth investigations will follow for the 
sequence-specific alkylation of oligonucleotides. From an analytical point of view these alkylation 
sites could be determined by primer extension of a DNA hairpin target and subjected to high-
resolution gel electrophoresis under denaturing conditions (Scheme 2.28). This method will allow the 
detection of single base-pair size differences and give detailed information on the preferences for 
nucleobase modification. 
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Scheme 2.28: Possible pathway for determining the sites of alkylation on a DNA hairpin. Primer extension with subsequent 
high-resolution gel electrophoresis. Products will give information on the site of modification and have to be compared with 
reference material. 
 
As mentioned before the rate of oxime bioconjugation in water is of much higher priority and 
fundamental for a successful assembly of the template catalyst. Future work has therefore to focus 
primarily on methods which allow for a quick and selective oxime condensation under physiological 
conditions. Major contributions towards this issue are described in the next chapter of the present 
thesis and provide a firm basis to promote this interesting project. 
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3 Novel methods for oxime bioconjugations in chemical biology 
 
3.1 Introduction 
 
Finding new methods for effective bioconjugations in chemical biology is a daunting challenge and of 
particular interest to the community. Although a broad set of different bioconjugation reactions exist, 
each individual method exhibits certain limits making them partially useful (vide supra). For many 
applications these reactions have to be chemoselective, perform superior in water at neutral pH and 
equimolar ratios, and display fast reaction rates even at low concentrations. While searching for 
completely new bioconjugation reactions is a tedious and expensive endeavor, optimization of current 
methods is a more direct and quicker way to address a particular research problem.  
As concluded in the previous chapter, the oxime condensation strategy we used for creating guided 
catalysts in water was found to exhibit rather slow reaction kinetics. The envisioned self-assembling 
system (see Scheme 2.10) however relies strongly on a rapid bioconjugation to form the catalytically 
active species used for nucleic acid modification. We therefore became interested in methods for fast 
oxime condensations which can be performed in water under neutral conditions. The subsequent 
sections will give the reader an in-depth overview on oxime condensations in general, their challenges 
and state-of-the-art methods for optimization. 
 
3.2 Characteristics and challenges of oxime condensations 
 
As previously described, oximes (C=N-OR) result from a condensation reaction of an O-
alkylhydroxylamine with either an aldehyde or a ketone. Since rotation around the final C=N double 
bond is restricted, oximes exist as two possible stereoisomers: the syn and anti-isomer. POLITZER and 
MURRAY investigated the effect of several substituents on the isomerism of oximes and their 
thermodynamic stabilities using computational models.
200
 While acetaldoxime was found to exist 
almost equally in the syn and the anti-form, a chloromethyl substituent slightly stabilizes the anti-
isomer whereas benzaldoxime prefers the syn conformation (Scheme 3.1, panel A). In the case of 
acetophenone ketoxime the isomer where the phenyl and hydroxyl group are anti to each other was 
found to be lower in energy (Scheme 3.1, panel B). Although equilibrium constants may help to make 
a statement on the isomerization equilibria, their studies in general showed that the magnitudes of the 
free energy difference (DG, see equation 1) are very similar and rather small. Therefore the stability 
of one specific oxime product will be mainly influenced by the interactions with e.g., solvent or other 
adjacent oxime molecules and cannot be generalized per se. Nevertheless, from a bioconjugation point 
of view both isomers represent a successful linkage of the starting components. 
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   (1) 
 
Equation 1: Relationship of the equilibrium constant (Keq) and the change in Gibbs free energy (DG) where R is the universal 
gas constant and T is the absolute temperature. 
 
 
Scheme 3.1: Isomerism in aldoximes and acetophenone ketoxime. The preference for the syn or anti isomer (corresponding 
substituents are underlined) was determined by computing the respective free energy change DG and equilibrium constant 
Keq. 
 
Structurally oximes are Schiff bases where the substituent attached to the nitrogen atom is an O-alkyl 
group rather than a simple aryl or alkyl group. In terms of stability the classical Schiff base is prone to 
rapid hydrolysis in aqueous media whereas oximes are far more hydrolytically stable.
170
 This unusual 
feature is explained by the -effect of the oxygen atom which participates in electron delocalization 
and decreases the electrophilicity of the sp
2
 carbon atom (Scheme 3.2). Nevertheless, their hydrolysis 
was found to be acid-catalyzed and has an optimum rate at pH 5 which decreases with increasing pH. 
Once the oxime nitrogen is protonated the electrophilic carbon atom is highly susceptible to attack by 
water. Subsequent cleavage of the C-N bond results in the formation of the starting aldehyde or ketone 
and O-alkylhydroxylamine.  
 
Scheme 3.2: The -effect in oximes renders them stable towards hydrolysis which is a reversible process depending on the 
reaction conditions.  
 
When comparing the hydrolytic stability of an isostructural oxime with hydrazides and an 
alkylhydrazone as potential linkages for bioconjugation, the RAINES group could further demonstrate 
that oximes have superior stabilities in water at neutral pH (Figure 3.1).
170
 They assessed the stability 
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by kinetic 
1
H-NMR quenching experiments plotting the hydrolysis fraction versus the half-life (t1/2) of 
the respective functionality. While the hydrazone and hydrazides were readily hydrolyzed in few 
hours, the oxime half-life was determined to be 25 days thus making it the ideal candidate for 
bioconjugations based on C=N linkages. This observation is explained by the higher electronegativity 
of oxygen (O compared to nitrogen (N which makes protonation of oximes less 
favorable compared to hydrazones and hydrazides. 
 
Figure 3.1: Comparison of the hydrolytic stabilities of a hydrazone, two hydrazides and an oxime. 
 
From a synthetic point of view, oximes are readily assembled from the corresponding O-
alkylhydroxylamines and carbonyl compounds. JENCKS’ seminal mechanistic studies in the mid-1960s 
showed that oxime formation is a two-step process with a tetrahedral intermediate. In a first reversible 
step the -nucleophile adds to the electrophilic carbonyl carbon to give a hemiaminal intermediate 
which then dehydrates to the final oxime product (Scheme 3.3).
201
 
 
Scheme 3.3: The JENCKS’ two-step mechanism for oxime condensation between a carbonyl compound and an O-
alkylhydroxylamine.  
 
While the addition step typically proceeds through a rapid pre-equilibrium with the tetrahedral 
hemiaminal intermediate, subsequent elimination of water was found to be rate-limiting. Most 
strategies for rapid oxime condensations focus therefore on methods which lower the barrier for the 
dehydration step, e.g., acid catalysis (vide infra).  
Although the reaction works quite well in organic solvents like DMF
170
, methanol
202
, ethanol
203
 or 
DMSO
204
 it is rather difficult to obtain a successful oxime ligation in water at pH 7.
205
 In addition 
when considered as a potential method for bioconjugation the reaction has to be employed at high 
dilutions that are often required in biological settings, hence fast reaction rates are essential.  
60 
 
It is therefore of particular importance to optimize the rates of oxime condensations at neutral pH to 
make them more practical for chemical biologists. The subsequent section will give an overview on 
present strategies and methods to improve this type of bioconjugation reaction. 
 
3.3 Present methods for the optimization of oxime condensations 
 
In his early review entitled “Mechanism and Catalysis of Simple Carbonyl Group Reactions”, JENCKS 
describes, amongst other things, the pH dependence of oxime condensations.
201
 His initial studies on 
the mechanism of oxime formation showed that this reaction exhibits a bell-shaped pH-rate curve with 
a maximum rate at pH 4.5.
206
 Acid catalysis therefore represents one way to accelerate oxime 
condensations and the observed rate enhancement is a result of the protonated hemiaminal which 
rapidly dehydrates to give the stable conjugate. Nevertheless, once the pH is below this optimum, O-
alkylhydroxylamine protonation becomes predominant and shuts down the reactivity of the -effect 
nucleophile. A more basic pH on the other hand decreases the reaction rate and prevents the 
intermediate from dehydration. In general these findings provide a good basis for understanding the 
specific requirements of oxime condensations. Nevertheless, fast reaction rates are still limited by the 
narrow pH range (pH 4-5) which makes it not applicable for effective bioconjugation under 
physiological conditions. However, an important advance was JENCKS’ trend-setting finding of 
nucleophilic aniline catalysis for semicarbazone formation.
207
 In 2006, DAWSON et al. demonstrated 
that this type of catalysis is a convenient method to accelerate oxime ligations.
205
 The use of aniline as 
a catalyst results in a highly populated protonated Schiff base which rapidly undergoes transimination 
to yield the desired ligated product (Scheme 3.4).  
 
Scheme 3.4: Mechanistic pathway for the aniline catalyzed oxime formation via transimination. 
Compared to the uncatalyzed condensation, the use of p-methoxyaniline was found to enhance the 
second-order rate constant for the ligation of two unprotected peptides by a 40-fold in phosphate 
buffer at pH 7 (Scheme 3.5). A more drastic acceleration up to 400-fold was observed at pH 4.5 where 
the reaction reaches 50% conversion in only 19 minutes. Although aniline (pKa = 4.6; p-
methoxyaniline: pKa = 5.3) has a similar pKa to that of -effect nitrogens (hydroxylamine: pKa ~4.6) 
the corresponding aniline Schiff base has a higher pKa than the oxime and is therefore partially 
protonated under these conditions.  
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 pH t1/2 
a
 kobs [M
-1
 s
-1
] catalyst 
     
   7.0 
b
 7.6 d 1.5 x 10
-3
 no 
   7.0 
b
 280 min 6.1 x 10
-2
 p-methoxyaniline 
c
 
   4.5 
d
 5.7 d 2.0 x 10
-3
 no 
   4.5 
d
 19 min 8.6 aniline 
c
 
     
 
 
a Time required to reach 50% conversion. b Peptide concentrations:  
1 mM. c 100 mM. d Peptide concentrations: 0.1 mM. 
 
 
 
 
Scheme 3.5: Oxime ligation of two unprotected peptides performed in either the absence or presence of an aniline catalyst at 
pH 7.0 and 4.5, respectively. 
 
Two years later they extended their concept of nucleophilic aniline catalysis on oxime and hydrazone 
ligations with aromatic aldehydes in a separate study.
208
 It was shown that an unprotected peptide and 
human serum albumin could be efficiently labeled at low M concentrations with oxime rate constants 
up to 8.2 M
-1
 s
-1
 under ambient conditions at pH 7.  
Recently, the principle of nucleophilic catalysis was further developed by the research group of 
DISTEFANO which reported the superior water solubility properties of a m-phenylenediamine (mPDA) 
catalyst.
93
 The use of high concentrations of mPDA up to 900 mM in phosphate buffer at pH 7.3 
allows oxime condensations to be performed up to 15-fold faster (kobs = 1.1 M
-1
 s
-1
, compared to 
Scheme 3.5) compared to aniline catalysis. Key to these findings is the additional aromatic amino 
group in mPDA which makes it highly water soluble beyond concentrations of 2 M. On the basis of 
their studies they could demonstrate that mPDA was an efficient catalyst for the selective capture of 
aldehyde-functionalized proteins from crude cell lysate via hydrazone-oxime exchange.  
Another way to overcome the rather slow reaction kinetics of oxime condensations is intramolecular 
proton assistance. In the context of their studies on water-soluble organocatalysts for hydrazone and 
oxime formation, the KOOL group reported that anthranilic acid and its derivatives can serve as 
catalysts superior to aniline under physiological conditions.
209
 Following up on these findings they 
separately tested nucleophilic aniline-based catalysts containing ortho proton donors for hydrazone 
formation. It was shown that tuning the pKa of the proton donor towards the biological buffer pH 
greatly accelerates the reaction rates up to 8-fold (5-methyl-2-aminobenzenephosphonic acid) 
compared to aniline (Figure 3.2, panel A).
210
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Figure 3.2: (A) Best performing aniline-based catalyst containing an ortho proton donor for hydrazone formation. (B) 
Proposed mechanism for intramolecular proton assistance of various ortho-substituted aryl aldehyde/hydrazine conjugates. 
 
Since the addition of an external catalyst can be undesired in some cases and enhances the complexity 
of the system, self-catalyzing carbonyl compounds were envisioned as an adequate alternative in a 
separate study by KOOL et al. Several ortho-substituted aryl aldehydes were found to speed up the 
hydrazone ligation rates due to intramolecular protonation of the tetrahedral hemiaminal which aids 
the dehydration step (Figure 3.2, panel B).
211
 Although this study was exclusively performed with 
hydrazines, two analogous O-alkylhyroxylamines were also examined recently and successfully 
connected to 2-formylpyridine with increased reaction rates.
212
  
In summary, the methods developed so far for optimizing oxime condensations under physiological 
conditions employ nucleophilic catalysis (e.g., aniline and its derivatives) and intramolecular proton 
donation of either an additional catalyst or a self-catalyzing substrate. Typical second-order reaction 
rates are found in the range from 10
-2
-10
1
 M
-1
 s
-1
 and have been applied to a broad spectrum of small 
molecules as well as peptides and proteins for efficient bioconjugation. Nevertheless additional 
strategies must be established which give access to reaction rates competitive with e.g., strain-
promoted cycloadditions (see Scheme 1.17, section 1.3.3). This would significantly broaden the 
applicability of oxime condensations and render it the method of choice for a variety of challenging 
bioconjugations in a neutral environment.  
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3.4 Results and discussion - Rapid oxime condensations using dialdehydes 
 
The results discussed within this section are the cumulative work of the author Pascal Schmidt, Linna 
Zhou, Kiril Tishinov, Kaspar Zimmermann, Dennis Gillingham and have been published in 2014.
213
 
The material is used with a personal permission of the publisher John Wiley and Sons and the 
corresponding license details can be found in the appendix (section 4.3.2). 
Our initial findings of sluggish oxime condensations for the rapid assembly of guiding catalysts under 
physiological conditions (see chapter 2, sections 2.3.6 and 2.3.7) have led us to explore this valuble 
strategy in more detail. An extensive literature search laid our focus finally to the fundamental 
publications of KOOL et al. on fast hydrazone/oxime formations
209-212
. Although we became interested 
in testing various ortho-substituted aromatic aldehydes to accelerate oxime condensations we were 
simultaneously terrified by the possibility of identical studies by the KOOL group. Consistent with 
their findings, we observed that aldehydes substituted with an acid delivered a substantial rate increase 
upon reaction with O-alkylhydroxylamines, but even this was still too slow at 10 M of each partner. 
We reasoned that bisoxime formation might deliver an additional increase in rate and were therefore 
drawn to the possibility of dialdehyde substrates. Upon mixing commercially available ortho-
phthalaldehyde (OPA, 2.1) and 1,3-diaminohydroxypropane (2.2) in a 1:1 ratio at 10 M we could 
only ever detect the bisoxime product 2.3 by HPLC after 10 minutes (Scheme 3.6). This surprising 
observation suggested that the second-order rate constant for this reaction was at least 10
4
 higher than 
a typical uncatalyzed monooxime condensation.
208
  
Scheme 3.6: Unprecedented speed in oxime conjugations: Bisoximes (top) and oximes (bottom) form in minutes without a 
catalyst at 10 M in both substrates and water (pH 7) as the reaction medium. 
Reaction of O-benzylhydroxylamine (2.4) with the same dialdehyde 2.1 also led to rapid oxime 
formation, indicating that the rate acceleration is attributable mainly to the dialdehyde motif and not to 
bisoxime formation as we initially hypothesized. The major advantage of the bisoxime for 
bioconjugations will likely be that a potentially reactive aldehyde is not left behind, and the 
equilibrium constant will overwhelmingly favour the product. To further explore the nature of the 
acceleration and to establish the reaction scope, we first varied the substrates based on our initial 
observations.  
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3.4.1 Substrate synthesis 
 
Inspired by DAWSONS’ studies on peptide ligation via oxime formation we were particularly interested 
in peptide substrates bearing an N-terminal mono- or bishydroxylamine functional group. We 
envisioned the LYRAG pentapeptide monohydroxylamine 2.6 and bishydroxylamine 2.7 as more 
complex test substrates for rapid bioconjugation containing a C-terminal carboxamide. The 
retrosynthetic analysis of both peptides is outlined in Figure 3.3. Peptide 2.6 was imagined to be 
assembled by conventional SPPS using the Fmoc/
t
Bu strategy, protected amino acids and Boc-AOAc-
OH 1.9 in the final coupling step. The bishydroxylamine terminated peptide 2.7 follows the same 
synthetic route, except that the bishydroxylamine carboxylic acid 2.8 has to be separately synthesized 
in three linear steps (O-alkylation, ozonolysis and reductive amination) from commercial 3-bromo-2-
bromomethyl-1-propene (2.11).  
 
Figure 3.3: Retrosynthetic analysis of two hydroxylamine-containing LYRAG peptides: Peptide 2.6 is synthesized 
exclusively from commercial compounds whereas the bishydroxylamine building block 2.8 in peptide 2.7 has to be 
synthesized separately in three linear steps. 
 
The synthetic route for the preparation of bishydroxylamine carboxylic acid 2.8 started from 
commercial dibromide 2.11 which was substituted with tert-butyl N-hydroxycarbamate (1.48) under 
basic conditions to give the Boc-protected bishydroxylamine 2.12. Ozonolysis of the terminal alkene 
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with subsequent reductive workup afforded the ketone 2.10 in good yield which was next subjected to 
reductive amination with sarcosine (2.9) and NaBH3CN to give the final product 2.8 (Scheme 3.7).  
  
 
Scheme 3.7: Synthetic sequence for the preparation of bishydroxylamine carboxylic acid 2.8: (a) tert-butyl N-
hydroxycarbamate (1.48), DBU; (b) O3 then Me2S; (c) sarcosine (2.9), NaBH3CN. 
 
Next, the two hydroxylamine terminated peptides were synthesized on rink amide resin using an 
automated peptide synthesizer. The synthetic sequence is depicted in Scheme 3.8 and starts with initial 
Fmoc deprotection by repetitive piperidine treatment. After each step several washing cycles were 
included which used DMF to remove excess reagents. The free amine was then reacted with a mixture 
of HCTU, DIPEA and the respective Fmoc-AA-OH for 1 h. This was followed by a subsequent 
capping step with Ac2O to block unreacted amino groups from chain elongation. Next the 
deprotection, coupling and capping cycles were repeated with different amino acids until the desired 
length of the peptide was achieved. In the final coupling steps the solid-phase bound LYRAG peptide 
was first Fmoc deprotected and then reacted with either commercial Boc-AOAc-OH 1.9 or the 
separately synthesized bishydroxylamine carboxylic acid 2.8. Treatment of the resin with high TFA 
concentrations and a silane-based cation scavenger removed all protecting groups and liberated the 
crude hydroxylamine equipped peptides 2.6 and 2.7 which were then precipitated from cold ether and 
purified preparatively employing acidic RP-HPLC. After lyophilizing the pure peptide fractions, 
aqueous stock solutions were prepared and quantified by UV spectrophotometry at 280 nm using a 
molar extinction coefficient 280 for the amino acid sequence (LYRAG) which was calculated 
according to the EnCor Biotechnology Inc. webpage.
214
 Both peptide substrates were then tested in 
mono- and bisoxime condensations with various aromatic aldehydes at different concentrations. 
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Scheme 3.8: SPPS of hydroxylamine-containing peptides 2.6 and 2.7: (a) (i) 40% piperidine/DMF, (ii) Fmoc-Gly-OH, 
HCTU, DIPEA, (iii) 5% Ac2O, 6% DIPEA, DMF/NMP, (iv) repetitive cycles of (i-iii) using Fmoc-Ala-OH, Fmoc-Arg(Pbf)-
OH, Fmoc-Tyr(tBu)-OH and Fmoc-Leu-OH. (b) (i) 40% piperidine/DMF, (ii) Boc-AOAc-OH 1.9, HATU, DIPEA, (iii) 
TFA/TIS/H2O (95:2.5:2.5). (c) (i) 40% piperidine/DMF, (ii) 2.8, HATU, DIPEA, (iii) TFA/TIS/H2O (95:2.5:2.5). LYRAG = 
leucine-tyrosine-arginine-alanine-glycine containing a C-terminal carboxamide. 
 
In addition to the peptide substrates we also synthesized a simple aromatic bishydroxylamine which 
served as a candidate for bisoxime formation (Scheme 3.9). Commercial ,′-dibromo-o-xylene 
(2.13) was double substituted with tert-butyl N-hydroxycarbamate (1.48) to give intermediate 2.14 
which was then deprotected using a TFA/CH2Cl2 mixture to afford the aromatic bishydroxylamine 
2.15 in moderate yield. 
 
Scheme 3.9: Synthetic sequence for the preparation of aromatic bishydroxylamine 2.15: (a) tert-butyl N-hydroxycarbamate 
(1.48), NaH; (b) TFA/CH2Cl2 (1:1). 
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3.4.2 HPLC studies 
 
In a first HPLC assay, we tested various commercial aldehyde/hydroxylamine substrate pairs for 
efficient and rapid oxime condensations under aqueous and neutral reaction conditions (Table 3.1). 
The reaction mixtures (100 or 10 M) were analyzed by acidic LC-MS at different time intervals. 
Table 3.1: Comparison of oxime ligation reactions with different aromatic aldehydes and mono- or bishydroxylamines.[a]
 
Entry Aldehyde RONH2 Product conv. [%] 
 
1 
[b]
   
 
  < 1 
[c]
 
2 
[b] 
 
 
 
 
< 10 
    3 
[d] [e]
 
 
 
 
> 98 
4 
[d]
 
 
 
 
> 98 
5 
[d]
 
  
 
> 98 
6 
[b]
 
 
 
 
< 10 
7 
[b]
 
 
 
 
< 10 
8 
[b]
 
 
 
 
  < 1 
[c]
 
9 
[b]
 
 
 
 
98 
 
[a] Note that the oxime products are reported as acidic LC-MS detection was employed. Each reaction in Table 3.1 that 
employs ortho-dialdehydes leads to complete conversion; the 90 min time point is shown for convenient comparison. [b] 
Substrate concentrations: 100 M. [c] < 1% means no product was detected by LC-MS. [d] Substrate concentrations: 10 M. 
[e] When this reaction is performed at substrate concentrations of ≤ 1 mM the major product was found to be the tetraoxime 
2.3b consisting of two molecules of each aldehyde and bishydroxylamine (product not shown, see experimental section 
4.2.2.1). KPi = potassium phosphate buffer. 
68 
 
A survey of carbonyl derivatives confirmed the primacy of OPA for rapid oxime condensations: The 
reactions of benzaldehyde (entry 1), 2-carboxybenzaldehyde (entry 2), diacetylbenzene (entry 8), and 
dialdehydes with other substitution patterns (entries 6 and 7) were significantly slower delivering only 
traces of the corresponding products. As shown in entries 3 and 5, bisoximes can also be formed, an 
approach that may be important when the presence of a residual aldehyde is undesirable. The special 
reactivity of ortho-dialdehydes is not limited to OPA; for example naphthalene dialdehyde was also a 
highly effective substrate, converting completely into the corresponding oxime within minutes (entry 
9).  
 
To demonstrate the broadened scope of oxime formation, we focused next on more complex and 
precious starting materials which represent “real” targets for bioconjugation applications (Table 3.2). 
Both hydroxylamine terminated peptides 2.6 and 2.7 follow up on the observed trend from the 
previous table and show good conversions even at low concentrations. As a calibration, the reaction of 
both peptides with benzaldehyde (see entries 1 and 2) over 1.5 h at 100 M gave undetectable levels 
of oxime formation. Recently 2-carboxybenzaldehyde was found to be an exceptionally fast partner 
for hydrazone condensations
210
; entry 3 suggests that this effect is not as pronounced with 
hydroxylamines. Some additional important points from Table 3.2: (1) Consistent with our results 
from Table 3.1, there is little difference between the rates of mono- and bisoxime formation with 
dialdehydes (compare entries 4-7); (2) In these more complex substrates the second-order rate 
constants are smaller, but still amongst the highest ever observed for oximes: judging from the first 
half-life they are typically around 30 M
-1 
s
-1
, but range between 1 and 50 M
-1
s
-1
; (3) although the 
reaction is viable in the presence of 20% (v/v) human serum (approximately 60% conversion: entry 8), 
there is some concomitant deamination of the hydroxylamine – an observation that sounds a note of 
caution for employing these reactions in vivo or in lysates. The capacity to reduce hydroxylamines and 
aldoximes has been known for some time, but in humans the enzymology has only recently been 
characterized.
215,216
 Potential users of hydroxylamine labeling in vivo should be aware that knockout of 
the reductases may be necessary. Background reduction of hydroxylamines is not often discussed in 
the bioconjugation literature, likely because at high concentrations the capacity of the reducing 
enzymes is overwhelmed making the effect negligible.  
 
Little is known about bisoxime condensations, and they seem only to have been employed to create 
macrocyclic ligands for transition metals.
217-219
 We suspect the reaction has never been studied in 
detail because it often gives mixtures of linear and cyclic oligomers when run at or above millimolar 
concentrations. We do not see this as a shortcoming, however, since bioconjugations at concentrations 
above 100 M can already be effectively achieved with the existing repertoire of reactions.2 At 
concentrations below 100 M dialdehyde oxime condensations are typically clean and selective, 
making these reactions best suited to applications where large second-order rate constants are crucial. 
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Table 3.2: Comparison of oxime ligation reactions with peptide substrates.[a]   
 
Entry Aldehyde RONH2 Product conv. [%] 
 
1 
[b]
  
  
< 1 
[c]
 
2 
[b]
  
  
< 1 
[c]
 
3 
[b]
 
   
< 5 
4 
[b]
 
  
 
79 
5 
[b]
 
 
  
58 
6 
[d]
 
  
 
37 
7 
[d]
 
 
  
57 
8 
[e]
 
 
  
~60 
 
[a] Note that the oxime products are reported as acidic LC-MS detection was employed. The 90 min time point is shown for 
convenient comparison. [b] Substrate concentrations: 100 M. [c] < 1% means no product was detected by LC-MS. [d] 
Substrate concentrations: 10 M. [e] Human serum (20% v/v) was added to the reaction mixture; aldehyde concentration in 
this experiment is 50 M; conversion is an estimate since the serum introduces peaks that obscure the starting peptide and 
product. The serum also leads to some reduction of the hydroxylamine function (loss of NH in the MS). KPi = potassium 
phosphate buffer. 
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3.4.3 Probing the effect of biological interfering additives 
 
For practical applications it is important for a bioconjugation reaction to proceed in complex 
environments and fulfill the criteria of being bioorthogonal (see Figure 1.1). It is particularly 
important to test the efficacy of oxime ligations in the presence of other nucleophilic amino acid 
functionalities. We therefore performed reactions between mono hydroxylamine-containing peptide 
2.6 and aromatic ortho-dialdehydes at a 1:1 ration with an equimolar amount of interfering additives 
such as unprotected tryptophan or lysozyme (Table 3.3). With simple amines, dialdehydes can form a 
great variety of products depending on the reaction conditions (solvent, stoichiometry, 
concentration)
220
, but are slower than what we observe with O-alkylhydroxylamines under aqueous 
conditions.
221
 In our case, the oxime formation was equally effective in the presence of equimolar 
tryptophan (compare entries 1 and 2, entries 4 and 5). In the presence of lysozyme, however, the 
conversions were lower (see entries 3 and 6), likely as a result of nucleophilic side-chains in the 
protein trapping some of the ortho-dialdehyde. These results suggest that O-alkylhydroxylamine 
additions may be conducted with complex samples, but that a slight excess of the ortho-dialdehyde 
may be necessary for complete conversion. 
 
Table 3.3: Effect of amino acids and proteins on the oxime formation between ortho-dialdehydes and mono hydroxylamine 
peptide 2.6.[a]   
 
Entry Dialdehyde Additive Product conv. [%] 
 
1 
 
─ 
 
79 
2 tryptophan 67 
3 lysozyme 37 
 
4 
 
─ 
 
77 
5 tryptophan 76 
6 lysozyme 57 
 
[a] Note that the oxime products are reported as acidic LC-MS detection was employed. The 90 min time point is shown for 
convenient comparison. 
  
71 
 
3.4.4 1H-NMR studies – a mechanistic and kinetic insight 
 
While trying to obtain an authentic sample of oxime 2.5 for full NMR characterization we were 
surprised to detect a stable intermediate which formed within seconds of mixing OPA 2.1 with O-
benzylhydroxylamine (2.4) in a 1:1 ratio at 100 M and neutral pH (Figure 3.4, panel A). A complete 
NMR characterization confirmed the structure of the cyclic isoindole bis(hemiaminal) (IBHA, 2.16) 
intermediate which slowly dehydrated to give the expected oxime 2.5 over a time scale of hours.  
 
Figure 3.4: (A) The approach outlined here is given in brown: ortho-phthalaldehyde (OPA, 2.1) reacts with O-
benzylhydroxylamine (2.4) to give a stable isoindole bis(hemiaminal) (IBHA, 2.16) within seconds at neutral pH values 
(conditions: 10 mM KPi, pH 7.1, 20% MeCN). Please note that the reaction coordinate diagram is qualitative; smooth curves 
are drawn between kinetically relevant steps although proton transfer steps and intermediate addition products are likely to be 
involved. (B) Known approaches for accelerating the reaction are shown in blue on the reaction coordinate diagram. (C) The 
JENCKS’ mechanism for condensations with O-alkylhydroxylamines.  
 
As described in section 3.2, JENCKS’ seminal work showed that oxime condensations typically 
proceed through a rapid pre-equilibrium with a tetrahedral hemiaminal intermediate followed by a 
rate-limiting dehydration (Figure 3.4, panel C). Most attempts to optimize oxime condensations have 
therefore focused on lowering the barrier of the dehydration step or destabilizing the starting aldehyde 
(Figure 3.4, panel B) (vide supra). The exciting observation of a cyclic IBHA intermediate motivated 
us to lay our focus on this particular reaction and elucidate its mechanistic pathway as well as collect 
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kinetic information on the slow dehydration step by performing a series of time course 
1
H-NMR 
studies (see Scheme 3.10 and Figure 3.5, A-C). 
Scheme 3.10: Mechanistic pathway of oxime condensation between OPA 2.1 and O-benzylhydroxylamine (2.4) with 
competing hydrate formation in aqueous media and the two possible IBHA intermediates 2.18a/b. The numbers represent the 
chemical shifts in ppm for the corresponding protons. 
 
OPA 2.1 is known to form a cyclic hydrate 2.17 in the presence of water.
222
 This hydration process 
was also observed while performing 
1
H-NMR measurements and the corresponding shifts for the 
acetal protons of the OPA hydrate 2.17 (meso form and its diastereomer) were found to be at 6.53 ppm 
and 6.22 ppm, respectively (Figure 3.5, C). The aldehyde peak of OPA 2.1 at 10.34 ppm is almost 
completely consumed after 15 minutes and vanishes over time to be indistinguishable from noise 
(Figure 3.5, A). At the same time the aldehyde peak of 2.5 at 10.01 ppm along with the oxime proton 
peak at 8.78 ppm are increasing. In the aromatic region (Figure 3.5, B) new peaks appear between 
7.50 ppm and 8.00 ppm over time which are also product related. A detailed assignment of all 
aromatic peaks during the reaction was not pursued since there is extensive overlap of all species. A 
full characterization of oxime 2.5 is described in the experimental part, sections 4.2.2.1 and 4.2.2.4. 
The two possible IBHA stereoisomers 2.18a and 2.18b were found to be a 9:1 mixture favouring the 
meso-IBHA 2.18a over its C2-symmetric diastereomer 2.18b. The corresponding shifts for the acetal 
protons were determined to be 5.61 ppm and 5.66 ppm, respectively. The benzylic protons of the 
major IBHA resonate as a singlet at 5.03 ppm (meso-isomer 2.18a) whereas the two diastereotopic 
benzylic protons of the minor IBHA 2.18b appear as a set of two doublets at 4.93 ppm and 4.88 ppm 
along with a roof effect. The peak at 5.37 ppm is unconfirmed but seems to come from an impurity 
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since its ratio doesn’t change over time. Preliminary exchange spectroscopy (EXSY) measurements 
strongly suggest cross peaks for the peaks at 10.01 ppm and 9.83 ppm (aldehyde proton) as well as for 
the peaks at 5.18 ppm and 5.04 ppm (benzylic protons) – an observation which most likely comes 
from a cis/trans isomerization of the final oxime 2.5.  
 
 
 
 
 
 
A 
B 
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Figure 3.5: Time dependent 1H-NMR analysis: (A) Aldehyde and oxime region. (B) Aromatic region. (C) Benzylic and 
acetal/bis-hemiaminal region of IBHA 2.18a/b and oxime 2.5. 
 
In addition to this mechanistic insight on rapid oxime condensations using dialdehydes, time course 
1
H-NMR analysis also provided a value for k2 and a lower bound for Keq (Figure 3.6, panel A). As the 
dehydration is effectively irreversible over the time scales we monitored,
223
 the appearance of oxime 
could be taken as a direct measure of k2 (see the Hc proton signal in Figure 3.6, panel B).  
 
 
 
A 
C 
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Figure 3.6: Kinetic analysis: (A) NMR tube reaction at 100 M substrate concentrations; characteristic proton signals Ha-c 
are highlighted in brown. Note: Minor species 2.18b was also formed but not of importance for this analysis. (B) 1H-NMR 
analysis indicating the peaks that were monitored with time to determine the value of k2. Kinetic parameters are an average of 
two experiments. 
 
The value obtained, 1.2 ± 0.2 x 10
-5
 s
-1
, is two to three orders of magnitude smaller than those of 
typical oxime condensations at pH 7,
205
 consistent with the intermediate IBHA sitting in a deep energy 
minimum. No equilibrium for the initial addition was measurable over the observed time scale (20 h), 
a point independently confirmed in a separate experiment: When the IBHA 2.16 was dissolved in 
phosphate buffer, and the reaction mixture monitored by 
1
H-NMR spectroscopy, the formation of OPA 
2.1 was not observed; instead, the substrate was gradually converted into the oxime. The IBHA 2.16 
could be preparatively isolated as a mixture with the oxime product 2.5 by performing the reaction in 
pure MeCN at room temperature in less than a minute (Figure 3.7, panel A). Leaving the neat mixture 
at room temperature or when redissolved in MeCN it converted completely to the oxime product over 
hours whereas treatment with DCl vapor resulted immediately in the exclusive formation of lactam 
derivative 2.19 which was confirmed by X-ray analysis (Figure 3.7, panel B). 
 
B 
76 
 
 
 
 
 
 
Figure 3.7: (A) 1H-NMR spectrum of the IBHA 2.16 and oxime 2.5 mixtures recorded in CD3CN. (B) Reaction conditions: 
0.4 M OPA 2.1 and O-benzylhydroxylamine (2.4) result in a 1:1.5 mixture of oxime 2.5 and IBHA 2.16. Treatment of the 
mixture with DCl vapor gives lactam derivative 2.19. 
 
Although an accurate Keq value could not be determined, a lower bound of approximately 10
7
 M
-1
 may 
be assumed since low micromolar concentrations of the aldehyde would be well above the detection 
limit of the 700 MHz NMR spectrometer. In terms of the reaction coordinate diagram (see Figure 
B 
A 
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3.4), the fact that the IBHA led to oxime formation but not to formation of OPA 2.1 suggests that 
dehydration is faster than retro-IBHA formation (e.g., k2 > k-1). This was corroborated in a separate 
1
H-
NMR experiment which also suggests that the first step is not in equilibrium: When a sample 
containing the IBHA of naphthalene dialdehyde 2.20 was treated with a large excess of OPA 2.1, no 
scrambling to the OPA-derived IBHA 2.16 was observed (Figure 3.8). This suggests that once the 
IBHA is formed, the O-alkylhydroxylamine is never released again.  
 
 
Figure 3.8: Time dependent 1H-NMR analysis to determine the reversibility of IBHA formation: (A) 100 M OPA 2.1. (B) 
100 M naphthalene IBHA 2.20. (C) 100 M naphthalene IBHA 2.20 + 10 eq. OPA 2.1 after 3 min. (D) 100 M 
naphthalene IBHA 2.20 + 10 eq. OPA 2.1 after 75 min. Conditions: 10 mM KPi (D2O/DMSO-d6, 1:1), pH 7.1. 
 
Overall, the mechanism of oxime formation that we observe with dialdehydes parallels JENCKS’ 
proposal for simple oximes (see Scheme 3.3 - above), with the key distinction that the equilibrium 
constant for the formation of the intermediate overwhelmingly favors addition. The formation of the 
IBHA was so rapid that even at a concentration of 100 M, 1H-NMR analysis lacked the time 
resolution to measure the initial bimolecular rate constant k1. However, a value for k1 is important in 
the planning of experiments because it forecasts the required concentrations and stoichiometries. 
 
3.4.5 Fluorescence quench assay – determining k1 
 
To access the initial rate of addition we developed a fluorescence quenching assay which is a common 
method for the determination of reaction kinetics.
224,225
 Fluorogenic probes equipped with reporter 
(fluorophore) and quencher dyes use a change in fluorescence upon association which allows 
monitoring of (bio)chemical events.
226
 Usually the reporter absorbs light (excitation) at a characteristic 
wavelength and emits light (fluorescence) of lower energy (longer wavelength). Depending on the 
nature of the quencher, the energy transferred by the fluorophore can either be re-emitted as light to a 
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certain extent or as heat through a non-radiative pathway, a characteristic of so-called dark quenchers. 
Two possible mechanisms for quenching fluorescence through non-radiative energy transfer are shown 
in Figure 3.9 and highlight the important differences. FÖRSTER resonance energy transfer (FRET) is a 
dynamic quenching mechanism based on dipole-dipole interactions of the reporter and quencher 
during excitation. It was found that FRET is highly dependent on the distance (r) between the reporter-
quencher pair with rmax ~100 Å and decreases at a rate of 1/r
6 
(Figure 3.9, panel A). Contact or static 
quenching occurs when the reporter and quencher bind together and result in a ground state complex 
with unique properties. As a result of this newly formed intramolecular dimer the fluorescent 
properties of the individual components can be lost completely depending on the reporter-quencher 
pair (Figure 3.9, panel B).
226
 
 
Figure 3.9: Comparison of fluorescence quenching pathways: (A) Dynamic quenching mechanism with energy transfer 
occurring during excitation of the reporter dye. (B) Static quenching mechanism in a ground state complex [RQ] proceeding 
through a non-radiative pathway. 
 
It seemed reasonable to us that a dynamic fluorescence quenching assay would be best suited to 
determine k1 for the oxime condensation between ortho-dialdehydes and O-alkylhydroxylamines. 
Therefore we synthesized a lissamine-tagged version of OPA 2.27 (Scheme 3.11) and a dabsyl 
derivative bearing a bishydroxylamine 2.31 (Scheme 3.12). Lissamine was chosen as a fluorophore 
because its excitation wavelength of around 568 nm does not interfere with biological autofluorescent 
molecules (e.g., NADH, tyrosine, flavins, porphyrins) and may be selectively monitored if considered 
for in vivo applications.
227
 Dabsyl, a dark quencher, was used since it is a typical, non-fluorescent 
quencher frequently used in FRET applications and may be easily attached to the target molecule.
228
 
 
The synthetic route for the lissamine fluorophore 2.27 commenced with a radical tetrabromination of 
3,4-dimethyl-benzoic acid (2.21) followed by lewis acid-catalyzed acetalization to give acid 2.23 
(Scheme 3.11). In a separate step, lissamine rhodamine B sulfonyl chloride (2.24) was substituted with 
N-Boc-ethylenediamine to give protected lissamine 2.25. N-Boc deprotection was followed by a DCC-
mediated peptide coupling with acid 2.23 to give lissamine bisacetal 2.26 which after final acidic 
cleavage provided the desired lissamine-tagged OPA derivative 2.27. 
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Scheme 3.11: Synthetic sequences for the preparation of lissamine-tagged OPA 2.27: (a) NBS, benzoyl peroxide; (b) (i) 10% 
Na2CO3 (aq.); (ii) Sc(OTf)3, MeOH; (c) N-Boc-ethylenediamine, NEt3; (d) (i) 4M HCl in 1,4-dioxane/MeOH (1:1); (ii) NEt3, 
DCC; (e) TFA/H2O (1:1). 
 
The second synthetic route shown in Scheme 3.12 started with a simple SN2 reaction of dabsyl 
chloride 2.28 with N-Boc-ethylenediamine to give sulfonamide 2.29. A two-step 
deprotection/reductive amination sequence using synthetic ketone 2.10 (see Scheme 3.7) gave access 
to the bis-protected dabsyl derivative 2.30. High TFA concentrations afforded finally the dabsyl 
quencher 2.31 ready to be tested in a fluorescence quenching assay. 
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Scheme 3.12: Synthetic sequences for the preparation of dabsyl quencher 2.31: (a) N-Boc-ethylenediamine, NEt3; (b) (i) 4M 
HCl in 1,4-dioxane/MeOH (1:1); (ii) 2.10, NaBH3CN; (c) TFA/TIS/H2O (95:2.5:2.5). 
 
With the target molecules in hand we next determined the kinetic parameters at concentrations of 5 
M and 2 M for each substrate (100 mM KPi, pH 7.2). The resulting data fit best to a second-order 
rate equation and gave an average over the two concentrations of k1 = 494 ± 108 M
-1
 s
-1
 (see Scheme 
3.13). Although the fluorescence quenching assay was run with different substrates (the tags necessary 
for the readout), the magnitude of k1 is qualitatively consistent with the rapid formation of the 
intermediate that was observed by 
1
H-NMR spectroscopy. Using these numbers (vide supra) we can 
now annotate the major elementary steps for oxime formation with dialdehydes: (1) a large 
equilibrium constant (Keq >10
7
 M
-1
); (2) a fast reaction rate for the initial addition step (k1 = 494 M
-1
 s
-
1
) and (3) a slow rate for the dehydration (k2 = 1.2 x 10
-5
 s
-1
). The most rapid extant small molecule 
bioconjugation is the tetrazine-strained olefin Diels–Alder reaction, which typically has second-order 
rate constants between 1 and 10
3
 M
-1
 s
-1
,
86,88,91
 and in the best cases up to 10
6 
M
-1
 s
-1
.
229,230
 Despite 
these impressive rate constants, the widespread adoption of the tetrazine-strained Diels–Alder reaction 
has been hindered by challenging substrate syntheses and the instability of the tetrazines. In 
comparison, IBHA formation has rate constants that compete with the fastest cycloaddition 
reactions,
229
 but employs far simpler substrates. 
 
 
Scheme 3.13: A fluorescence quenching assay was used to establish the rate of the initial bimolecular addition. k1 is the 
combined average of six repeats at two different concentrations (see Figure E3 in section 4.2.2.5 for the kinetic plots). 
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3.4.6 Bioconjugation with a complex DNA substrate 
 
To further demonstrate the practical potential of the dialdehyde method we examined a bioconjugation 
with a complex DNA substrate. We synthesized a 5’-O-alkylhydroxylamine terminated DNA 41-mer 
2.32 and tested it with various concentrations of fluorescent lissamine-tagged OPA derivative 2.27 
(Figure 3.10, left). As the gel data illustrate, under neutral conditions, even down to 5 M of DNA, 
almost complete conversion into the labeled product 2.33 was observed after one hour (compare lanes 
3–7), whereas the control lanes using either a monoaldehyde (lane 8) or a native DNA (lane 9) showed 
no labeling (Figure 3.10, right). Given the proclivity of nucleic acids to depurinate at the low pH 
values needed for most oxime condensations, the neutral conditions employed here provide a mild 
alternative for DNA and RNA bioconjugations. 
  
 
Figure 3.10: Left: DNA was efficiently labeled under mild conditions (pH 7). Please note that for simplicity, the IBHA 2.33 
is drawn, but the conjugation products were likely to be a mixture of IBHA and oxime. Gel: Lane 1: lissamine dialdehyde 
2.27. Lane 2: 41-mer 5’-O-alkylhydroxylamine DNA 2.32. Lanes 3–7: IBHA conjugations at various DNA concentrations. 
Lane 8: control reaction of 5’-O-alkylhydroxylamine DNA 2.32 with the fluorescent monoaldehyde 2-naphthaldehyde. Lane 
9: control reaction confirming that the lissamine dialdehyde 2.27 does not react with a native DNA oligomer (39-mer). Note 
that the reactions were run in unbuffered water; the pH value measured at the end of the reaction was 7. 
 
Most effort in optimizing oxime and hydrazone condensations has been devoted to accelerating the 
final dehydration step as it has the highest activation barrier (see Figure 3.4). However, at sufficiently 
low concentrations, bimolecular elementary steps will begin to dominate the rate equation of any 
reaction irrespective of barrier heights. Further development of O-alkylhydroxylamine bioconjugations 
at low concentrations will therefore require an increased focus on the initial bimolecular addition step. 
The propensity of OPA 2.1 to form a stable IBHA is one such example, but additional possibilities 
could be imagined: Other dicarbonyl compounds that lead to stable IBHAs or O-alkylhydroxylamines 
that also deliver stable intermediates present new targets for future studies. 
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3.4.7 Conclusion and outlook 
 
The work presented within this section should find broad applicability in the labeling of biomolecules 
at high dilutions and provide a framework for engineering further variants of O-alkylhydroxylamine 
addition reactions. Dialdehyde conjugations present a novel method for rapid oxime formation under 
physiological conditions with unusually high reaction rates of 500 M
-1
 s
-1
 as determined by a kinetic 
fluorescence quenching assay. Mechanistic studies revealed that dialdehydes provide an internal trap 
to stabilize hemiaminals as IBHAs, leading to an enormous shift in the equilibrium position. The Keq is 
so large that the initial addition step becomes effectively irreversible; this simplifies hydroxylamine-
based bioconjugations because the timing of the typically slow dehydration reaction is rendered 
immaterial: Both IBHAs and oximes represent successful conjugations at low M concentrations. In 
addition 
1
H-NMR analysis revealed that the low energy IBHA intermediate is not in a measurable 
equilibrium with the starting materials. Instead it dehydrates at unprecedented low rates of 10
-5
 s
-1
 
when compared to normal oxime condensations under similar conditions. All tested substrates bearing 
the ortho-dialdehyde motif resulted in a fast formation of the corresponding oxime conjugates, even 
whith complex hydroxylamine peptides, oligonucleotides or fluorescence quenchers. Varying the 
aldehyde substitution pattern (meta or para) was found to be detrimental to the reaction and confirmed 
the primacy of the OPA scaffold. The reaction tolerates other nucleophilic amino acid functionalities 
and can be performed in the presence of human serum (20% v/v). Bishydroxylamines were found to 
be as effective as simple O-alkylhydroxylamines with the difference that the formed bisoxime lacks 
the reactive aldehyde moiety present in a simple oxime. To the best of our knowledge IBHAs have 
never been observed with O-alkylhydroxylamines or simple amines under aqueous conditions.
221
 In 
retrospect our strategy may be considered an innovation for rapid oxime-based bioconjugations at 
neutral pH and provides a basis for further developments in this particular research field.  
 
Future work should focus on the exploration of other substrate pairs which may exhibit improved 
accelerating abilities. In particular it would be interesting to test aliphatic dialdehydes which might 
react with a totally different second-order rate constant than we observed for OPA 2.1 (Scheme 3.14).  
 
Scheme 3.14: Proposed synthetic sequences for the preparation of aliphatic dialdehydes separated by one231,232 or two carbon 
atoms233. 
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When reconsidering aromatic aldehydes it would be worth to test some species which were not 
included in our studies and could give additional information on the influence of further or different 
substituents. Although diketones were found to be unsuitable (see Table 3.1) the reactivity of 
aldehydes containing an ortho-keto group is unknown to us so far. In dependence on the work of the 
KOOL group
211
 additional functional groups (e.g., -NO2, -OMe, -OH, -CO2H and -CO2R) on the 
aromatic ring of OPA could give access to candidates with superior reaction rates (Figure 3.11, left). 
Likewise we would be keen to know if there is a way to connect two O-alkylhydroxylamines through 
an OPA-derived linker containing several formyl groups and if commercial triformylmethane is also a 
suitable candidate for oxime condensations (Figure 3.11, right). 
 
Figure 3.11: Left: 2-Acetylbenzaldehyde (top) and various substituted OPA derivatives (bottom) which could be employed 
to extend the scope of the reaction. Right: Possible candidates for multiple oxime condensations. 
 
Probably one of the most interesting questions to answer would be to know if O-alkylhydroxylamines 
can be varied structurally to either accelerate the dehydration or stabilize the IBHA intermediate. 
Inspired by previous work on intramolecular proton assistance (vide supra) two possible structures are 
presented in Scheme 3.15. A carboxylic acid group, deprotonated under the reaction conditions, is 
imagined to participate in hydrogen bonding of the IBHA intermediate which after lowering the pH 
(e.g., acidic LC analysis) becomes a proton donor facilitating the dehydration step (Scheme 3.15, 
panel A). In analogy a tertiary amine (pKa ~10 for Me3N
+
H)
234
 in close proximity to the hydroxyl 
group of the IBHA intermediate could provide a proton thus lowering the barrier for the rate-limiting 
step (Scheme 3.15, panel B).  
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Scheme 3.15: Proposed O-alkylhydroxylamines equipped with functional groups for intramolecular proton assistance: (A) 
Carboxylic acids as tunable groups to stabilize or accelerate oxime formations depending on the pH chosen. (B) Tertiary 
amines as promoters for the usually slow dehydration step. 
 
Although the method we reported within this section represents a very successful improvement of 
oxime-based bioconjugations, optimizing and fine tuning of substrate pairs and reaction conditions is a 
never-ending story on the way of finding the perfect method. The next chapter is directly related to 
this work and represents an advancement of the present method based on boronic acids facilitating 
rapid oxime condensations. 
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3.5 Results and discussion - Rapid oxime condensations using boronic 
acids 
 
The results discussed within this section are the cumulative work of the author Pascal Schmidt, Cedric 
Stress, Dennis Gillingham and have been published in 2015.
235
 Figures, schemes and paragraphs 
described in this thesis are partially reproduced from reference #235 with permission from the Royal 
Society of Chemistry. 
Our fundamental findings of rapid oxime formation using dialdehydes at neutral pH were 
accompanied by the drawback of in vivo incompatibility since the OPA motif is well known to react 
with amines and thiols in a three-component reaction to give fluorescent isoindoles.
236,237
 In addition 
the left over formyl group in the oxime product is susceptible to other nucleophiles and may deliver 
by-products over time. While this particular method is only applicable for in vitro applications we 
were keen to probe other proximal functional groups able to form a stable and rapid oxime linkage. 
From that point on, it was clear to us that the second aldehyde group has to be replaced with a more 
tolerable functionality suitable for later in vitro studies. Based on this requirement and the insights of 
our previous study we hypothesized that the Lewis acidity of boron
238
 coupled with its ability to 
modulate alcohol pKas through coordination (Scheme 3.16),
239,240
 might facilitate rapid oxime 
formation. Moreover, boron is a chemically versatile element and its presence in oxime products 
would open the door to many applications in chemical biology. For example boron compounds have 
found uses in medicinal chemistry,
241,242
 cross-coupling reactions,
243,244
 carbohydrate detection,
245,246
 
promoting endocytosis,
247
 and reactivity-based peroxide sensing.
248,249
 Boron's rich coordination 
chemistry is pivotal for many of its applications. For example the N → B dative interaction has been 
proposed to stabilize otherwise labile Schiff bases, and these iminoboronates have been used in 
supramolecular chemistry,
250,251
 enantiomer analysis by NMR,
252,253
 and protein labeling.
254,255
 
Scheme 3.16: The unique abilities of boron led to the hypothesis that proximal boron substituents would have an impact on 
oxime condensations. 
 
We selected the 2-formylphenylboronic acid (2-FPBA, 2.34) scaffold as a model system to explore 
boron's influence on oxime condensations. 2-FPBA has previously been shown to modify lysine 
residues or N-termini in proteins in a process controlled by rapid equilibria.
255
 Little is known, 
however, about the analogous condensation with -effect nucleophiles. We have found two cases of 
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alkoxyiminoboronates (AIBs),
253,256
 two cases of O-alkylAIBs
257,258
 and two cases of the related 
hydrazinoiminoboronates;
256,259
 but in each of those studies the coupling itself was not of central 
importance and therefore not examined in detail.  
 
3.5.1 1H-NMR studies – initial findings 
 
We began our studies on boron-assisted oxime ligations with the reaction of 2-FPBA 2.34 and O-
benzylhydroxylamine (2.4) monitoring its progress by 
1
H-NMR under neutral (pH 7.2), aqueous 
conditions (10 mM KPi in D2O) as shown in Figure 3.12. Initial experiments at equimolar substrate 
concentrations of 100 M at room temperature clearly indicated a fast reaction rate. Oxime 2.35 was 
the exclusive product present after the first measurement (~5 min) and its structure was additionally 
confirmed by a separate X-ray analysis (see top of Figure 3.12).  
 
 
 
 
 
 
Figure 3.12: All spectra were recorded at 15°C. (A) 10 M 2-FPBA 2.34 (9.88 ppm, Ha) reference spectrum in 4:1 (10 mM 
KPi in D2O/CD3CN). (B) 10 M reaction (8.31 ppm, Hb) spectrum in 4:1 (10 mM KPi in D2O/CD3CN) after ~3.5 min. (C) 1 
M reaction (8.24 ppm, Hb) spectrum in 54:1 (10 mM KPi in D2O/CD3CN) after ~8.5 min – the difference in the chemical 
shift is attributed to the solvent ratio. 
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To be able to observe a potential intermediate species the reaction was repeated at substrate 
concentrations as low as 10 M and 1 M, respectively. In addition the cryoprobe was cooled down to 
15°C to retard the process of oxime formation, increasing the chance of detecting an intermediate. 
Both reactions were identical in their final outcome – after the earliest possible 1H-NMR measurement 
(10 M ~3.5 min; 1 M ~8.5 min) the reactions were nearly complete (>90% conversion) showing 
exclusively the product signals. Limited by the nature of the solvent system and the S/N ratio neither 
the temperature nor the concentration could be further tuned to get a more detailed insight into the 
reaction kinetics and potential intermediate species. These findings confirmed the potential of boron to 
accelerate oxime formation in aqueous media at neutral pH with high reaction rates. 
 
3.5.2 HPLC studies 
 
The potential of this particular oxime formation as a powerful and fast method for effective 
bioconjugation was further explored by HPLC employing neutral elution conditions (acidic conditions 
led to some reversibility).  
The reaction of 2-FPBA 2.34 with O-benzylhydroxylamine (2.4) at near-equimolar concentrations of 
100 M and 10 M in 100 mM KPi, pH 7.2 was found to deliver the desired product after the first 
HPLC injection (~1 min) with >98% conversion (Table 3.4, entry 1). The control experiment using 
benzaldehyde as substrate was found to be inappropriate as previously mentioned in section 3.4.2 
(Table 3.1 and Table 3.2). The corresponding meta- and para-substituted structural isomers of FPBA 
behaved similar, delivering nearly undetectable levels of oxime even after 90 min (entries 3 and 4). 
These results emphasize the importance of boronic acid positioning which facilitates rapid oxime 
formation under the reported conditions. Next, the necessity for the aldehyde and boronic acid motif 
were explored by replacing the respective functional groups with closely related ones. In general, 
aldehydes are substantially more reactive than ketones which cause greater steric interaction as the 
hydbridization changes from trigonal to tetrahedral.
260
 Therefore the aldehyde moiety was substituted 
for a simple ketone and the boronic acid function was replaced by its boronic acid pinacol ester (BPin) 
analogue. All three possible combinations were investigated separately and proved to be highly 
reactive substrates. Condensation with 2-acetylphenylboronic acid gave a marginal lower conversion 
(94%) after the first measurement compared to the 2-FPBA 2.34 (entry 5), but it is still faster than 
normal ketoxime formations.
261
 The BPin-containing aldehyde 2.40 and ketone 2.42 derivatives were 
equally efficient and gave complete conversion after one minute but the hydrolyzed boronic acid 2.35 
was the main product with only 10% BPin oxime 2.41 observed; after ninety minutes only 2.35 was 
present (entry 6). These findings are supported by ACHILLI describing fast BPin hydrolysis at 
physiological pH in buffered aqueous media.
262
 The ketoxime pinacol product 2.43 (entry 7), on the 
other hand, was more stable and comprised ~97% of the product after the first injection (the remainder 
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being 2.39); after thirty minutes 2.43 had also completely hydrolyzed to 2.39. The increased hydrolytic 
stability of pinacol ester 2.43 could also be attributed to the extended steric hindrance of the ketoxime 
and BPin moiety which hinder nucleophilic attack of water. The ability to use boronic acid pinacol 
esters is additionally valuable since these are readily obtained from Pd-catalyzed routes to boronic 
esters, and their deprotections in organic solvents are often tricky and require additional reagents.
263-266
 
More complex hydroxylamines, such as the pentapeptide shown in entry 8, were also excellent 
substrates, delivering complete conversion after the first injection. We also tested 2,5-
diformylphenylboronic acid pinacol ester (2.45) containing two reactive sites for hydroxylamine 
condensations (entry 9). Contrary to our assumption that this type of bifunctional molecule may 
improve the rate of oxime formation initial conversions were significantly lower and didn’t exceed 
93% even after almost a day. A series of additional experiments indicated the bisoxime 2.47 to be the 
kinetic product forming after the first injection as the major product and equilibrating over time to the 
thermodynamically favored monooxime 2.46. When two equivalents of O-benzylhydroxylamine (2.4) 
were added a mixture of mono- and bisoxime was observed which after adding another two 
equivalents of 2.4 completely converted to the C2-symmetric product 2.47. These results clearly show 
that unfortunately the strategy to rapidly connect two different O-alkylhydroxylamines through this 
linker-type boronic ester 2.45 is unsuitable and needs further investigations.  
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Table 3.4: Probing the importance of boron positioning and substitution on oxime condensations. 
 
Entry Ar X Product conv. [%] 
[b]
 
   1 
[c]
 
 
H 
 
 > 98 
2 
 
H 
 
   < 5 
[d]
 
3 
 
H 
 
  < 5 
[d]
 
4 
 
H 
 
   < 5 
[d]
 
5 
 
Me 
 
94 
6 
 
H 
 
   > 98 
[e]
 
7 
 
Me 
 
> 98 
8 
 
H 
 
> 98 
9 
 
H 
 
     61 
[f]
 
 
[a] Time is approximate since samples are injected directly after mixing. [b] Conversions are based on the peak 
disappearance of 2-FPBA 2.34 after ~1 min at 254 nm. [c] Reaction was also performed at 10 M giving the same 
conversion number after the first injection. [d] Injections after 90 minutes still show < 5% conversion. [e] At the first 
injection approximately 10% of the boronic acid pinacol ester oxime 2.40 is observed, but only the hydrolyzed product 2.35 
is detected after 1.5 h. [f] Concentrations were 100 M for both substrates; 73% conversion after 90 minutes and 93% after 
21 h with bisoxime 2.46 beeing the kinetic (t ~1 min) and monooxime 2.47 the thermodynamic product (t = 21 h). 
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The results obtained from NMR and HPLC studies makes it clear that boronic acids facilitate rapid 
oxime condensations at neutral pH, in most respect the reaction turned out to be superior to the 
dialdehyde method. The reaction is very fast and displays second order kinetics. With a generously 
assumed half-life of around 30 seconds (HPLC) or 120 seconds (
1
H-NMR) these observations imply a 
rate upwards of 10
3
 M
-1
 s
-1
 and represent only a lower bound for the rate constant (Equation 2). 
 
  
 
 
 
      
 (2) 
 
Equation 2: t1/2 = half life [s], k = rate constand [M
-1 s-1], [A0] = initial concentration of the starting material [M]. 
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3.5.3 Fluorescence quench assay: determining k1 
 
Since reactions with half-lives smaller than several seconds to minutes are hard to follow and monitor 
with standard methods (e.g., NMR, HPLC, GC or UV-spectroscopy), special techniques have to be 
considered which are more sensitive and allow for an extended time resolution. In addition a good S/N 
ratio will also allow substrate ratios near unity at low concentrations (e.g., M-nM regime) which are 
among the key criteria in the field of bioconjugation.
7
 A more quantitative assessment of the rate 
constant was obtained using fluorescence quenching which is a very sensitive technique to study 
chemical and biological interactions (vide supra).
267
  
3.5.3.1 Synthesis 
 
The initial design of the target molecules used in the assay comprised a dabsyl quencher bearing a 
terminal hydroxylamine 2.49 (Scheme 3.17, panel A) and a 2-FPBA connected to a lissamine 
fluorophore 2.58 (Scheme 3.17, panel B) as a proof of principle.  
 
Scheme 3.17: (A) Preparation of dabsyl quencher 2.49: (a) O,O’-1,3-propanediylbishydroxylamine dihydrochloride, NEt3. 
(B) Synthetic attempt for the preparation of lissamine fluorophore 2.58: (a) Boc2O, NEt3; (b) 2-bromo-5-
hydroxybenzaldehyde, K2CO3; (c) CH2Cl2/TFA (1:1); (d) 2.53, NEt3, DMAP; (e) 2-bromo-5-hydroxybenzaldehyde, NEt3, 
DMAP; (f) bis-(pinacolato)diboron, NaOAc, Pd(dppf)Cl2; (g) pinacolborane, NEt3, Pd(P(
tBu)3)2. 
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The synthetic effort to isolate the desired components however turned out to be more challenging and 
time consuming as previously expected. While the dabsyl hydroxylamine 2.49 was isolated in a one-
step SN2 process
268
 from commercial dabysl chloride 2.48 and O,O’-1,3-propanediylbishydroxylamine 
dihydrochloride in moderate yield the fluorophore synthesis failed at its second last step. The primary 
amine 2.53 was synthesized in a three step synthesis from commercial 3-bromopropylamine 
hydrobromide (2.50). N-Boc protection was straightforward yielding almost quantitative amounts of 
2.51. Subsequent aromatic O-alkylation with 2-bromo-5-hydroxybenzaldehyde didn’t give full 
conversion after 21 h but yielded the aromatic N-Boc derivative 2.52 in 71% yield after two 
chromatographic purification cycles. Unfortunately the starting 2-bromo-5-hydroxybenzaldehyde co-
eluted with the desired product and decreased its purity by 10%. Although N-Boc deprotection of 2.52 
proceeded quickly with full conversion the isolated crude amine 2.53 showed a higher mass balance 
than expected. It is very likely that the TFA salt of 2.53 was isolated although the 
13
C-NMR spectrum 
lacked both TFA anion signals. Nonetheless the obtained product was further reacted with lissamine™ 
rhodamine B sulfonylchloride (2.54) employing DMAP-accelerated nucleophilic catalysis
269
 under 
basic conditions. Reaction controls by UPLC-MS indicated primarily hydrolyzed lissamine derivative 
along with unreacted starting amine 2.53 and the undesired side product 2.55 which is probably the 
thermodynamically favored species comparing the S-N (464 kJ/mol) and S-O (522 kJ/mol) bond 
energies.
270
 The addition of more equivalents of 2.53, NEt3 as well as increasing the reaction time 
(overnight) didn’t help formation of the envisioned product 2.57. Although the undesired sulfonate 
ester 2.55 could be prepared selectively in 50% yield it was attractive enough to serve as a test 
substrate for the final palladium-catalyzed MIYAURA borylation using bis-(pinacolato)diboron.
271
 
Unfortunately the reaction failed twice, even when elevated temperatures, extended reaction times (19 
h) and up to 50 mol% of Pd(dppf)Cl2 were used no conversion of the starting bromide 2.55 was 
observed. In a third attempt the borylation protocol developed by CHRISTOPHERSEN et al. using 
pinacolborane and Pd(P(
t
Bu)3)2 was applied.
272
 Reaction controls after several time intervals by 
UPLC-MS indicated a mixture of unreacted starting material, reduced aldehyde of 2.55 and the proto-
dehalogenated side product as the major species without any evidence for the desired boronic acid 
2.56. These results showed that although oxidative addition is achieved the transmetalation of the 
boron derivative is unfavored and the increase in reaction time leads to the observed 
protiodepalladation which is most affected for aldehyde substrates.
273
 
 
Since the final cross-coupling reaction turned out to be rather difficult with the deactivated sulfonate 
ester substrate 2.55 a more convenient approach was envisioned (Scheme 3.18). 
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Scheme 3.18: Synthetic sequence for the preparation of the fluorophore analogue 2.61: (a) bis-(pinacolato)diboron, KOAc, 
Pd(dppf)Cl2; (b) 2.54, NEt3. 
 
Lissamine boronic acid 2.61 was synthesized in very low yield starting from commercial 2-bromo-5-
hydroxybenzaldehyde (2.59) by a MIYAURA borylation and subsequent aromatic O-alkylation. The 
electron deficient boronic acid product was found to be prone to autoxidation resulting in the phenol 
2.62 after a few days. The concept of oxime formation between the quencher 2.49 and the fluorophore 
analogue 2.61 was tested in a UPLC-MS assay under neutral reaction conditions (Scheme 3.19). 
 
Scheme 3.19: UPLC-MS assay of the oxime condensation using 2-FPBA tagged fluorophore 2.61 and the hydroxylamine 
quencher 2.49. Reaction conditions: 100 M final concentration in both substrates in 100 mM KPi at pH = 7.2. The reaction 
was monitored at 254 nm by UPLC-MS tracing the disappearance of starting materials and formation of the oxime conjugate 
2.63. The inset shows the extracted ESI-MS spectra for the successful formation of 2.63 after 10 min. 
 
Mixing the two starting materials at equimolar concentrations of 100 M in 100 mM KPi and neutral 
pH afforded the desired oxime 2.63 in 10 minutes along with its oxidized oxime analogue (see Figure 
E11 in section 4.2.3.4). This result corroborated the suitability of this particular reaction in a kinetic 
fluorescence quench assay but indicated also the need for a more stable, synthetically accessible 
fluorophore at the same time. Therefore the 2-FPBA motif was envisioned to be installed into the 
dabsyl quencher containing a C3 linking unit via electron rich sulfonamide formation preventing the 
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boronic acid moiety from autoxidation. The hydroxylamine was considered to be easily introduced 
into the lissamine fluorophore counterpart in a single chemical transformation from commercial 
starting materials (Scheme 3.20). 
 
 
 
Scheme 3.20: (A) Synthetic sequences for the preparation of the 2-FPBA connected dabsyl quencher 2.65: (a) (a) (i) 
CH2Cl2/TFA (4:1); (ii) 2.48, NEt3; (b) bis-(pinacolato)diboron, NaOAc, Pd(PPh3)2Cl2. (B) Preparation of hydroxylamine-
containing lissamine fluorophore 2.66: (a) O,O’-1,3-propanediylbishydroxylamine dihydrochloride, NEt3. 
 
The target 2-FPBA equipped quencher 2.65 was synthesized in two steps. Initial N-Boc deprotection 
of carbamate 2.52 and subsequent sulfonamide formation afforded dabsyl precursor 2.64 in low yield. 
Palladium-catalyzed MIYAURA borylation followed by acidic preparative HPLC purification resulted 
finally in the free boronic acid-containing quencher 2.65 in moderate yield. We were delighted to 
discover that the product was air stable and didn’t decompose according to HPLC injections of 
aliquots over several days. Hydroxylamine-containing fluorophore 2.66 was obtained in a single 
chemical step by reacting lissamine™ rhodamine B sulfonylchloride (2.54) with O,O’-1,3-
propanediylbishydroxylamine dihydrochloride under basic conditions in 27% isolated yield. 
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3.5.3.2 Kinetic assay 
 
Recent work by us
213
 and others
225
 have shown that fluorescence quenching can be used as an indirect 
but quantitative technique for the determination of rate constants. The two promising substrates for 
oxime condensation 2.65 and 2.66 shown in Figure 3.13, panel A were tested using a fluorescence 
plate reader device. The decrease of the fluorescence signal was monitored at the maximum absorption 
of lissamine derivative 2.66 (566 nm) in 100 mM KPi at pH 7.2 after adding equimolar amounts of 2-
FPBA tagged dabsyl quencher 2.65. Initial experiments at 5 M, 2 M and 500 nM clearly indicated 
second order behavior of the reaction within the first 105 seconds as determined by inverse 
concentration plots (Figure 3.13, panel B). 
 
 
 
Figure 3.13: (A) General reaction scheme of the oxime condensation between lissamine fluorophore 2.66 and dabsyl 
quencher 2.65. (B) Fluorescence quench assay at 500 nM in 100 mM KPi at pH 7.2 and 26°C. • Data points recorded over 15 
min; • Data points within the linear region of the first 105 seconds fitted by an extrapolated trend line. Second order rate 
constant k was directly determined from the trend line slope and was uncorrected for the time and photobleching. 
 
An extrapolated trend line of the initial linear region indicated a second order rate constant of 3 x 10
4
 
M
-1
 s
-1
 which was considered vague according to the marginal collection of data points. This result 
suggested that monitoring at 100 nm would be required to obtain sufficient data at early reaction 
conversion. Additionally the crude set of data was uncorrected for the time between mixing the 
samples, recording of the first measurement (~30 sec) as well as for photobleaching (Figure 3.14, 
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panel A). The latter, being a dynamic and irreversible decomposition of the fluorescent molecule in its 
excited state, is due to interactions with molecular oxygen or surrounding molecules prior to emission. 
This often results in chemical damage or covalent modification and reduces the effective concentration 
of the fluorophore over time.
274
 To account for this photochemical alteration we performed a control 
reaction to determine fluorescence correction values caused by dabsyl-induced and lissamine 
photobleaching and to assure the validity of the respective fluorescence quench assay (Figure 3.14, 
panel B). 
 
Figure 3.14: (A) Schematic diagrams depicting the differences between the decay (left) and photobleaching process (right). 
After each pulsed excitation the intensity of the fluorescence emission rapidly decreases through a decay process which can 
be resolved on the time scale of nanoseconds. At continuous excitation of e.g. hydroxylamine substituted lissamine 2.66 a 
constant photobleaching effect can be observed on the time scale of microseconds to minutes. The photobleached lissamine 
fluorophore is highlighted in grey. (B) Reaction scheme of a control experiment using hydroxylamine substituted lissamine 
2.66 and hydroxylamine substituted dabsyl derivative 2.49 at 100 nM in 100 mM KPi at pH 5.00 and 26°C to determine the 
effect of dabsyl-induced phtobleaching. 
 
Having established correction values for the photobleaching process we next set up a series of rate 
measurements by fluorescence quenching of the oxime conjugate 2.67 varying the pH (Figure 3.15). 
Triplicate rate measurements at 100 nM showed excellent linearity in inverse concentration plots (see 
Figure 3.15, Figure E12 and Figure E13) with a rate constant of ~11,000 M
-1
 s
-1
 – several orders of 
magnitude faster than the fastest neutral pH oxime condensations.
208
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Although fluorescence quenching is an indirect measurement technique, HPLC injections of aliquots 
from the assay mixture showed only product and starting materials (indicating a clean reaction) and 
gave conversions qualitatively in agreement with the fluorescence measurements. In addition, the fact 
that 10 and 1 M reactions monitored by 1H-NMR showed >90% conversion at the earliest possible 
measurements (Figure 3.12) provides independent verification of a rate constant >10
4
 M
-1
 s
-1
 since the 
first half-life would have to be less than 90 seconds. The general pH dependence, with a maximum in 
the range of 4.5–5, is consistent with normal oxime formation201 except there is a distortion in the 
sigmoidal shape at higher pH (e.g. 7.2 & 8.1). The asymmetry in the pH dependence curve is inverted 
in comparison to a typical oxime condensation (acetone with hydroxylamine),
201
 which shows a more 
pronounced drop-off in rate at higher pH than at lower pH. Based on the build-up of a tetrahedral 
intermediate at higher pH, JENCKS attributed this pH dependence to the need for a proton in the 
dehydration step.
201
 Although we have thus far not been able to detect intermediates, we speculate that 
the near neutral pKa of amine-substituted aqueous boronates
240,275
 provides the ideal environment for 
acceleration of the normally rate-limiting dehydration. 
 
 
 
 
 
Figure 3.15: Fluorescence quenching assay at 100 nm and 26°C to determine rate constants and pH dependence. All 
measurements were done in triplicate and are corrected by subtracting a control measurement where everything was identical 
except that the dabcyl moiety lacked a 2-FPBA function. 
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3.5.4 Probing the effect of biological interfering additives 
 
In a subsequent set of experiments we explored the efficacy of the boron-assisted oxime ligation in the 
presence of common interfering additives (sugars, biothiols, proteins and human serum). As 
mentioned before it is important for a bioconjugation to proceed in complex environment when 
considered for practical applications or in vivo studies. The additives led to no detectable reduction in 
reaction efficiency with the exception of human serum (see Table 3.5).  
 
Table 3.5 Tolerance of the boron-assisted oxime condensation to biological interfering agents. 
 
 
Entry Addtive (conc.) 
Normalized 2.35 
integral 
[b]
 (%) 
Significance 
 
1 - 100 - 
2 Glutathione (5 mM) 98 Biothiols do not interfere 
3 
Sucrose (100 M & 5 
mM) 
106/92 
[c]
 Boron chelators do not interfere 
4 Lysozyme (100 M) 105 
Amino acid side-chains cannot compete 
with O-alkylhydroxylamine for 2-FPBA 
5 Human serum (20% v/v) 80 
[d]
 
Reaction is compatible with complex 
media 
 
[a] Time is approximate since samples are injected directly after mixing. [b] Determined by reverse phase HPLC analysis 
under neutral conditions. [c] This reaction was also performed by pre-mixing the boronic acid with the sucrose, with no 
measurable change in conjugation efficiency. [d] Human serum leads to oxidation of the boronic acid to a phenol probably 
through a Baeyer–Villiger type reaction.264 The 80% number represents only the measurement of 2.35, when the phenol is 
included nearly complete mass balance was observed. KPi = potassium phosphate buffer. 
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Interestingly in human serum the boronic acid in 2.35 partially oxidized to a phenol, leading to an 
apparent loss of material: after the first injection 80% of 2.35 were present while after 18 h only 20% 
remained (see Figure E8 in section 4.2.3.3). Even in the oxidized product, however, the oxime was 
still intact and if both components are added together the mass balance was nearly complete. 
Furthermore, lysozyme, which has previously been shown to react with 2-FPBA 2.34,
255
 showed no 
modification according to LC-MS, indicating that the O-alkylhydroxylamine entirely outcompetes 
nucleophilic amino acid functionalities for 2-FPBA 2.34 (see Figure E10 in section 4.2.3.3). 
 
 
3.5.5 Stability and reversibility tests 
 
As mentioned before a bioconjugation reaction ideally forms stable conjugates which do not 
decompose or hydrolyze under the conditions they are generated. To make a statement on the stability 
of the respective oxime bond under neutral conditions we performed continuous recordings of 
1
H-
NMR spectra of oxime 2.35 integrating and comparing its characteristic proton signals over time 
(Figure 3.16). A water soluble internal standard (IS = TMSP-d4) was used as reference and served for 
accurate integral comparisons. The NMR data collected over the course of three days led to little 
change in concentration (< 5%) as indicated by the respective oxime (blue), benzyl (red) and IS (pink) 
protons and corroborates the fact that this oxime conjugate is stable under the present conditions. 
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Figure 3.16: 1H-NMR stability test of a 100 M oxime 2.35 solution over the course of 72 h at pH 7.2. The change in 
concentration over the course of time was determined to be < 5% which lies within the accuracy of integration at 100 M. 
 
Next we were keen to get insights into the equilibrium process between oxime 2.35 and its starting 
materials. Therefore we added a five-fold excess of O-methylhydroxylamine to an NMR sample of 
oxime 2.35 and recorded continuous 
1
H-NMR spectra (Figure 3.17, panel A). As shown in panel B of 
Figure 3.17, O-methylhydroxylamine leads to a new oxime product 2.68, with equilibrium being 
established after 10–15 hours at 100 M in pH 7.2 phosphate buffer. Although the equilibrium 
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constant is too large to allow a static equilibrium measurement, k-1 can be calculated directly from the 
exchange rate between oximes 2.35 and 2.68 (4.2 ± 0.4 x 10
-5
 s
-1
). From this value and the k1 value 
obtained from fluorescence quenching (Figure 3.15) an equilibrium constant of 2.6 ± 0.3 x 10
8
 M
-1
 
can be estimated. The reversibility assay shown in panel A of Figure 3.17 would not be able to 
distinguish between hydrolysis and direct O-methylhydroxylamine attack; therefore we also ran the 
experiment by adding a different boronic acid to 2.35 instead of O-methylhydroxylamine (Figure 
3.18, panel A). A stack of selected 
1
H-NMR spectra is presented in panel B of Figure 3.18 and shows 
the process of oxime interconversion from 2.35 to 2.69 over 24 h. Within experimental error, the data 
clearly indicates the exchange of reaction partner which is only possible through initial oxime 
hydrolysis of 2.35. The liberated O-benzylhydroxylamine (2.4) is then able to undergo another oxime 
condensation with 2.60 to give oxime 2.69 as the major species after 24 h. This reaction pathway 
shows that the oxime equilibration takes place by oxime hydrolysis and subsequent condensation 
rather than a direct addition of the O-alkylhydroxylamine to the oxime. 
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Figure 3.17: (A) Qualitative reversibility scheme of oxime 2.35 which is treated with a five-fold excess of O-
methylhydroxylamine. The respective oxime protons Ha and Hb are highlighted for clearer differentiation. Conditions: 10 
mM KPi, pH 7.2 (D2O/CD3CN, 4:1), IS = TMSP-d4. (B) Quantitative reversibility test of oxime 2.35 and O-
methylhydroxylamine. Only six selected 1H-NMR time points are shown from a total of 30 measurements: zoomed region 
(8.28 - 8.34 ppm) of the oxime protons Ha and Hb. (C) full 
1H-NMR spectrum of the reaction mixture at different time points 
containing integration values (up- to downfield) for the internal standard, methyl group of methoxyamine, methyl group of 
the newly formed oxime 2.68, benzyl protons of 2.35 and the two different oxime protons Ha and Hb. 
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Figure 3.18: (A) Qualitative reversibility scheme of oxime 2.35 which was treated with a five-fold excess of aldehyde 2.60. 
The respective oxime protons Ha, Hb and aldehyde proton Hc are highlighted for clear differentiation. Conditions: 10 mM 
KPi, pH 7.2 (D2O/CD3CN, 4:1), IS = TMSP-d4. (B) Time dependent 
1H-NMR interconversion of oxime 2.35 to oxime 2.69. 
The 1H-NMR spectrum shows only the zoomed regions (7.8 - 10.3 ppm) of the relevant protons Ha, Hb and Hc. The 
equilibrium is reached after 10 h where the final ratio of 2.69 to 2.35 is 10:1. 
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3.5.6 Conclusions and outlook 
 
Herein we described that O-alkyliminoboronates form with remarkable speed and selectivity in neutral 
aqueous buffer at low substrate concentrations. The reaction is unaffected by proteins, carbohydrates, 
biothiols, human serum and has an equilibrium constant of >10
8
 M
-1
. A great advantage of the present 
method over many coupling reactions is the simplicity and ready availability of the starting materials. 
There are commercial libraries of phenylboronic acid and boronic ester compounds, many of which 
contain an aldehyde or can be trivially elaborated to incorporate one. Furthermore, the widespread use 
of oxime conjugations for connective processes at high concentration means that a variety of O-
alkylhydroxylamines are also available. A shortcoming of the present method in comparison to the 
classical oxime condensation is the size of required 2-FPBA motif. Although for most applications this 
should present no difficulties, examples where the compactness of the oxime is critical (such as, for 
example, as a functional isostere of peptide bonds)
276
 would not be possible. The ability to run 
conjugations at 1:1 ratios of partners at biological pH means that either or both components can be 
complex, precious materials. Although we have focused on oxime condensation for proof of concept 
the coordinating properties of boron in aqueous media could potentially be exploited to accelerate 
other important reactions whose rates are limited by the kinetics of Schiff base formation.
277
 
 
A potential application of this method could be its use in the filed of imaging or labeling as a “turn-
on” fluorescence probe. A non-fluorescent molecule equipped with a hydroxylamine and a boron 
chelator could be reacted with 2-FPBA (2.34) which after rapid oxime formation results in a 
fluorescent conjugate. This method would allow visualizing a target within seconds under neutral and 
aqueous conditions as shown in Figure 3.19. 
 
Figure 3.19: Schematic principle for a potential application of boron-assited oxime formation based on a “turn on” 
fluorogenic probe.  
 
BODIPY-based chelators are well known for the fluorescence imaging of biomolecules in living cells 
and represent a promising scaffold to test this hypothesis.
278
 These dyes, consisting of a difluoroboron-
dipyrromethane core, have outstanding properties e.g., high quantum yields contributing to the overall 
brightness, sharp excitation and emission bands as well as a reasonable stability to physiological 
conditions.
279,280
 Introducing new substituents on the BODIPY scaffold offers the possibility to built a 
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molecular structure capable to incorporate 2-FPBA (2.34) via oxime condensation and subsequent 
boron complexation to give a fluorescent dye (Scheme 3.21). 
 
Figure 3.21: Retrosynthetic analysis of a possible “turn-on” fluorescent BODIPY oxime target. The non-fluorescent 
dipyrromethene core can be prepared by a functionalized aldehyde and pyrrole. The reaction with a water soluble and azide 
equipped hydroxylamine gives access to the “clicked” triazole ready for rapid oxime condensation with 2-FPBA followed by 
an intramolecularly favoured boron complexation resulting in a fluorescent BODIPY dye. 
 
So far we were able to isolate the alkyne-containing dipyrromethane shown in Figure 3.21 but 
preliminary boron complexations in water led unfortunately to no fluorogenesis. In due course this 
project will be investigated in more detail and the need for the intramolecular hydroxylamine handle 
will provide valuble information on our hypothesis of a “turn-on” fluorescent BODIPY oxime. 
 
If we reconsider the oximes formed in the course of our studies, the boronic acid/ester group which is 
left behind could be used as a potential reactive group for subsequent Suzuki-Miyaura cross-coupling. 
DAVIS et al. demonstrated the ability to cross-couple boronic acid-containing molecules with proteins 
under aqueous, neutral conditions with excellent conversions in only 30 min.
243
 Despite the huge 
excess of boronic acid they used, further functional group manipulation would be very useful and 
informative with regards to other potential applications. 
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4 Experimental 
4.1 General Information 
 
All commercial reagents and solvents used were of analytical grade unless otherwise mentioned in the 
respective synthetic procedure and purchased from ABCR, Acros, Alfa Aesar, Apollo Scientific, 
Bachem, Fischer Chemicals, Fluorochem, Iris, Novabiochem, Sigma Aldrich or Strem. 1,4-dioxane 
was freshly distilled from sodium benzophenone ketyl under dry nitrogen prior to use. Buffers and 
HPLC eluents were prepared with Milli-Q water (electrical resistivity of 18.2 MΩcm) which was 
filtered through a Quantum® TEX polishing cartridge from Merck Millipore. Analytical TLC was 
performed on Silica gel 60 F254 pre-coated aluminium sheets (Merck) or glass plates (Merck) and 
visualized by fluorescence quenching under UV light at 254 nm or by staining with potassium 
permanganate and heating. Flash chromatography was performed on SilicaFlash® gel P60 40-63 µm 
(230-400 mesh) (SiliCycle, Quebec). Concentration under reduced pressure was performed by rotatory 
evaporation of solvents at 40°C (unless otherwise specified). Manual PNA synthesis was performed 
using Fmoc-protected rink amide AM resin (100-200 mesh) from NovaBiochem with an initial 
loading of 0.61 mmol/g. Couplings were performed using 2 mL polyethylene syringe (BD Discardit™ 
II) reactors equipped with a fritted disc and closed with a luer stopper (both parts from MultiSynTech 
GmbH, Witten, Germany). PNA monomers (Fmoc-A(Bhoc)-OH, Fmoc-C(Bhoc)-OH, Fmoc-G(Bhoc)-
OH and Fmoc-T-OH) were purchased from Panagene. Automated solid-phase oligonucleotide 
synthesis was carried out on an Expedite 8909 nucleic acid synthesizer (PerCeptiveBiosystems, 
Framingham, Ma, USA). Phosphoramidites for DNA synthesis (A
Bz
, G
dmf
, C
Ac
, T) were purchased 
from Proligo Reagents, SAFC. SynBase 500/110 AllFit pre-modified oligonucleotide synthesis 
columns, MeCN anhydrous wash, BTT activator, CapA, CapB and oxidizer for the Expedite device 
were purchased from Link Technologies. Automated solid-phase peptide synthesis (SPPS) was 
performed on a Syro I Peptide synthesizer (MultiSynTech GmbH, Witten, Germany) using the 
software SyroXP Peptide. 
1
H, 
13
C, 
31
P, 
19
F, 
11
B and 2D-NMR spectra were acquired on a 
BrukerAvance (250, 400, 500, 600 or 700 MHz proton frequency) spectrometer at 298.15 K unless 
otherwise mentioned. Chemical shifts ( values) relative to TMS are referenced to the solvent’s 
residual peak and reported in ppm. Multiplicities are reported as follows: s = singlet, sbr = broad 
singlet, d = doublet, t = triplet, q = quartet, quint. = quintet, m = multiplet or unresolved and coupling 
constant J in Hz. Low resolution ESI-MS spectra were recorded on a Bruker Esquire3000+ 
spectrometer by direct injection in positive or negative polarity of the ion trap detector. High 
resolution mass spectra (HRMS) were recorded by the mass spectrometric service of the University of 
Basel (Dr. Heinz Nadig) on a Bruker maXis 4G QTOF ESI mass spectrometer. The crystal structures 
of selected compounds were solved by the X-ray crystallographic service of the University of Basel on 
a Bruker Kappa Apex2 diffractometer at 123 K. Preparative flash column chromatography was 
performed either using an Isolera Four device (Biotage, Uppsala, Sweden) equipped with pre-loaded 
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silica gel cartridges and monitoring elution at 254/280 nm or by manual column chromatography using 
nitrogen pressure. The crude compound mixtures were either dry loaded by adsorption onto silica gel 
or directly applied as liquids using the eluent mixture. Analytical and micro-preparative RP-HPLC 
was carried out at room temperature on a Hewlett Packard 1100 Liquid Chromatograph or a Shimadzu 
Prominence UFLC Liquid Chromatograph system using a C18 column (Eclipse XDB, 5 m, 4.6 x 150 
mm) from Agilent with a flow rate of 1 mL/min monitoring and collecting the products at 254 nm or 
280 nm if not otherwise specified. Semi-preparative RP-HPLC was carried out on a Shimadzu VP 
Liquid Chromatograph using a C18 column (LiChroCART
®
, 5 m, 10 × 250 mm) from Merck with a 
flow rate of 5 mL/min monitoring and collecting the products at 254 nm or 280 nm if not otherwise 
specified. Detection was done by monitoring the absorbance of the column effluent at 254 nm. 
Preparative RP-HPLC was carried out at room temperature on a Shimadzu Prominence UFLC 
Preparative Liquid Chromatograph using a C18 column (Gemini NX5u, 110Å, AXIA, 250 x 21.2 mm) 
from Phenomenex with a flow rate of 20 mL/min monitoring and collecting the products at 254 nm if 
not otherwise specified. The crude compound mixtures were injected as DMSO solutions. UPLC-MS 
was carried out on an Agilent 1290 Infinity system equipped with an Agilent 6130 Quadrupole LC/MS 
using a C18 column (ZORBAX Eclipse Plus RRHD, 1.8 mx 50 mmfrom Agilent with a flow 
rate of 0.45 mL/min or 0.60 mL/min at 40°C. Elution was done with 0.1% (v/v) formic acid in H2O 
/10% (v/v) MeCN (A) and 0.1% (v/v) formic acid in MeCN/10% (v/v) H2O (B) using the following 
gradient: 5-90% (B) in 3.5 min, 90% (B) in 1 min, detection at 254/280 nm, ESI-MS in positive ion 
mode of the ion trap. MALDI-TOF-MS analyses were carried out on a Bruker Microflex or PerSeptive 
Biosystems Voyager mass spectrometer in linear positive or negative mode using 3-hydroxypicolinic 
acid/ammonium citrate buffer, pH 6.0 as the matrix. A Chirascan Plus device (Applied Photophysics 
Ltd, Leatherhead, UK) was used for CD measurements. The solutions were measured in a quartz cell 
with a path length of 10 mm (Hellma 110-QS). 
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4.2 Chemical synthesis 
 
4.2.1 Guided catalysts studies 
 
4.2.1.1 Synthesis of small molecules and dirhodium catalysts 
 
Compound 1.2 was prepared in analogy to a literature procedure by GAGNON et al.
281
  
Acid 1.5 (266 mg, 1.41 mmol, 1.00 eq.) and p-Nitrophenol (196 
mg, 1.41 mmol, 1.00 eq.) were dissolved in 6 mL of EtOAc. A 
DCC solution in EtOAc (323 mg, 1.57 mmol, 1.11 eq. in 4 mL) 
was added to the mixture at room temperature. The mixture was 
stirred for 4 h, filtered through Celite and the cake was washed with 
15 mL of EtOAc. The solvent was removed under reduced pressure to give 740 mg of a colorless 
solid. Upon re-dissolving the solid in 2 mL of EtOAc, dicyclohexylurea precipitated which was 
filtered off followed by solvent removal under reduced pressure to give 528 mg of a yellow oil which 
was 90% pure as determined by 
1
H-NMR. The crude was used without further purification for the 
subsequent peptide coupling.  
H2N-Glu(O
t
Bu)-OH (431 mg, 2.12 mmol, 1.50 eq.) and NEt3 (290 L, 2.12 mmol, 1.50 eq.) were 
dissolved in 10 mL of H2O using sonication and added to a solution of the p-Nitrophenyl ester (437 
mg, 1.41 mmol, 1.00 eq.) in MeCN (10 mL). The mixture turned immediately yellow and was stirred 
at room temperature for 24 h. Then the MeCN was removed under reduced pressure and the remaining 
aqueous solution was cooled to 0°C and acidified with 1M HCl until pH 2 was reached. The mixture 
was extracted with CH2Cl2 (4 x 10 mL) and the combined organics were washed once with brine (10 
mL) and H2O (10 mL). The organics were dried over MgSO4, filtered and the solvent removed under 
reduced pressure to give 825 mg of a slightly yellow oil. The crude was purified by flash 
chromatography (40:1 → 10:1 CH2Cl2/MeOH, ninhydrin stain) to afford acid 1.2 (299 mg, 801 mol, 
56%) as white crystalline solid. 
1
H-NMR (500 MHz, CDCl3) /ppm: 9.89 (sbr, 1H), 6.84 (d, J = 7.1 
Hz, 1H), 4.56-4-50 (m, 1H), 2.50-2.39 (m, 1H), 2.38-2-33 (m, 1H), 2.33-2.26 (m, 4H), 2.21-2.12 (m, 
1H), 2.05-1.96 (m, 1H), 1.95-1.87 (m, 2H), 1.44 (s, 9H), 1.43 (s, 9H). 
13
C-NMR (126 MHz, CDCl3) 
/ppm: 174.36, 173.66, 173.18, 172.92, 81.45, 80.80, 52.30, 35.36, 34.65, 31.84, 28.23, 28.17, 26.86, 
21.09. HRMS (ESI): C18H31NNaO7
+
 calcd.: 396.1993, found: 396.1995 [M+Na]
+
. 
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cis-Rh2(OAc)2(TFA)2 1.3: Compound 1.3 was synthesized in analogy to a 
literature procedure by LOU et al.
282
 
1
H-NMR (400 MHz, CDCl3) ppm: 2.54 (s, 3H), 1.98 (s, 3H). 
19
F-NMR (400 
MHz, CDCl3) ppm: -74.42. (This compound was synthesized and characterized 
by Prof. Dr. Dennis Gillingham). 
 
Compound 1.6 was prepared according to a literature procedure by LELAIS 
et al.
283
 The analytical data are in agreement with the values reported by 
BITAN et al.
284
 
1
H-NMR (500 MHz, CDCl3) ppm: 2.42 (t, J = 7.5 Hz, 2H), 2.30 (t, J = 7.5 Hz, 2H), 1.92 (quint., J = 
7.4 Hz, 2H), 1.45 (s, 9H). 
13
C-NMR (126 MHz, CDCl3) ppm: 179.11, 172.40, 80.68, 34.58, 33.14, 
28.24, 20.14. HRMS (ESI): C9H16NaO4
+
 calcd.: 211.0941, found: 211.0941 [M+Na]
+
. 
 
The synthesis and spectroscopic characterization of diester 1.11a and diacid 1.12a has been described 
by BONAR-LAW et al.
175
 
 
 
 
 
Triester 1.11b: A round bottom flask was charged with methyl 
3,5-dihydroxybenzoate (840 mg, 5.00 mmol, 1.00 eq.) and 
dissolved in 12 mL DMF. Then K2CO3 (2.76 g, 20.0 mmol, 4.00 
eq.), Cs2CO3 (1.63 g, 5.00 mmol, 1.00 eq.) and Ethyl 2-
bromoisobutyrate (3.72 mL, 25.0 mmol, 5.00 eq.) were added. The mixture was stirred at 80°C for 24 
h and allowed to cool down to room temperature. The mixture was poured into 50 mL H2O and 
extracted with Et2O (3 x 20 mL). The combined organics were consecutively washed with a 1M 
aqueous HCl solution (portions of 10 mL), H2O (20 mL), dried over Na2SO4, filtered and evaporated 
under reduced pressure. In order to remove the excess of Ethyl 2-bromoisobutyrate the obtained oil 
was heated to 50°C under high vacuum for 2 h to afford 1.11b (1.63 g, 4.10 mmol, 82%) as a pale 
yellow oil. 
1
H-NMR (400 MHz, CDCl3) ppm: 7.17 (d, J = 2.3 Hz, 2H), 6.59 (t, J = 2.3 Hz, 1H), 4.25 
(q, J = 7.1 Hz, 4H), 3.86 (s, 3H), 1.58 (s, 12H), 1.26 (t, J = 7.1 Hz, 6H). 
13
C-NMR (101 MHz, CDCl3) 
ppm: 173.9, 166.5, 156.3, 131.5, 115.4, 114.3, 79.8, 61.7, 52.4, 25.5, 14.2. HRMS (ESI): 
C20H28NaO8
+
 calcd.: 419.1677, found: 419.1676 [M+Na]
+
. 
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Triacid 1.12b: A round bottom flask was charged with 1.11b (300 
mg, 757 mol, 1.00 eq.) and dissolved in 5 mL THF. Then 5 mL 
H2O were added which resulted in a milky suspension. LiOH · 
H2O (953 mg, 230 mmol, 30.0 eq.) was added in one scoop and 
the mixture was heated to 60°C for 20 h. After cooling to room temperature 13 mL of a 2M aqueous 
HCl solution were added slowly and the mixture extracted with EtOAc (3 x 20 mL). The combined 
organics were dried over MgSO4, filtered and concentrated under reduced pressure to give a yellow 
oil. The crude product was then applied as a solution in DMSO (3 mL) on a 50g C-18 reverse phase 
column and eluted using a Biotage Isolera Four device (MeCN in H2O, 5-40% over 11 CV, eluted 
after 9 CV). The product fractions were lyophilized to afford 1.12b (190 mg, 583 mol, 77%) as a 
white semi solid. 
1
H-NMR (400 MHz, MeOD) ppm: 7.20 (d, J = 2.3 Hz, 2H), 6.67 (s, 1H), 1.58 (s, 
12H). 
13
C-NMR (101 MHz, MeOD) ppm: 177.3, 157.6, 133.3, 115.8, 115.0, 80.6, 25.7 (one carbon 
missing). HRMS (ESI): C15H18NaO8
+
 calcd.: 349.0895, found: 349.0894 [M+Na]
+
. 
 
 
Ketone 1.11c: A round bottom flask was charged with 3,5-
dihydroxyacetophenone (380 mg, 2.50 mmol, 1.00 eq.) and 
dissolved in 6 mL DMF. Then K2CO3 (1.38 g, 10.0 mmol, 4.00 
eq.), Cs2CO3 (800 mg, 2.50 mmol, 1.00 eq.) and Ethyl 2-
bromoisobutyrate (1.86 mL, 12.0 mmol, 5.00 eq.) were added. The mixture was stirred at 80°C 
overnight and allowed to cool down to room temperature. The mixture was poured into 50 mL H2O 
and extracted with Et2O (3 x 20 mL). The organic phase was consecutively washed with H2O (portions 
of 20 mL), dried over Na2SO4, filtered and evaporated under reduced pressure. The resulting brown oil 
was purified by flash chromatography (hexane/EtOAc 6:1) to afford 1.11c (775 mg, 2.04 mmol, 81%) 
as a colorless oil. 
1
H-NMR (500 MHz, CDCl3) ppm: 7.08 (d, J = 2.2 Hz, 2H), 6.55 (t, J = 2.2 Hz, 
1H), 4.25 (q, J = 7.1 Hz, 4H), 2.51 (s, 3H), 1.59 (s, 12H), 1.26 (t, J = 7.2 Hz, 6H). 
13
C-NMR (126 
MHz, CDCl3) ppm: 197.2, 173.9, 156.5, 138.6, 114.7, 113.0, 79.7, 61.8, 26.8, 25.5, 14.2. HRMS 
(ESI): C20H28NaO7
+
 calcd.: 403.1728, found: 403.1727 [M+Na]
+
. 
 
Diacid 1.12c: A round bottom flask was charged with ketone 1.11c 
(330 mg, 860 mol, 1.00 eq.) and dissolved in 4 mL MeOH. Then, 
2 mL of a solution containing LiOH · H2O (300 mg, 12.5 mmol, 
15.0 eq., in 2 mL H2O) was added. After heating the mixture for 3 
h at 60°C it was allowed to cool to room temperature and the reaction mixture was poured into 20 mL 
of a 1M aqueous HCl solution and extracted with EtOAc (3 x 20 mL). The combined organics were 
washed with H2O (20 mL), dried over Na2SO4, filtered and evaporated under reduced pressure to give 
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1.12c (280 mg, 860 mol, 99%) colourless crystals. 1H-NMR (500 MHz, DMSO-d6) ppm: 13.21 (s, 
2H), 7.01 (d, J = 2.3 Hz, 2H), 6.50 (t, J = 2.2 Hz, 1H), 2.49 (s, 3H), 1.52 (s, 12H). 
13
C-NMR (126 
MHz, DMSO-d6) ppm: 174.7, 156.2, 122.4, 111.0, 99.5, 97.4, 78.9, 26.7, 25.0. HRMS (ESI): 
C16H20NaO7
+ 
calcd.: 347.1102, found: 347.1101 [M+Na]
+
. 
 
Aldehyde 1.11d: A round bottom flask was charged with 3,5-
dihydroxybenzaldehyde (345 mg, 2.50 mmol, 1.00 eq.) and 
dissolved in 6 mL DMF. Then K2CO3 (1.38 g, 10.0 mmol, 4.00 
eq.), Cs2CO3 (800 mg, 2.50 mmol, 1.00 eq.) and Ethyl 2-
bromoisobutyrate (1.86 mL, 12.0 mmol, 5.00 eq.) were added. The mixture was stirred at 80°C 
overnight and allowed to cool down to room temperature. The mixture was poured into 50 mL H2O 
and extracted with Et2O (3 x 20 mL). The combined organics were consecutively washed with a 1M 
aqueous HCl solution (portions of 10 mL), H2O (portions of 20 mL), dried over Na2SO4, filtered and 
evaporated under reduced pressure. The resulting brown oil was purified by flash chromatography 
(hexane/EtOAc 6:1) to afford 1.11d (525 mg, 1.4 mmol, 56%) as a colorless oil. 
1
H-NMR (400 MHz, 
CDCl3) ppm: 9.83 (s, 1H), 6.97 (d, J = 2.3 Hz, 2H), 6.64 (t, J = 2.3 Hz, 1H), 4.25 (q, J = 7.1 Hz, 
4H), 1.60 (s, 12H), 1.25 (t, J = 7.1 Hz, 6H).
 13
C-NMR (101 MHz, CDCl3) ppm: 191.4, 173.8, 157.0, 
138.0, 116.3, 113.7, 79.9, 61.8, 25.5, 14.2. HRMS (ESI): C19H26NaO7
+ 
calcd.: 389.1576, found: 
389.1571 [M+Na]
+
. 
 
Diacid 1.12d: A round bottom flask was charged with 1.11d (525 
mg, 1.40 mmol, 1.00 eq.) and dissolved in 4 mL MeOH. Then, 2 
mL of a solution containing LiOH · H2O (300 mg, 12.5 mmol, 
9.00 eq., in 2 mL H2O) was added. After heating the mixture for 3 
h at 60°C a TLC control (5% MeOH/EtOAc) indicated full conversion of the diester 1.11d. The 
reaction mixture was poured into 20 mL of a 1M aqueous HCl solution and extracted with EtOAc (3 x 
20 mL). The combined organics were washed with H2O (20 mL), dried over Na2SO4, filtered and 
evaporated under reduced pressure to afford 1.12d (345 mg, 1.10 mmol, 79%) as a yellow oil. 
1
H-
NMR (400 MHz, CD2Cl2) ppm: 9.85 (s, 1H), 7.08 (d, J = 2.2 Hz, 2H), 6.59 (t, J = 2.2 Hz, 1H), 1.61 
(s, 12H). 
13
C-NMR (101 MHz, CD2Cl2) ppm: 191.8, 178.4, 156.9, 139.0, 115.4, 114.6, 80.1, 25.6. 
HRMS (ESI): C15H18NaO7
+
 calcd.: 333.0950, found: 333.0945 [M+Na]
+
. 
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Bromide 1.11e: A flame dried round bottom flask under N2 
atmosphere was charged with 3-Bromoresorcinol (200 mg, 1.06 
mmol, 1.00 eq.), Ethyl 2-bromoisobutyrate (780 L, 5.29 mmol, 
5.00 eq.) and dissolved in 3 mL dry DMF. Then K2CO3 (585 mg, 
4.23 mmol, 4.00 eq.) and Cs2CO3 (345 mg, 1.06 mmol, 1.00 eq.) were added. The slurry was 
subsequently immersed into a preheated oil bath at 80°C and stirred vigorously for 22 h. After cooling 
down to room temperature the mixture was poured into H2O (25 mL) and extracted with Et2O (3 x 20 
mL). The combined organics were then washed once with a 1M aqueous HCl solution (10 mL), H2O 
(20 mL), dried over MgSO4, filtered and concentrated under reduced pressure. The yellow oil was 
purified by flash chromatography (cyclohexane/EtOAc 9:1) to afford 1.11e (211 mg, 510 mol, 48%) 
as a colourless oil. 
1
H-NMR (400 MHz, CDCl3) ppm: 6.66 (d, J = 2.2 Hz, 2H), 6.28 (t, J = 2.2 Hz, 
1H), 4.24 (q, J = 7.1 Hz, 4H), 1.56 (s, 12H), 1.26 (t, J = 7.1 Hz, 6H).
 13
C-NMR (101 MHz, CDCl3) 
ppm: 173.81, 156.82, 122.05, 116.56, 109.16, 79.83, 61.75, 25.48, 14.18. HRMS (ESI): 
C18H25BrNaO8
+
 calcd.: 439.0727, found: 439.0726 [M+Na]
+
. (This compound was synthesized and 
characterized by Daniel Bachmann). 
 
Diacid 1.12e: A round bottom flask was charged with 1.11e (103 
mg, 247 mol, 1.00 eq.) and dissolved in 3 mL THF/H2O (1:1) 
resulting in a milky suspension. LiOH · H2O (207 mg, 4.94 mol, 
20.0 eq.) was added in one scoop and the mixture was heated to 
60°C for 13 h. After cooling to room temperature 3 mL of a 2M aqueous HCl solution were added 
slowly and the mixture transferred into a separation funnel. Extraction was performed with EtOAc (3 x 
10 mL) and the combined organics were dried over MgSO4, filtered and concentrated under reduced 
pressure to give a yellow oil. The crude product was then applied as a solution in DMSO (3 mL) on a 
50g C-18 reverse phase column and eluted using a Biotage Isolera Four device (MeCN in H2O, 
gradient 5-40% over 8 CV, elutes after 3 CV). The product fractions were lyophilized to afford 1.12e 
(89 mg, 207 mol, 84%) as a colorless oil. 1H-NMR (400 MHz, MeOD) ppm: 6.70 (d, J = 2.1 Hz, 
2H), 6.39 (t, J = 2.2 Hz, 1H), 1.56 (s, 12H). 
13
C-NMR (101 MHz, MeOD) ppm: 177.1, 158.3, 122.8, 
117.2, 110.0, 80.8, 25.7. HRMS (ESI): C14H17BrNaO6
+
 calcd.:  383.0101, found: 383.0104 [M+Na]
+
. 
(This compound was synthesized and characterized by Daniel Bachmann). 
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Alkyne 1.10f: A round bottom flask equipped with a stir bar was charged with 
propargyl bromide (80% in toluene, 600 L, 5.42 mmol, 1.08 eq.), K2CO3 (760 mg, 
5.50 mmol, 1.10 eq.) and dissolved in 2.2 mL DMF. Then phloroglucinol (637 mg, 
5.05 mmol, 1.00 eq.) dissolved in 3.6 mL DMF was added dropwise to the yellow 
suspension during 10 min. After heating the mixture to 60°C for 24 h a TLC 
control (cyclohexane/EtOAc 1:1) indicated full conversion of the phloroglucinol. The solid was 
filtered off, washed with DMF and the solvent was evaporated under reduced pressure. The remaining 
red brown oil was diluted with CH2Cl2 (15 mL) and a 1M aqueous HCl solution (10 mL) was added. 
The organic layer was separated and the aqueous layer was washed again with CH2Cl2 (2 x 10 mL). 
The combined organics were dried over MgSO4 filtered and concentrated under reduced pressure. The 
crude dark red oil was purified by flash chromatography (cyclohexane/EtOAc 3:1) to afford 1.10f (155 
mg, 651 mol, 13%, 69% purity) as a slightly orange oil and as a mixture of mono- and di-alkylated 
species. A pure analytical sample for characterization was obtained after preparative RP-HPLC 
purification as a white sticky semi solid. 
1
H-NMR (500 MHz, DMSO-d6) ppm: 9.25 (s, 2H), 5.86 (t, 
J = 2.1 Hz, 1H), 5.83 (d, J = 2.1 Hz, 2H), 4.63 (d, J = 2.4 Hz, 2H), 3.54 (t, J = 2.4 Hz, 1H). 
13
C-NMR 
(126 MHz, DMSO-d6) ppm: 159.1, 159.0, 96.1, 93.4, 79.6, 78.0, 55.2. HRMS (ESI): C9H8NaO3
+
 
calcd.: 165.0546, found: 165.0546 [M+Na]
+
. 
 
Diester 1.11f: A round bottom flask equipped with a stir bar was 
charged with alkyne 1.10f (155 mg, 651 mol, 69% purity, 1.00 
eq.) and Ethyl 2-bromoisobutyrate (690 L, 4.70 mmol, 7.22 eq.) 
in dry MeCN. While stirring K2CO3 (522 mg, 3.78 mmol, 5.80 
eq.) and Cs2CO3 (308 mg, 945 mol, 1.45 eq.) were added. The 
mixture was stirred at 80°C for 24 h. Then it was poured into a 2M aqueous HCl solution (5 mL) and 
EtOAc (5 mL) was added. The organic layer was separated and the aqueous layer extracted with 
EtOAc (3 x 5 mL). The combined organics were washed with H2O (5 mL), dried over MgSO4 filtered 
and concentrated under reduced pressure. The crude brown oil was purified by flash chromatography 
(cyclohexane/EtOAc 9:1) to afford diester 1.11f (122 mg, 311 mol, 48%). 1H-NMR (500 MHz, 
CDCl3) ppm: 6.16 (d, J = 2.1 Hz, 2H), 5.99 (t, J = 2.2 Hz, 1H), 4.24 (q, J = 7.0 Hz, 4H), 2.51 (t, J = 
2.5 Hz, 1H), 1.56 (s, 12H), 1.25 (t, J = 7.1 Hz, 6H). 
13
C-NMR (126 MHz, CDCl3) ppm: 174.2, 158.8, 
156.9, 103.8, 102.8, 100.6, 79.5, 75.7, 61.6, 56.0, 25.5, 14.2. HRMS (ESI): C21H28NaO7
+
 calcd.: 
415.1727, found: 415.1726 [M+Na]
+
. 
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Diacid 1.12f: A round bottom flask equipped with a stir bar was 
charged with diester 1.11f (116 mg, 296 mol, 1.00 eq.) and 
dissolved in 4 mL MeOH. A solution of LiOH · H2O (333 mg, 
7.94 mmol, 26.0 eq.) in H2O (2 mL) was added. After heating the 
mixture for 3 h at 60°C a TLC control (cyclohexane/EtOAc 3:1) 
indicated the full conversion of the diester. The reaction mixture was poured into a 1M aqueous HCl 
solution (5 mL) and extracted with EtOAc (3 x 5 mL). The combined organic phases were washed 
with H2O (5 mL) dried over MgSO4 and evaporated under reduced pressure. The product 1.12f (96.0 
mg, 285 mol, 93%) was isolated as a colourless oil. 1H-NMR (500 MHz, DMSO-d6) : 13.07 (s, 2H), 
6.06 (d, J = 2.1 Hz, 2H), 5.89 (t, J = 2.3 Hz, 1H), 4.69 (d, J = 2.7 Hz, 2H), 3.58 (t, J = 2.5 Hz, 1H), 
1.49 (s, 12H). 
13
C-NMR (126 MHz, DMSO-d6) : 174.8, 158.3, 156.6, 78.6, 78.4, 55.5, 25.1 (three 
carbon signals missing). HRMS (ESI): C17H20NaO7
+
 calcd.: 359.1102 found: 359.1101 [M+Na]
+
. 
 
The synthesis and spectroscopic characterization of dirhodium dicarboxylate (1.13) has been described 
by BONAR-LAW et al.
184
  
Rhodium complex 1.13: A dry round bottom flask under a N2 atmosphere was 
charged with Rh2(OAc)4 (156 mg, 348 mol, 1.00 eq.), 1.12a (98.2 mg, 348 
mol, 1.00 eq.) and dissolved in 15.6 mL N,N-dimethylaniline. The mixture was 
stirred at 140°C for 3 h and allowed to cool down to room temperature. Then 
the mixture was extracted first with CH2Cl2 (50 mL) followed by MeCN (3 
mL). In order to remove excess of N,N-dimethylaniline, the organic phase was 
extracted with a 2M aqueous HCl solution (3 x 90 mL) and washed with H2O (2 
x 100 mL). The combined organics were dried over Na2SO4, filtered and concentrated under reduced 
pressure to give a blue oil. The crude was purified by flash chromatograpy on 17 g of silica gel to elute 
first the bis-adduct (CH2Cl2/EtOAc: 95:5) 1.17 (23.0 mg, 30.0 mol, 10%) followed by 1.13 after 
changing the gradient (CH2Cl2/EtOAc: 90:10). The product fractions were combined to afford 1.13 
(125 mg, 210 mol, 60%) as a green solid. 
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Rhodium complex 1.14: A dry round bottom flask under a N2 atmosphere was 
charged with cis-Rh2(OAc)2(TFA)2
282
 (30.0 mg, 54.6 mol, 1.00 eq.) and 
subsequently dissolved in 3 mL 1,2-dichloroethane. Then triacid 1.12b (18.0 
mg, 54.6 mol, 1.00 eq.) was added followed by a dropwise addition of 0.6 
mL dry EtOAc to dissolve the ligand upon sonication. The green/blue solution 
was then immersed into a preheated oil bath at 60°C and stirred for 16 h. 
After cooling down to room temperature all volatiles were removed under 
reduced pressure. The crude solid was then applied as a solution in DMSO (1 
mL) to preparative RP-HPLC (MeCN/0.1% TFA in H2O, 2% to 50% over 28 min, tR = 26 min, 254 
nm). The product eluted as a purple liquid. The corresponding product fractions were lyophilized to 
afford 1.14 (11.0 mg, 17.0 mol, 31%) as a green solid. 1H-NMR (400 MHz, 5% v/v MeOD in 
CD2Cl2) ppm: 7.16 (d, J = 2.3 Hz, 2H), 6.20 (t, J = 2.3 Hz, 1H), 1.87 (s, 6H), 1.37 (s, 12H). 
13
C-
NMR (101 MHz, 5% v/v MeOD in CD2Cl2) ppm: 192.9, 192.0, 168.4, 156.4, 132.4, 116.9, 114.1, 
81.4, 25.1, 23.7. HRMS (ESI): C19H22NaO12Rh2
+
 calcd.: 670.9119, found: 670.9112 [M+Na]
+
. 
 
Rhodium complex 1.15: A dry round bottom flask under a N2 atmosphere was 
charged with diacid 1.12e (20.0 mg, 55.5 mol, 1.00 eq.) as a solution in EtOAc 
and all volatiles were subsequently removed under reduced pressure. Then 2 mL 
of 1,2-dichloroethane were added followed by cis-Rh2(OAc)2(TFA)2
282
 (30 mg, 
54.7 mol, 1.00 eq.). The green solution was immersed into a preheated oil bath 
at 60°C and stirred for 7 h. At this time most of the ligand was consumed and 
the amount of side products was lowest compared to the desired complex 1.15. 
After cooling to room temperature all volatiles were removed under reduced 
pressure. The crude green solid was then applied as a solution in DMSO (1 mL) to preparative RP-
HPLC (MeCN/0.1% TFA in H2O, 2% to 70% over 28 min, tR = 27 min, 254 nm). The product eluted 
as a purple liquid. The corresponding product fractions were lyophilized to afford 1.15 (10.0 mg, 14.7 
mol, 27%) as a green solid. Excess cis-Rh2(OAc)2(TFA)2 (3 mg, tR = 26 min) could be re-isolated.
 
1
H-NMR (500 MHz, 5% v/v MeOD in CDCl3 ) ppm: 6.67 (d, J = 2.1 Hz, 2H), 5.93 (t, J = 2.1 Hz, 
1H), 1.89 (s, 6H), 1.36 (s, 12H). 
13
C-NMR (126 MHz, 5% v/v MeOD in CDCl3) ppm: 192.5, 191.7, 
156.4, 121.8, 118.1, 107.7, 81.1, 25.0, 23.6. HRMS (ESI): C18H21BrNaO10Rh2
+
 calcd.: 704.8320, 
found: 704.8311 [M+Na]
+
. 
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Rhodium complex 1.16: A dry round bottom flask under a N2 atmosphere was 
charged with 1.12d (23.0 mg, 73.0 mol, 1.00 eq.) as a solution in EtOAc and 
all volatiles were subsequently removed under reduced pressure. Then 12 mL 
of 1,2-dichloroethane were added followed by cis-Rh2(OAc)2(TFA)2
282
 (80.0 
mg, 150 mol, 2.00 eq.). The green-blue solution was immersed into a 
preheated oil bath at 70°C and stirred for 2 h. A 
1
H-NMR aliquot suggested 
full conversion of the ligand. Thus, all volatiles were removed under reduced 
pressure to give a green solid. The crude product was then applied as a solution 
in DMSO (2 mL) to preparative RP-HPLC (MeCN/0.1% TFA in H2O, 2% to 70% over 25 min, tR = 
23 min, 254 nm). The product eluted as a purple liquid. The corresponding product fractions were 
lyophilized to afford 1.16 (16.0 mg, 25.3 mol, 35%) as a green solid. Excess cis-Rh2(OAc)2(TFA)2 
(27 mg, tR = 26 min) could be re-isolated. 
1
H-NMR (400 MHz, 5% v/v MeOD in CD2Cl2) ppm: 9.83 
(s, 1H), 7.00 (d, J = 2.2 Hz, 2H), 6.22 (t, J = 2.2 Hz, 1H), 1.87 (s, 6H), 1.39 (s, 12H). 
13
C-NMR (101 
MHz, 5% v/v MeOD in CD2Cl2) ppm: 192.8, 192.2, 192.0, 157.1, 138.5, 116.2, 115.1, 81.6, 25.2, 
23.7. HRMS (ESI): C19H22NaO11Rh2
+
 calcd.: 654.9164, found: 654.9163 [M+Na]
+
. 
 
Dirhodium tetracarboxylate 1.17 was prepared according to the synthesis protocol of ESPINO et al. 
174
 
The chelate was synthesized by reacting Rh2(TFA)4 (50.0 mg, 77.2 mol, 1.00 
eq.) with six equivalent portions of diacid 1.12a (43.0 mg, 152 mol in total, 
2.00 eq.) in 1.5 mL 1,2-dichloroethane at 130°C for a total of 3 h. A TLC 
control (cyclohexane/EtOAc 1:1) indicated full conversion of the Rh2(TFA)4. 
The solvent was removed under reduced pressure to give a green solid (80.0 
mg) which was purified by flash chromatography (cyclohexane/EtOAc 9:1). 
First the mono-substituted complex 1.13 (12.0 mg, 19.9 mol, 26%) was 
isolated as a green solid followed by dirhodium tetracarboxylate 1.17 (46.0 
mg, 60.0 mol, 78%) as a green solid. 1H-NMR (400 MHz, CD2Cl2) ppm: 
7.11 (t, J = 8.2 Hz, 2H), 6.52 (dd, J = 8.2, 2.1 Hz, 4H), 5.91 (t, J = 2.3 Hz, 2H), 1.39 (s, 24H). 
13
C-
NMR (101 MHz, CD2Cl2) ppm: 194.4, 156.4, 130.0, 115.2, 108.8, 81.2, 25.3. HRMS (ESI): 
C28H32NaO12Rh2
+
 calcd.: 788.9923, found: 788.9896 [M+Na]
+
. 
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Dirhodium tetracarboxylate 1.18 was prepared according to the synthesis protocol of dirhodium 
tetracarboxylate 1.19. 
The chelate was synthesized by reacting dirhodium carboxylate 1.14 (35.0 
mg, 54.0 mol, 1.00 eq.) with three equivalent portions of diacid 1.12c 
(19.0 mg, 58.6 mol in total, 3.00 eq.) in 1,2-dichloroethane (1.5 mL) at 
130°C for a total of 105 min. A TLC control (cyclohexane/EtOAc 1:1) 
indicated full conversion of the dirhodium carboxylate 1.14. Upon cooling 
down the mixture to room temperature a green solid precipitated (26.0 mg). 
The supernatant was collected and the solvent was evaporated under 
reduced pressure to give 30 mg of a green solid. ESI-MS analysis indicated 
unreacted diacid 1.12c as well as Rh2(OAc)4(N,N-dimethylaniline)2. ESI-
MS analysis of the remaining green precipitate indicated the desired product 
mass along with some impurities. The crude was purified by flash 
chromatography (cyclohexane/EtOAc 4:1 to 1:2) to afford dirhodium tetracarboxylate 1.18 (12.0 mg, 
14.0 mol, 26%) as a pale blue solid. 1H-NMR (600 MHz, 5% v/v MeOD in CD2Cl2) ppm: 7.17 (d, 
J = 2.3 Hz, 2H), 7.07 (d, J = 2.2 Hz, 2H), 6.15 (t, J = 2.3 Hz, 1H), 6.12 (t, J = 2.2 Hz, 1H), 2.50 (s, 
3H), 1.37 (s, 12H), 1.37 (s, 12H). 
13
C-NMR (151 MHz, 5% v/v MeOD in CD2Cl2) ppm: 197.7, 
193.6, 167.8, 156.6, 156.4, 139.3, 132.1, 116.8, 115.0, 113.8, 113.3, 81.4, 81.4, 30.3, 27.1, 25.2, 25.2. 
HRMS (ESI): C31H34NaO15Rh2
+ calcd.: 874.9922, found: 874.9900 [M+Na]+. 
 
Dirhodium tetracarboxylate 1.19 was prepared according to a slightly modified procedure described by 
DU BOIS et al.
174
 
A 4 mL microwave vial equipped with a stirring bar was charged with 
dirhodium complex 1.13 (72.0 mg, 119 mol, 1.00 eq.) and dissolved in 1.5 
mL 1,2-dichloroethane. To this solution was added diacid 1.12c (16.0 mg, 49.1 
mol, 0.34 eq.) and the vial was sealed with the corresponding cap and heated 
to 130°C in an oil bath. After 35 min the vial was removed from the oil bath 
and cooled down to room temperature in a H2O bath. Another portion of diacid 
1.12c (14.0 mg, 42.9 mol, 0.31 eq) was added before resealing the vial. The 
mixture was heated to 130°C for another 35 min, cooled down to room 
temperature and charged with the third portion of diacid 1.12c (15.0 mg, 46.0 
mol, 0.33 eq), sealed and heating was resumed at 130°C for another 35 min. 
After the mixture was allowed to cool down to room temperature the solvent was evaporated under 
reduced pressure to give a dark green solid which was purified by flash chromatography 
(cyclohexane/EtOAc 4:1 to 2:3). A light green solid was isolated (76 mg) which was purified again by 
flash chromatography (cyclohexane/EtOAc 9:1 to 1:1). Three green bands were isolated where the 
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second one was identified as the desired product. Dirhodium tetracarboxylate 1.19 (39.0 mg, 48.3 
mol, 41%). 1H-NMR (400 MHz, DMSO-d6) ppm: 7.10 (t, J = 8.0 Hz, 1H), 7.05 (d, J = 2.2 Hz, 2H), 
6.49 (dd, J = 8.1, 2.3 Hz, 2H), 6.03 (t, J = 2.2 Hz, 1H), 5.83 (t, J = 2.3 Hz, 1H), 2.51 (s, 3H), 1.31 (s, 
12H), 1.28 (s, 12H). 
13
C-NMR (101 MHz, DMSO) ppm: 197.2, 193.1, 192.6, 155.6, 155.4, 138.6, 
129.4, 114.8, 114.4, 112.5, 108.5, 80.6, 80.1, 26.9, 24.5, 24.4 (one carbon missing). HRMS (ESI): 
C30H34NaO13Rh2
+ 
calcd.: 831.0024, found: 831.0002. calcd.: 788.9923, found: 788.9896 [M+Na]
+
. 
 
Serine methylether 1.33 was prepared according to LY et al.
188
  Spectroscopic data was in agreement 
with their published data. 
It is noteworthy to mention that the crude product was purified by 
flash chromatography using 2.5-10% MeOH in CH2Cl2. 
1
H-NMR 
(400 MHz, CDCl3) ppm: 5.59 (d, J = 6.8 Hz, 1H), 4.46-4.37 (m, 
1H), 3.98-3.89 (m, 1H), 3.78-3.69 (m, 2H), 3.67-3.56 (m, 7H), 3.41 (s, 3H), 1.45 (s, 9H). LRMS 
(FAB): C13H25NNaO7
+
 calcd.: 330.1, found: 330.1 [M+Na]
+
, C13H26NO7
+
 calcd.: 308.2, found: 308.1 
[M+H]
+
.  
 
Primary alcohol 1.34 was prepared according to LY et al.
188
  Spectroscopic data was in agreement with 
their published data. 
It is noteworthy to mention that the crude product was purified by 
flash chromatography using 2:1 EtOAc/cyclohexane and later 5% 
MeOH in EtOAc. 
1
H-NMR (400 MHz, CDCl3) ppm: 5.26 (sbr, 
1H), 3.85-3.71 (m, 2H), 3.70-3.61 (m, 9H), 3.57-3.53 (m, 2H), 3.39 (s, 3H), 1.45 (s, 9H). LRMS 
(FAB): C13H28NO6
+
 calcd.: 294.2, found: 294.2 [M+H]
+
, C8H20NO4
+
 calcd.: 194.1, found: 194.1 [M-
C5H8O2]
+
. 
 
Nosyl sulfonamide 1.35 was prepared in analogy to LY et al.
188
   
To a stirred, cold solution of 1.40 (1.12 g, 4.09 mmol, 
1.00 eq.), triphenylphosphine (1.07 g, 4.91 mmol, 1.00 
eq.), and compound 1.34 (1.20 g, 4.09 mmol, 1.00 eq.) in 
dry THF (8 mL) under an inert atmosphere was added 
DEAD (1.86 mL, 4.09 mmol, 1.00 eq., 40% in toluene) 
dropwise over a period of 30 min at 0°C. The reaction mixture was allowed to warm to room 
temperature and then stirred for 14 h. The solvent was evaporated, and the oily residue was purified by 
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flash chromatography (1:1 EtOAc/cyclohexane) to give 1.35 (1.51 g, 2.75 mmol, 67%) as a yellow oil. 
1
H-NMR (400 MHz, CDCl3) ppm: 8.12-8.03 (m, 1H), 7.72-7.66 (m, 2H), 7.61-7.57 (m, 1H), 5.15 (d, 
J = 8.4 Hz, 1H), 4.45-4.34 (m, 1H), 4.26-4.17 (m, 1H), 3.95-3.85 (m, 1H), 3.71-3.46 (m, 15H), 3.39 (s, 
3H), 1.45 and 1.42 (2 x s, 9H, rotamers). Mass spectrometry was unsuccessful although electron 
impact (EI) and FAB ionization were used. 
 
Methyl ester 1.36 was prepared in analogy to FUKUYAMA et al.
285
  
An oven dried 4 mL vial, equipped with a magnetic 
stirring bar and a rubber septum was charged with 
thiophenol (345 L, 3.38 mmol, 2.50 eq.) and dissolved in 
MeCN (1 mL) under an N2 atmosphere. While cooling with an ice bath, a solution of KOH(aq) (10.9 M, 
2.50 eq.) was added at once and the mixture allowed to warm up to room temperature. Then a solution 
of 1.35 (743 mg, 1.35 mmol, 1.00 eq.) dissolved in MeCN (1 mL) was added dropwise over 2 min. 
The reaction was heated to 50°C for 1 h (TLC, 10% MeOH/CH2Cl2 indicated full conversion), cooled 
to room temperature, diluted with 5 mL of H2O and extracted with CH2Cl2 (3 x 10 mL). The combined 
organics were washed with 5 mL brine, dried over MgSO4 and concentrated under reduced pressure to 
give 1.06 g of a yellow malodorous oil. The crude was purified by flash chromatography (1% 
MeOH/CH2Cl2 to 10% MeOH/CH2Cl2) to give 1.36 (518 mg, 1.42 mmol, 105%, containing 
approximately 6% of PPh3=O) as a light yellow oil. Therefore the yield can be given as 99%. 
1
H-NMR 
(400 MHz, CDCl3) ppm: 5.16 (sbr, 1H), 3.84-3.39 (m, 15H), 3.38 (2 x s, 3H, rotamers), 2.82 and 2.72 
(2 x dd, J = 6.0 Hz, 2H, rotamers), 1.75 (sbr, 2H), 1.44 (2 x s, 9H, rotamers). LRMS (FAB): 
C16H32N2NaO7
+
 calcd.: 387.2, found: 387.2 [M+Na]
+
, C16H33N2O7
+
 calcd.: 365.2, found: 365.2 
[M+H]
+
, C11H25N2O5
+
 calcd.: 265.2, found: 265.2 [M-C5H8O2]
+
. 
 
Amide 1.37 was prepared in analogy to BIALY et al.
286
 
To a solution of 1.42 (230 mg, 1.25 mmol, 1.10 eq.) and 
1.36 (415 mg, 1.14, 1.00 eq.) in 4 mL of dry DMF at 0°C 
was added PyBrop (559 mg, 1.14 mmol, 1.00 eq.) and 
DIPEA (395 L, 2.28 mmol, 2.00 eq.). The ice bath was 
removed and the reaction was stirred at room temperature 
for 4.5 h (TLC, 10% MeOH/CH2Cl2 indicated full 
conversion of the amine). The solvent was evaporated under reduced pressure and dried under high 
vacuum over night. The next day the crude turbid residual oil was dissolved in 15 mL CH2Cl2 and 
extracted with 1 M KHSO4 (15 mL), 10% NaHCO3 (15 mL) and brine (15 mL). The combined 
organics were re-extracted with H2O (5 mL), dried over MgSO4 and concentrated to give 1.02 g of a 
yellow oil. The crude product was then applied on a 50g C-18 reverse phase column and eluted using a 
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Biotage Isolera Four device (MeCN in H2O, 0-40% over 13 CV). The product fractions were 
lyophilized to afford 1.37 (321 mg, 605 mol, 53%) as a white solid. 1H-NMR (400 MHz, DMSO-d6) 
ppm: 11.29 (s, 1H), 7.31-7.21 (m, 1H), 6.91-6.57 (2 x d, J = 8.4 Hz, 1H), 4.75-4.39 (2 x q, J = 16.7 
Hz, 2H), 4.34 (s, 1H), 4.14-4.05 (m, 1H), 4.04-3.95 (m, 1H), 3.89-3.78 (m, 1H), 3.72 (s, 1H), 3.62 (s, 
2H), 3.59-3.45 (m, 8H), 3.44-3.35 (m, 3H), 3.35-3.25 (m, 3H), 3.23 and 3.22 (2 x s, 3H, rotamers), 
1.75 (s, 3H), 1.38 and 1.37 (2 x s, 9H, rotamers). Please note that there are too many proton signals (41 
instead of 38) and it was not clear to us which signals don’t belong to the product. It is assumed that 
the signal at 3.33 ppm where residual H2O would resonate in DMSO-d6 has a bigger integral and 
potentially contributes to the additional protons since it overlaps with product signals. UPLC-MS 
(ESI): tR = 2.714 min, C23H38N4NaO10
+
 calcd.: 553.2, found: 553.3 [M+Na]
+
, C18H31N4O8
+
 calcd.: 
431.2, found: 431.2 [M-C5H8O2]
+
.  
 
Carboxylic acid 1.38 was prepared in analogy to BIALY et al.
286
 
Amide 1.37 (334 mg, 630 mol, 1.00 eq.) was dissolved in 
3.5 mL of MeOH followed by the addition of 3.5 mL of a 
2M Cs2CO3 solution at room temperature. The reaction 
mixture was then stirred for 2 h (TLC, 5% MeOH/CH2Cl2 
indicated full conversion). After the MeOH was evaporated 
under reduced pressure 5 mL of H2O were added. The 
mixture was then extracted with EtOAc (3 x 10 mL). The combined aqueous layers were acidified at 
0°C with 5% HCl to pH ~1-2 and then extracted with EtOAc (4 x 15 mL), dried over MgSO4, filtered 
and concentrated under reduced pressure to give 200 mg of a white solid after extensive drying under 
high vacuum over night. 
1
H-NMR and UPLC-MS analysis indicated the desired product 1.38 (200 mg, 
387 mol, 61%) which was clean enough for further usage. 1H-NMR (400 MHz, DMSO-d6) ppm: 
12.58 (sbr, 1H), 11.29 (s, 1H), 7.28 and 7.25 (2 x s, 1H, rotamers), 6.87 and 6.67 (2 x d, J = 8.6 Hz, 1H, 
rotamers), 4.66 (q, J = 16.4 Hz, 2H), 4.50-4.42 (m, 1H), 4.22 (s, 1H), 4.02-3.88 (m, 1H), 3.87-3.70 (m, 
1H), 3.58-3.45 (m, 7H), 3.44-3.34 (m, 3H), 3.31-3.25 (m, 1H), 3.23 and 3.22 (2 x s, 3H, rotamers), 
1.91 (s, 1H), 1.75 (s, 3H), 1.37 (s, 9H). LRMS (ESI): C22H35N4O10
-
 calcd.: 515.2, found: 515.3 [M-H]
-
. 
UPLC-MS (ESI): tR = 2.279 min, C22H36N4NaO10
+
 calcd.: 539.2, found: 553.3 [M+Na]
+
, C17H29N4O8
+
 
calcd.: 417.2, found: 417.2 [M-C5H8O2]
+
.  
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osyl sulfonamide 1.40 was prepared according to FUKUYAMA et al.287 Spectroscopic data was in 
agreement with their published data. 
1
H-NMR (500 MHz, CDCl3) ppm: 8.12-8.07 (m, 1H), 7.97-7.91 (m, 1H), 
7.78-7.71 (m, 2H), 6.04 (t, J = 5.5 Hz, 1H), 4.03 (d, J = 5.9 Hz, 2H), 3.61 
(s, 3H). 
13
C-NMR (126 MHz, CDCl3) ppm: 169.1, 134.1, 133.8, 133.1, 
130.7, 125.8, 52.7, 44.9. LRMS (FAB): C9H11N2O6S
+
 calcd.: 275.0, found: 
275.0 [M+H]
+
. 
  
Thymine-1-acetic acid 1.42 was prepared according to KATRITZKY et al.
133
 Spectroscopic data was in 
agreement with their published data. 
1
H-NMR (500 MHz, CDCl3) ppm: 13.13 (sbr, 1H), 11.34 (s, 1H), 7.49 (s, 1H), 4.36 
(s, 1H), 1.75 (s, 3H). LRMS (ESI): C7H8N2NaO4
+
 calcd.: 207.0, found: 206.9 
[M+Na]
+
, C7H9N2O4
+
 calcd.: 185.0, found: 184.9 [M+H]
+
. 
 
 
Compound 1.49 was prepared in analogy to a literature procedure by MAYNAR et al.
288
 
In a flame dried flask under N2 atmosphere, 2-bromoethanol (1.47) (300 L, 4.11 
mmol, 1.00 eq.) and tert-butyl N-hydroxycarbamate (1.48) (1.15 g, 8.21 mmol, 
2.00 eq.) were dissolved in 10 mL of dry CH2Cl2. Then DBU (614 L, 4.11 mmol, 1.00 eq., filtered 
over neutral aluminum oxide) was added dropwise and the mixture stirred for 72 h at room 
temperature. Next, it was diluted with another 10 mL of CH2Cl2 and extracted with H2O (3 x 10 mL). 
The combined organics were dried over MgSO4, filtered and concentrated under reduced pressure to 
give 323 mg of a slight yellow oil. Since the mass balance was too low, the aqueous phase was 
concentrated (50°C, 23 mbar) and the organic residue combined with the first portion to give 2.64 g of 
a slight yellow oil. The crude was purified by flash chromatography (cyclohexane/EtOAc 4:1 to 1:1) 
to afford 1.49 (511 mg, 2.88 mmol, 70%) as a colorless oil. TLC (cyclohexane/EtOAc, 2:1, KMnO4) 
Rf = 0.14. 
1
H-NMR (500 MHz, CDCl3) ppm: 7.22 (sbr, 1H), 3.92-3.89 (m, 2H), 3.75-3.72 (m, 2H), 
1.49 (s, 9H). 
13
C-NMR (126 MHz, CDCl3) ppm: 158.72, 82.87, 78.42, 59.57, 28.27. HRMS (ESI): 
C7H15NNaO4
+
 calcd.: 200.0893, found: 200.0894 [M+Na]
+
. 
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Compound 1.50 was prepared in analogy to a literature procedure by YEUNG et. al.
289
  
To an ice-cold, stirred suspension of NaH (24.0 mg, 600 mol, 3.54 eq., 
60% in mineral oil) in dry THF (300 L) was added a solution of 
alcohol 1.49 (30.0 mg, 169 mol, 1.00 eq.) in dry THF (100 L) 
dropwise. After 10 min a solution of bromoacetic acid (24.0 mg, 171 mol, 1.01 eq.) in dry THF (100 
L) was added dropwise and the reaction mixture stirred at 70°C. The progress of the reaction was 
monitored by UPLC-MS at 195 nm and after 2.5 h the reaction mixture was diluted with H2O (3 mL) 
and washed with Et2O (2 x 3 mL). The aqueous phase was then acidified with cold 1M HCl to pH 1 
and quickly extracted with Et2O (3 x 3 mL). The combined organics were washed with brine (5 mL), 
dried over MgSO4, filtered and concentrated under reduced pressure to give the desired acid (1.50) 
(19.0 mg, 80.8 mol, 43%) as a clear semisolid. 1H-NMR indicated a purity of 91% with some 
residual starting alcohol 1.49. The batch was pure enough to be used for a peptide coupling reaction 
and was used without further purification. 
1
H-NMR (400 MHz, CDCl3) ppm: 8.09 (sbr, 1H), 7.77 (s, 
1H), 4.18 (s, 2H), 4.06-4.01 (m, 2H), 3.80-3.76 (m, 2H), 1.47 (s, 9H). 
13
C-NMR (101 MHz, CDCl3) 
ppm: 173.59, 157.47, 82.48, 75.39, 69.60, 68.34, 28.32. HRMS (ESI): C9H17NNaO6
+
 calcd.: 
258.0948, found: 258.0950 [M+Na]
+
. 
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4.2.1.2 Substrate synthesis and experimental details for dirhodium catalyzed nitrene, 
C-H and O-H insertion 
 
Nitrene insertion 
Sulfamate ester 1.20 was prepared according to a published procedure by FRUIT et al.
290
 The analytical 
data is in agreement with the values reported by DILLON et al.
291
 
1
H-NMR (500 MHz, CDCl3) ppm: 4.97 (sbr, 2H), 4.24 (t, J = 6.8 Hz, 2H), 1.81-1.70 
(m, 1H), 1.63 (q, J = 6.8 Hz, 2H), 0.94 (d, J = 6.6 Hz, 6H). 
 
The intramolecular nitrene insertion was performed on a 646 mol scale according to and compared 
with the results of BRODSKY et al.
292
 
 
The oxathiazinane 1.21 was isolated as a white, crystalline solid (105 mg, 636 mol, 
98%). 
1
H-NMR (400 MHz, CDCl3) ppm: 4.70-4.65 (m, 2 H), 4.15 (sbr, 1 H), 1.79-
1.73 (m, 2H), 1.42 (s, 6H). 
13
C-NMR (101 MHz, CDCl3) ppm: 69.30, 56.56, 35.61, 
28.36. 
 
C-H insertion 
-diazoacetamide 1.22 was prepared in two steps according to HOFFMAN et al.293 and ROßBACH et 
al.
294
 
1
H-NMR (500 MHz, CDCl3) ppm: 3.39 (q, J = 7.1 Hz, 4H), 2.34 (s, 3H), 1.20 
(t, J = 7.2 Hz, 6H). 
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To a solution of -diazoacetamide 1.22 (43.3 mg, 236 µmol, 1.00 eq.) in CH2Cl2 (1.18 mL), a stock 
solution of dirhodium catalyst 1.17 (1.18 mL, 4 mM in CH2Cl2, 2 mol%) was added and the reaction 
mixture was stirred at room temperature. Analysis of the mixture by 
1
H-NMR spectroscopy after 10 
min indicated full conversion of the starting material to the C-H insertion products in a ratio of 9:1 
(1.23:1.24). The solvent was removed under reduced pressure and the residue was purified by flash 
chromatography (EtOAc/cyclohexane 3:1) to afford γ-lactam 1.23 (5.20 mg, 33.5 mol, 14%) and β-
lactam 1.24 (24.1 mg, 155 µmol, 66%) as colorless oils. (This synthesis was performed by Stefanie 
Geigle) 
 
γ-lactam 1.23: 
1
H-NMR (250 MHz, CDCl3) ppm: 3.54 (dd, J = 9.2, 6.0 Hz, 1H), 3.42 – 3.30 
(m, 2H), 3.27 (q, J = 7.3 Hz, 2H), 2.49 (ddt, J = 12.8, 8.5, 5.7 Hz, 1H), 2.38 (s, 
3H), 1.99 (dtd, J = 13.1, 8.9, 5.5 Hz, 1H), 1.07 (t, J = 7.2 Hz, 3H). 
13
C-NMR (101 
MHz, CDCl3) ppm: 204.00, 169.35, 55.99, 44.87, 37.66, 30.05, 19.59, 12.44. 
 
β-lactam 1.24: 
1
H-NMR (250 MHz, CDCl3) ppm: 4.08 (qd, J = 6.3, 2.1 Hz, 1H), 3.71 (d, J = 2.1 
Hz, 1H), 3.43-3.27 (m, 1H), 3.07 (dtd, J = 14.6, 7.4, 6.6 Hz, 1H), 2.30 (s, 3H), 1.34 
(d, J = 6.2 Hz, 3H), 1.17  (t, J = 7.3 Hz, 3H). 
13
C-NMR (101 MHz, CDCl3) ppm: 
200.80, 162.40, 69.51, 48.56, 35.38, 29.97, 17.82, 13.34. 
 
For comparison the dirhodium catalyst 1.19 was tested in a 
1
H-NMR reaction. A stock solution of 1.19 
(810 g, 1.00 mol, 2 mol%) in CD2Cl2 (250 L, Cambridge Isotope Laboratories, Inc.) was prepared 
adding one drop of MeOD-d4 for complete catalyst dissolution. A second stock solution of the -
diazoacetamide 1.22 (9.20 mg, 50.2 mol, 1.00 eq.) in CD2Cl2 (250 L) was prepared. 
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1
H-NMR reaction setup 
250 L of the -diazoacetamide 1.22 stock solution was transferred into a NMR tube (throw away 
quality) and mixed with 250 L of the dirhodium catalyst 1.19 stock solution. Time was taken after 
catalyst addition and the NMR tube was shaken on a Vortex Genie2. After 10 min the first 
measurement indicated ≥ 95% conversion with a product ratio of 9:1 (1.23:1.24). (These experiments 
were performed by Stefanie Geigle and Daniel Bachmann) 
 
-diazoacetamide 1.25 was prepared in two steps according to QI et al.295 and CHOI et al.296 
Spectroscopic data was in agreement with their published data. (This synthetic sequence was 
performed by Stefanie Geigle) 
 
To a suspension of -diazoacetamide 1.25 (21.5 mg, 70.6 µmol, 1.00 eq.) in H2O (671 L) a stock 
solution of dirhodium catalyst 1.18 (71.7 µL, 4.93 mM in H2O/500 mM MES, pH = 7.6, few drops 1M 
NaOH for solubility, 0.5 mol%) were added and the reaction mixture was stirred at 80°C. Analysis of 
the mixture by 
1
H-NMR spectroscopy after 10 min indicated full conversion of the starting material to 
the target C-H insertion products. The obtained white solid was filtered off and washed with H2O to 
afford the β-lactams 1.26 and 1.27 (17.6 mg, 63.9 µmol, 91%) as a white solid. (This synthesis was 
performed by Stefanie Geigle) 
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O-H insertion 
The synthesis and spectroscopic characterization of -diazoester 1.28, as well as its catalytic 
decomposition to 1.29 has been previously described by our group.
36
 
O-H insertion product 1.29: A stock solution of 1.28 (125 mM in MES 
pH 6, ca. 0.7 mL) was treated with Rh2(OAc)4 (4.00 mg, 89.0 mol, 10 
mol%) and the mixture stirred under ambient conditions. The progress 
of the reaction was monitored by UPLC-MS (254 nm) and after 
stirring for two days the creamy pink solution was lyophilized. The grayish solid was dissolved in 
CH2Cl2 and the precipitate (MES) was filtered off through a plug of cotton followed by removal of the 
solvent under reduced pressure. The crude sample was purified by flash chromatography on a Biotage 
Isolera Four device (20% MeOH/CH2Cl2). The product eluted after two column volumes and the 
purity of the fractions was analyzed by TLC (20% MeOH/CH2Cl2, KMnO4). The pure fractions were 
combined and concentrated under reduced pressure to give 1.29 (8.40 mg, 37.6 mol, 43%) as 
colorless oil which crystallized upon standing. TLC (20% MeOH/CH2Cl2, KMnO4) Rf = 0.26. 
1
H-
NMR (400 MHz, CDCl3) ppm: 7.39-7.35 (m, 2H), 7.33-7.29 (m, 2H), 5.17 (s, 1H), 3.76 (s, 3H), 
3.43 (s, 2H), 2.23 (s, 6H). 
13
C-NMR (126 MHz, CDCl3) ppm: 174.25, 138.72, 137.42, 129.64, 
126.74, 72.86, 63.85, 53.16, 45.22. HRMS (ESI): C12H18NO3
+
 calcd.:  224.1287, found: 224.1284 
[M+H]
+
. 
 
The catalytic comparison of dirhodium catalyst 1.18 with Rh2(OAc)4 in an O-H insertion reaction by 
water was performed using HPLC on an Agilent 1100 LC system equipped with a Chromolith 
Performance RP18e 4.6 × 100 mm column from Merck with a flow rate of 1 mL/min. Elution was 
performed using the following gradient: 0-80% MeCN in H2O/0.1% TFA in 16 min, then 80% in 2 
min. 
 
The following stock solutions were used for this experiment: 
-diazoester 1.28 (250 mM in 500 mM MES, pH 6), Rh2(OAc)4 (1 mM in H2O) and dirhodium 
catalyst 1.18 (4.90 mM in H2O/500 mM MES, pH = 7.6, few drops 1M NaOH for solubility). 
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Reaction setup 
Typically 20 L reaction mixtures containing 0.1 mM Rh2-cat, 50 mM -diazoester 1.28 and H2O in a 
HPLC vial (Agilent) were kept at room temperature and analyzed by injecting 2 L of the reaction 
mixture every 23 min for a total of 160 min. Conversions (%) were determined by integrating the peak 
area of starting -diazoester 1.28 at 254 nm and plotted against the time (min). For both catalysts 
triplicate measurements were done and the data points in the plotted graph below represent the mean 
values including their experimental error. 
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4.2.1.3 Synthesis of PNA, PNA-Rh2 catalysts and oligonucleotides 
 
Manual solid-phase PNA synthesis according to the Fmoc-strategy 
For manual PNA synthesis, the rink amide AM resin (100-200 mesh, attached to 
aminomethylpolystyrene, 0.61 mmol/g, from Novabiochem) was weighed and added to a 2 mL 
polyethylene syringe equipped with a plunger and a fritted disc. This resin contains a linker which 
yields a C-terminal amide upon TFA cleavage of the final PNA. Syntheses were routinely carried out 
on a 10-20 mol scale based upon the stated loading capacity of the resin. The dry resin was swollen 
with N-methylpyrrolidinone (NMP, peptide grade from IRIS) for 1 h at room temperature, reacted 
with two successive portions of 20 or 40% piperidine (Alfa or Sigma) in NMP for 10 min (Fmoc 
removal), then washed three times with NMP/CH2Cl2 1:1 for 1 min. PNA coupling was achieved at 
room temperature through careful shaking of the reactor fixed on top of a vortex-genie 2 (Scientific 
Industries) by treating the resin for 20-30 min with a fourfold excess of PNA monomer (Panagene or 
1.38) in NMP (0.1 M) containing four equivalents each of HATU (Fluorochem), DIPEA (Sigma) and 
2,4,6-collidine (Acros).
136
 Couplings were repeated for each Fmoc-PNA-G(Bhoc)-OH monomer using 
a freshly prepared coupling solution. When amino acid couplings were performed (PNA 1.4, 1.8 and 
1.30), the resin was treated for 30 min with a fivefold excess of amino acid (Bachem) in DMF (0.5 M, 
peptide grade from IRIS) containing five equivalents of HCTU (Novabiochem), 13.5 eq. of DIPEA 
(Sigma) and 11.5 eq. of 2,6-lutidine (Sigma) according to a published procedure.
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 For commercial 
amino acids this coupling was repeated once to ensure completion. Unreacted amino groups were 
“capped” with 5% Ac2O and 6% 2,4,6-collidine in NMP for 5-10 min. Capping was usually done prior 
to cleavage after coupling of PNA monomer 1.38 and in general after double couplings. After 
coupling or capping, the resin was washed three times with NMP/CH2Cl2 1:1 for 1 min, then the 
appropriate number of iterations of the deprotection/coupling cycle was performed as described above. 
When a coupling was performed the next day, the Fmoc-protected resin was washed first with three 
portions of NMP/CH2Cl2 1:1 for 1 min followed by a triple wash with CH2Cl2 for 1 min, dried under 
high vacuum for at least 10 min and stored at -20°C after the previous coupling. The same procedure 
was performed when the resin-bound and fully protected PNA had to be stored after its final assembly. 
 
Resin cleavage and PNA isolation 
For cleavage, the dry resin was weighed and transferred to a fresh 1 or 2 mL polyethylene syringe 
equipped with a plunger and a fritted disc. A mixture of TFA/m-cresol/thioanisole/TFMSA (6:1:1:2)
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for PNA 1.4 or TFA/TIS/H2O (95:2.5:2.5)
298
 for PNA 1.4, 1.8, 1.30, 1.45 and 1.51/1.53. (1-2 mL) was 
added. The reactor was closed with a luer stopper and the mixture was gently shaken on top of a 
vortexer at room temperature for 2 h. The PNA-containing cleavage cocktail was transferred into a 2 
mL Eppendorf plastic vial and carefully concentrated (30 mbar, 40-45°C) under reduced pressure to 
0.1-0.2 mL. To the residual oil was added ice-cold Et2O (1-1.5 mL) to precipitate the PNA. The 
Eppenorf tube was closed, vortexed and centrifuged at room temperature (2500 rmp, 3 min). The 
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supernatant was carefully discarded using a pipette and the beige PNA pellet was diluted with fresh 
ice-cold Et2O, vortexed and centrifuged. This process was done for a total of three times and the final 
crude PNA was then air dried. 
 
Purification and analysis 
The crude PNA pellet was dissolved in 100-500 L of Milli-Q water and purified by preparative RP-
HPLC at 254 nm with a flow rate of 5 mL/min using MeCN and H2O containing 0.1% TFA as eluents. 
All product fractions were re-analyzed by LC-MS prior to lyophilization. The corresponding gradients 
used for the purification of each individual compound as well as the UPLC-MS or MALDI-TOF-MS 
analysis data are given on the next page(s). 
 
Stock solutions 
The purified and re-analyzed white PNA powder (5-25 mg) was dissolved in Milli-Q water (20-100 
L) and the concentration of the stock solutions determined using a NanoDrop 2000 
spectrophotometer from Thermo Scientific with a path length of 1 mm. For each individual PNA the 
extinction coefficient () was calculated according to the guidelines provided by Panagene Inc.140 
Triplicate measurements of various dilutions were performed and the final concentration was 
calculated according to equation 3 as the average of all concentrations. 
 
 
  
       
   
 (3) 
 
Equation 3: c = concentration [mol/L], A260 = absorption at 260 nm (< 1), df = dilution factor, d = path length [cm],  = 
extinction coefficient [L/mol cm]. 
 
All stock solutions were stored at -20°C if not used. For reactions the corresponding PNA stock 
solution was thawn up, vortexed and the appropriate amount added to the respective reaction vial with 
a Gilson pipette. When a stock solution was used after more than 4-6 months, the concentration was 
determined again as described above. 
 
Qualitative chloranil test
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A few beads (2-4 mg) were placed in a petri dish and treated with three drops of 2% acetaldehyde in 
DMF and three drops of 2% chloranil in DMF and left at room temperature for 5 min. The beads were 
then inspected under a microscope. Blue beads indicted free amines (positive) whereas colorless beads 
were indicative for protected amino groups (negative). 
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PNA-diacid 1.4: 
 
 
RP-HPLC: 5-10% MeCN in H2O, 0.1% TFA in 25 min, 1 mL/min, tR = 22.264 min. 
 
MALDI-TOF-MS: 1872.3 [M+H]
+
, 1894.4 [M+Na]
+
, 1910.4 [M+K]
+
, 1932.7 [M-H+Na+K]
+
, 1948.6 
[M-H+2K]
+
. 
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N-acetly PNA 1.8: 
  
 
 
MALDI-TOF-MS: 1798.0 [M+H]
+
. 
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PNA-ONH2 1.30: 
 
 
At that time double peaks were observed for each compound as a result of column aging. 
Gradient: 5-100% MeCN in H2O, 0.1% TFA in 5 min, 0.5 mL/min. 
 
UPLC-MS (ESI): tR = 3.616 min, 1700.4 [M+H]
+
, 850.9 [M+2H]
2+
, 567.7 [M+3H]
3+
. 
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PNA-Rh2 1.31: 
To the hydroxylamine terminated PNA 1.30 (4.25 mg, 2.50 mol, 1.00 eq.) was added 330 L 
(~3:1:0.5 H2O/MeOH/CH2Cl2) of a 10 mM stock solution of ketone functionalized dirhodium catalyst 
1.19 (2.67 mg, 3.30 mol, 1.32 eq.) and left at room temperature with occasional mixing. The 
heterogenous mixture turned immediately pink and LC/MS analysis over a total of 22 h indicated a 
sluggish reaction although the desired product could be identified. 
 
 
LC/MS after 22 h: 
 
LRMS (ESI): 2491.5 [M+H]
+
, 1246.5 [M+2H]
2+
.  
RP-HPLC: 5-100% MeCN in H2O, 0.1% TFA in 40 min, 1 mL/min, tR = 20.945 min. 
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T-PNA 1.45: 
T-PNA 1.45 was synthesized according to the above described protocol for manual solid-phase PNA 
synthesis except for the selective on-bead N-Boc removal after coupling of thymine monomer (
R-MPT-
PNA) 1.38. This was achieved using the protocol published by ZHANG et al.
189
 To the resin was added 
a solution containing 1M TMSOTf, 1.5M 2,6-lutidine in CH2Cl2 (1.5 mL) and shaken at room 
temperature for 1 h. The resin was then washed as described above and a qualitative chloranil test
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was found to be positive. 
 
 
Gradient: 5-70% MeCN in H2O, 0.1% TFA in 5 min, 0.4 mL/min. 
 
 
UPLC-MS (ESI): tR = 1.189 min, 2098.9 [M+H]
+
, 1050.5 [M+2H]
2+
, 700.5 [M+3H]
3+
. 
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PNA-Rh2 1.46: 
A stocksolution of T-PNA 1.45 (81.8 L, 7.4 mM) was mixed with a stock solution of dirhodium 
catalyst 1.18 (81.8 L, 4.93 mM in Milli-Q water + 1 drop of conc. NaOH for solubility) in a 0.5 mL 
Eppendorf tube. Excess of T-PNA 1.45 was used to assure full conversion of the dirhodium catalyst 
1.18. Upon mixing the solution turned immediately pink (see Scheme 2.23 in section 2.3.6) and after 
centrifuging the sample a pink solid settled. UPLC-MS indicated exclusively unreacted T-PNA 1.45 
in the supernatant whereas the analysis of the pink solid (dissolved in DMSO) indicated a mixture of 
starting materials and PNA-Rh2 1.46 product. The crude solid was dissolved in 100 L of DMSO and 
purified by semi-preparative HPLC (5-80% MeCN in H2O, 0.1% TFA in 30 min, 5 mL/min). A pink 
fluffy solid was obtained and a stock solution in DMSO (2.56 mM, determined 
spectrophotometrically) was prepared and stored at -20°C. 
 
 
 
At that time double peaks were observed for each compound as a result of column aging. 
Gradient: 5-100% MeCN in H2O, 0.1% TFA in 5 min, 0.5 mL/min. 
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UPLC-MS (ESI): tR = 2.985 min, 1467.5 [M+2H]
2+
, 978.5 [M+3H]
3+
. 
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PNA 1.51/1.53: 
 
 
Peak at 4.25 min was unrelated to PNA. 
Gradient: 5-70% MeCN in H2O, 0.1% TFA in 5 min, 0.4 mL/min. 
 
UPLC-MS (ESI): tR = 0.364 min, 1062.6 [M+2H]
2+
, 708.9 [M+3H]
3+
. 
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Oligonucleotide synthesis and purification 
Solid-phase oligonucleotide synthesis was carried out on four 1-mol CPG columns (pre-loaded with 
G) using standard phosphoramidite chemistry with 0.3 M 5-benzylthio-1-H-tetrazole as activator. The 
DNA oligonucleotides were cleaved from the support with 32% (v/v) aqueous ammonia for 2 h at 
room temperature and deprotected for 18 h at 55C, then freeze-dried and purified by semi-
prepeparative HPLC. Purification was done using the following gradient: 0-18% MeCN in 100 mM 
triethylammonium acetate (pH 7.0) in 15 min, 18-80% in 5 min. The DNA concentration was 
determined using a NanoDrop 2000 spectrophotometer from Thermo Scientific at 260 nm with a path 
length of 1 mm and GCG TAT ACG) = 89900 M
-1
 cm
-1
. A stock solution (14.6 mM) in Milli-Q water 
containing 160 mM MgCl2 was prepared and stored at -20°C. 
  
  
 
 
d(GCG TAT ACG): 
 
RP-HPLC: 0-80% MeCN in 100 mM triethylammonium acetate (pH 7.0) in 16 min, 1 mL/min, tR = 
7.192 min. 
MALDI-TOF-MS: 2738.8 [M+H]
+
. 
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4.2.1.4 Alkylation studies using PNA-dirhodium carbenoids 
 
Procedure used for entries 1-7 in table 2.1 
Typically 20 L reaction mixtures containing 0.1-1 mM T-PNA-hydroxylamine 1.45, 0.1-1 mM 
dirhodium catalyst, 0.1-5 mM oligonucleotide and 50 mM -diazocarbonyl compound 1.28 in 100 
mM MES buffer, pH 6.0 were sequentially mixed at room temperature. The reaction was analyzed 
every 2 h (2 L injections) for a total of 14 h and the remaining sample (6 L) purified by micro-
preparative HPLC-separation. The collected peak fractions were analyzed by MALDI-TOF-MS. 
 
Analytical data 
Representative HPLC trace at t = 0 h for entry 1 in table 2.1. -diazocarbonyl compound 1.28 
contained a small impurity which did not interfere during the course of the reaction as stated by 
integration values. 
 
RP-HPLC: 0-80% MeCN in 100 mM triethylammonium acetate (pH 7.0) in 16 min, 1 mL/min, tR (oligo) 
= 7.192 min. 
 
Representative HPLC trace at t = 14 h for entry 1 in table 2.1 (identical to entries 2 and 4-7). The 
conversions were determined to be 3% for the oligonucleotide and > 99% for the -diazocarbonyl 
compound 1.28. The new peak at 7.583 min was confirmed as a (+1) modified oligonucleotide 
species. 
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RP-HPLC: 0-80% MeCN in 100 mM triethylammonium acetate (pH 7.0) in 16 min, 1 mL/min, tR 
(modified oligo) = 7.583 min. 
MALDI-TOF-MS: 2945.8 [M+H]
+
, 2983.9 [M+K]
+
, 3022.9 [M-H+2K]
+
, 3059.9 [M-2H+3K]
+
, 3100.0 
[M-3H+4K]
+
. 
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Procedure for the alklation using PNA-Rh2 oxime 1.46 
A 20 L reaction mixture containing 0.5 mM T-PNA-Rh2 oxime 1.46, 0.5 mM oligonucleotide and 
50 mM -diazocarbonyl compound 1.28 in 100 mM MES buffer, pH 6.0 were sequentially mixed at 
room temperature. The reaction was analyzed every 2 h (2 L injections) for a total of 14 h and the 
remaining sample (6 L) purified by micro-preparative HPLC-separation after 17 h. The collected 
peak fractions were analyzed by MALDI-TOF-MS. 
 
 
 
RP-HPLC: 0-80% MeCN in 100 mM triethylammonium acetate (pH 7.0) in 18 min, 1 mL/min, tR 
(modified oligo) = 7.638 min.  
MALDI-TOF-MS: 2946.6 [M+H]
+
. 
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4.2.1.5 Circular dichroism studies 
 
Circular Dichroism (CD) 
 
All CD data were recorded at room temperature from 190-320 nm at the rate of 100 nm/min using a 
spectral bandwidth of 1 nm with a time constant of 5 s and a step resolution of 0.5 nm. A 10 mm path 
length cuvette was used and the temperature was maintained at 22°C. The resulting CD signal, 
obtained as ellipticity in mdeg was converted into a difference in absorption DA and is reported in 
mAU. 
 
Stock solutions of the T-containing PNA-hydroxylamine 1.45 (12.1 mM), d(GCG TAT ACG) (14.6 
mM containing 160 mM MgCl2) and PNA-Rh2oxime 1.46 (2.56 mM in DMSO) were used. The stock 
solutions were mixed and diluted in KPi buffer (10 mM in Milli-Q water, pH 7.6) to a final hybridizing 
concentration of 8.1 M. All solutions were equilibrated at room temperature for 5-10 min before the 
measurements.  
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4.2.2 Dialdehyde studies 
 
4.2.2.1 Synthesis of small molecules and dirhodium catalysts 
 
Bisoxime 2.3a: The reaction of OPA 2.1 and 1,3-diaminohydroxypropane (2.2) 
was conducted at 10 M (at a 1:1 ratio) in H2O/1% MeCN. After 10 min an 
aliquot was analyzed by UPLC-MS indicating full conversion of OPA 2.1 
showing bisoxime 2.3a as the single product. HRMS (ESI): C11H13N2O2
+
 calcd.: 205.0972, found: 
205.0974 [M+H]
+
. NMR characterization was impossible since at high substrate concentrations (>1 
mM) the tetraoxime 2.3b was the exclusive product.  
 
 
 
 
Tetraoxime 2.3b: 
1
H NMR (400 MHz, CDCl3) δ/ppm: 8.56 (s, 4 H), 7.59-7.55 (m, 4 H), 7.40-7.36 (m, 
4 H), 4.36 (t, J = 6.3 Hz, 8 H), 2.17-2.11 (m, 4 H). LRMS (ESI): C22H25N4O4
+
 calcd.: 409.2, found: 
409.2 [M+H]
+
. (These compounds were synthesized and characterized by Dr. Linna Zhou). 
 
Oxime 2.5: The reaction of OPA 2.1 and O-benzylhydroxylamine (2.4) 
was conducted at 10 mM (at a 1:1 ratio) in MeCN. The crude was purified 
by preparative RP-HPLC to give oxime 2.5 as colorless oil. 
1
H-NMR (500 
MHz, CDCl3) δ/ppm: 10.26 (s, 1 H), 8.92 (s, 1 H), 7.86 (t, J = 8.7 Hz, 2 
H), 7.61 (t, J = 7.5 Hz, 1 H), 7.55 (t, J = 7.5 Hz, 1 H), 7.47-7.34 (m, 5 H), 5.28 (s, 2 H). 
13
C-NMR 
(101 MHz, CDCl3) δ/ppm: 192.46, 146.97, 137.26, 133.90, 133.53, 133.02, 132.08, 129.72, 128.50, 
128.48, 128.32, 128.10, 76.78. HRMS (ESI): C15H14NO2
+ 
calcd.: 240.1019, found: 240.1019 [M+H]
+
. 
 
Bis(carbamate) 2.12: 3-Bromo-2-bromomethyl-1-propene 2.11 (704 mg, 
3.19 mmol, 1.00 eq.) was dissolved in dry CH2Cl2 (8.0 mL) under 
nitrogen. While stirring tert-butyl N-hydroxycarbamate (1.48) (868 mg, 
6.39 mmol, 2.00 eq.) was added and the resulting mixture cooled to 0°C. DBU (1.43 mL, 9.58 mmol, 
3.00 eq.) was added dropwise and the mixture allowed to warm up to room temperature. The reaction 
was monitored by TLC (cyclohexane/EtOAc, 3:1, KMnO4) and full conversion was observed after 3 h. 
The solvent was removed under reduced pressure and the residue was purified by flash 
chromatography (cyclohexane/EtOAc 3:1) to afford the target product 2.12 as an off-white solid (662 
mg, 2.08 mmol, 65%). TLC (cyclohexane/EtOAc, 3:1, KMnO4) Rf = 0.23. 
1
H-NMR (400 MHz, 
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CDCl3) ppm: 7.55 (s, 2H), 5.34 (s, 2H), 4.41 (s, 4H), 1.47 (s, 18H). 
13
C-NMR (101 MHz, CDCl3) 
/ppm: 156.88, 139.29, 120.96, 81.85 77.59, 28.36. HRMS (ESI): C14H26N2NaO6
+ 
calcd.: 341.1684, 
found: 341.1683 [M+Na]
+
. 
 
Ketone 2.10: A 25 mL two-necked flask equipped with a stir bar, 
containing a gas inlet (pasteur pipet and quick fit) and a connected tygon 
tube filled with blue silica gel was charged with olefin 2.12 (207 mg, 
0.65 mmol, 1.00 eq.) dissolved in dry MeOH/CH2Cl2 (4 mL, 1:3). The mixture was cooled to -78°C 
and O
3
 gas was gently bubbled through the stirred solution. After 5 min the solution was saturated 
with O
3
 and turned blue. The gas supply was ceased and air was bubbled through the solution until all 
excess of O
3
 was removed as indicated by the disappearance of the blue color. The reaction mixture 
was allowed to warm up to room temperature and Me2S (480 L, 6.57 mmol, 10.1 eq.) was added. The 
solvent was removed under reduced pressure to give 238 mg of a colorless oil which had a purity of 
83% as determined by 
1
H-NMR. A 102 mg sample was passed through a short plug of silica with 
cyclohexane/EtOAc 1.5:1. The target ketone was dried extensively over night at 40°C under high 
vacuum to give the title compound 2.10 as a colorless oil (78 mg, 0.24 mmol, 86%, yield is based on 
the molar percentage of the total sample taken in the aliquot). TLC (cyclohexane/EtOAc, 1:1, KMnO4) 
Rf = 0.37. 
1
H-NMR (500 MHz, CDCl3) ppm: 7.65 (s, 2H), 4.63 (s, 4H), 1.48 (s, 18H). 
13
C-NMR 
(126 MHz, CDCl3) /ppm: 204.07, 156.56, 82.59, 78.95, 28.29. HRMS (ESI): C13H24N2NaO7
+ 
calcd.: 
343.1476, found: 343.1475 [M+Na]
+
. 
 
Carboxylic acid 2.8: To a nitrogen flushed 2.5 mL screw cap vial 
equipped with a stir bar containing ketone 2.10 (51.0 mg, 80.7 mol, 
50% purity, different batch than described above) was added dry MeOH 
(0.50 mL), followed by sarcosine (22.0 mg, 0.24 mmol, 3.04 eq.) and 
finely crushed and flame dried 4Å molecular sieve. Then 1.25 M HCl in MeOH (130 L, 163 mol, 
2.02 eq.) was added and the mixture stirred for 10 min at room temperature. It was cooled with an ice 
bath to 0°C and NaBH3CN (6.00 mg, 95.5 mol, 1.14 eq.) was added. The ice bath was removed and 
the reaction stirred at room temperature for 18 h. UPLC-MS confirmed the desired product mass of 
m/z = 394 [M+H]
+
 along with an unknown mass of m/z = 424 Da. The reaction mixture was filtered 
over Celite and washed with MeOH. The solvent was removed under reduced pressure to give 65 mg 
of a viscous turbid oil which was purified by reverse phase flash chromatography (dry loaded) on a 
Biotage Isolera Four device using RP-C18 silica gel and H2O/MeCN (0-70% MeCN over 24 min). The 
non UV-active fractions were analyzed by direct injection into an ESI-MS device using positive and 
negative ion polarity mode. The fractions containing the product mass (33-35% MeCN) were 
additionally analyzed by UPLC-MS, combined and lyophilized to give the desired product 2.8 as a 
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white fluffy powder (7.0 mg, 17.8 mol, 22%, estimated purity from 1H-NMR is ~95%). No further 
purification was necessary for the subsequent SPPS. 
1
H-NMR (400 MHz, DMSO-d6) ppm: 10.05 (s, 
1H), 4.75 (s, 1H), 4.01-3.72 (m, 4H), 3.36 (s, 2H), 3.12-3.04 (m, 1H), 2.36 (s, 3H), 1.41 (s, 18H); the 
signals at 3.36, 2.36 and 1.41 ppm were sets of two overlapping singlets from the corresponding 
rotamers and were integrated together. Additionally one of the acidic protons seems not to be 
observable under the conditions we ran the 
1
H-NMR. Even with 2-D spectra it was not possible to 
clearly assign the signals at 10.05 and 4.75 ppm. 
13
C-NMR (126 MHz, DMSO-d6) /ppm: 172.28, 
156.11/154.65 (rotamer), 80.85/79.74 (rotamer), 73.78/72.88/71.50 (rotamer), 59.24, 56.03, 
38.48/38.30 (rotamer), 27.89. HRMS (ESI): C16H32N3O8
+ 
calcd.: 394.2184, found: 394.2191 [M+H]
+
. 
 
Bis(carbamate) 2.14: NaH (110 mg, 2.80 mmol, 2.54 eq., 60% in mineral oil) 
was suspended in dry THF (9 mL) under nitrogen. tert-butyl N-
hydroxycarbamate (1.48)  (330 mg, 2.48 mmol, 2.25 eq. as a solution in 1 mL 
dry THF) was carefully added dropwise to the stirring suspension. After gas evolution had ceased, 
,′-dibromo-o-xylene (2.13) (300 mg, 1.10 mmol, 1.00 eq.) was added and the mixture was stirred 
for 2 h at room temperature. The mixture was concentrated under reduced pressure and the residue was 
partitioned between EtOAc and H2O. The aqueous phase was extracted once more with EtOAc, the 
combined organic layers were washed with brine, dried over Na2SO4 and evaporated. The residue was 
purified by flash chromatography (cyclohexane/EtOAc and CH2Cl2/MeOH) to yield the desired 
product 2.14 as a colorless oil (310 mg, 842 mol, 76%). 1H-NMR (500 MHz, CD3CN) δ/ppm: 8.27-
8.14 (sbr, 2H), 7.40-7.36 (m, 4H), 4.94 (s, 4H), 1.42 (s, 18 H). 
13
C-NMR (126 MHz, CD3CN) δ/ppm: 
157.50, 136.31, 131.83, 129.57, 81.50, 76.29, 28.36. HRMS (ESI): C18H28N2NaO6
+ 
calcd.: 391.1840, 
found: 391.1843 [M+Na]
+
. (This compound was synthesized and characterized by Dr. Linna Zhou). 
 
bishydroxylamine 2.15: Bis(carbamate) 2.14 (120 mg, 326 mol, 1.00 eq.) was 
dissolved in 1 mL dry CH2Cl2 under nitrogen and concentrated TFA (1 mL) was 
added with continuous stirring at room temperature. After 4 h the reaction was 
concentrated under reduced pressure and the residue was partitioned between a saturated sodium 
carbonate solution and CH2Cl2. The aqueous phase was extracted twice with CH2Cl2, the combined 
organic layers were washed with brine, dried over Na2SO4, filtered and concentrated under reduced 
pressure. The residue was purified by flash chromatography (CH2Cl2/MeOH) to yield the target 
product 2.15 as a colorless oil (20.0 mg, 119 mol, 36%). 1H-NMR (500 MHz, CD3CN) δ/ppm: 7.37-
7.36 (m, 2H), 7.32-7.30 (m, 2H), 5.57 (sbr, 4H), 4.71 (s, 4H). 
13
C-NMR (126 MHz, CD3CN) δ/ppm: 
137.55, 130.17, 128.65, 75.82. HRMS (ESI): C8H13N2O2
+ 
calcd.: 169.0972, found: 169.0972 [M+H]
+
. 
(This compound was synthesized and characterized by Dr. Linna Zhou). 
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Lactam 2.19: A NMR sample containing a mixture of IBHA 2.16 (ds 9:1) 
and oxime 2.5 in CD3CN was treated with DCl gas (pipetting the vapor 
phase of a DCl bottle into the NMR tube). The tube was sealed and 
homogenized through gentle shaking. Subsequent NMR analysis 
indicated the exclusive formation of lactam derivative 2.19. The crystal structure of 2.19 is shown in 
Figure 3.7. 
1
H-NMR (400 MHz, CD3CN) δ/ppm: 7.76 (d, J = 7.5 Hz, 1H), 7.62 (t, J = 7.5 Hz, 1H), 
7.56-7.35 (m, 7H), 5.13 (s, 2H), 4.47 (s, 2H). 
13
C-NMR (101 MHz, CD3CN) δ/ppm: 165.88, 140.04, 
136.57, 133.07, 131.37, 130.49, 129.80, 129.54, 129.19, 124.37, 124.03, 78.46, 51.27.  
 
IBHA of naphthalene dialdehyde 2.20: A 2.5 mL screw-cap vial 
equipped with a stir bar was charged with 2,3-
naphthalenedicarboxaldehyde (15.0 mg, 81.5 mol, 1.02 eq.) 
dissolved in 0.5 mL dry MeCN. A solution of O-
benzylhydroxylamine (2.4) (10.0 mg, 80.1 mmol, 1.00 eq.) in dry MeCN (0.20 mL) was added to the 
stirring solution at room temperature. The reaction was stopped when a white solid precipitated (45 
sec) which prevented efficient stirring. The stir bar was removed, washed with dry MeCN and the 
solvent evaporated under reduced pressure. The sample was extensively dried under high vacuum to 
give 23 mg of a white fluffy solid which turned out to be a 9:1 mixture naphthalene IBHA 2.20 (as a 
24:1 mixture of diastereomers) and its oxime 2.20a (see below). Due to this ratio the 
13
C-NMR in 
DMSO-d6 of the mixture only indicated the signals for 2.20. 
1
H NMR (400 MHz, DMSO-d6) δ/ppm: 
8.02-7.95 (m, 2H), 7.81 (s, 2H), 7.54-7.48 (m, 4H), 7.41-7.35 (m, 2H), 7.35-7.30 (m, 1H), 6.63 (d, J = 
8.3 Hz, 2H), 5.62 (dd, J = 8.4 Hz, J = 1.0 Hz, 2H), 5.12 (s, 2H). 
13
C NMR (101 MHz, DMSO-d6) 
δ/ppm: 137.66, 137.00, 133.38, 128.41, 128.27, 128.08, 127.64, 125.84, 121.47, 88.42, 77.67. HRMS 
(ESI): C19H17NNaO3
+ 
calcd.: 330.1101, found: 330.1103 [M+Na]
+
. 
 
Oxime 2.20a: The above mixture was heated in the NMR tube at 
80°C for 5 h whereupon all the intermediate was converted to oxime 
2.20a. 
1
H NMR (600 MHz, DMSO-d6) δ/ppm: 10.28 (s, 1H), 9.02 (s, 
1 H), 8.59 (s, 1H), 8.33 (s, 1H), 8.17 (d, J = 8.2 Hz, 1H), 8.12 (d, J = 
8.2 Hz, 1H), 7.77-7.72 (m, 1H), 7.72-7.67 (m, 1H), 7.49-7.43 (m, 2H),  7.43-7.38 (m, 2H), 7.36-7.30 
(m, 1H), 5.25 (s, 2H). 
13
C NMR (151 MHz, DMSO-d6) δ/ppm: 193.50, 148.04, 137.47, 135.85, 
134.47, 132.28, 131.67, 129.89, 129.38, 128.44, 128.41, 128.29, 128.22, 128.04, 127.92, 127.55, 
75.69. HRMS (ESI): C19H15NNaO2
+ 
calcd.: 312.0995, found: 312.0997 [M+Na]
+
. 
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Tetrabromide 2.22: Compound 2.22 was synthesized in analogy to literature 
procedures by HARIS et al.
299
 and SHOKAT et al. 
237
 3,4-dimethylbenzoic acid 
2.21 (6.00 g, 39.9 mmol, 1.00 eq.) was dissolved in warm carbon tetrachloride 
(40 mL). N-bromosuccinimide (28.9 g, 162 mmol, 4.06 eq.) and benzoyl 
peroxide (810 mg, 3.35 mmol, 0.08 eq.) were added slowly and the reaction mixture was refluxed 
overnight. After cooling down, the white precipitate was filtered off and washed twice with toluene 
(60 mL) and Et2O (80 mL). The filtrate was concentrated and the residue was recrystallized from 
MeCN to give the desired tetrabromide 2.22 (9.54 g, 20.5 mmol, 51%) as a white solid. 
1
H-NMR (400 
MHz, DMSO-d6) δ/ppm: 13.53 (s, 1H), 8.34 (s, 1H), 7.99 (d, J = 7.8 Hz, 1 H), 7.95 (s, 1H), 7.78 (s, 
1H), 7.77 (d, J = 7.8 Hz, 1 H). LRMS (ESI): C9H5Br4O2
- 
calcd.: 464.7, found: 464.7 [M-H]
-
. (This 
compound was synthesized and characterized by Dr. Linna Zhou). 
 
Acid 2.23: Compound 2.23 was synthesized in analogy to literature procedures 
by HARIS et al.
299
 and SHOKAT et al.
237
 Tetrabromide 2.22 (2.00 g, 4.29 mmol, 
1.00 eq.) was dissolved in 10% Na2CO3 (20 mL). The reaction mixture was 
heated to 70
o
C and stirred for 4 h. After cooling down, the reaction mixture was 
acidified carefully with concentrated HCl to pH 1, followed by extraction with 
EtOAc (3 x 20 mL). The combined organics were washed with brine (30 mL), dried over Na2SO4, 
filtered and concentrated under reduced pressure. The light yellow solid was then dissolved in dry 
MeOH (20 mL) and Sc(OTf)3 (100 mg, 203 mol, 0.05 eq.) was added. The reaction mixture was 
stirred at room temperature overnight. The solvent was removed under reduced pressure and the 
residue purified by flash chromatography (CH2Cl2/MeOH) to afford the target product 2.23 (550 mg, 
2.45 mmol, 57%) as a white solid. 
1
H-NMR (400 MHz, DMSO-d6) δ/ppm: 13.21 (sbr, 1H), 8.05 (d, J = 
7.6 Hz, 1 H), 7.93 (s, 1H), 7.55 (d, J = 7.6 Hz, 1 H), 6.36 (s, 1H), 6.11 (s, 1H), 3.37-3.32 (m, 6H). 
LRMS (ESI): C11H11O5
- 
calcd.: 223.1, found: 223.2 [M-H]
-
. (This compound was synthesized and 
characterized by Dr. Linna Zhou). 
 
N-Boc protected lissamine 2.25: Lissamine™ rhodamine B 
sulfonyl chloride 2.24 (200 mg, 347 mol, 1.00 eq.) and N-Boc-
ethylenediamine (110 L, 694 mol 2.00 eq.) were dissolved in 
EtOH (30 mL). NEt3 (97.0 L, 694 mol, 2.00 eq.) was added 
dropwise and the reaction mixture was stirred at room 
temperature under N2 atmosphere. The solvent was removed 
under reduced pressure and the residue purified by flash 
chromatography (CH2Cl2/MeOH) to afford the target product 
2.25 (85.0 mg, 142 mol, 41%) as a dark purple solid. 1H-NMR 
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(500 MHz, DMSO-d6) δ/ppm: 8.42 (d, J = 1.8 Hz, 1 H), 8.04 (t, J = 6.0 Hz, 1 H), 7.93 (dd, J = 8.0 Hz, 
J = 1.8 Hz, 1 H), 7.49 (d, J = 8.0 Hz, 1 H), 7.05-6.94 (m, 6H), 6.89 (t, J = 5.6 Hz, 1 H), 3.68-3.60 (m, 
8H), 3.04-3.00 (m, 2H), 2.90-2.86 (m, 2H), 1.38 (s, 9H), 1.19 (t, J = 7.0 Hz, 12 H). 
13
C-NMR (101 
MHz, DMSO-d6) δ/ppm: 157.43, 157.08, 155.47, 154.97, 148.02, 141.40, 133.04, 132.67, 130.65, 
126.48, 125.63, 113.59, 113.44, 95.35, 77.79, 45.23, 42.19, 40.42, 28.18, 12.44.  HRMS (ESI): 
C34H45N4O8S2
+ 
calcd.: 701.2673, found: 701.2674 [M+H]
+
. (This compound was synthesized and 
characterized by Dr. Linna Zhou). 
 
Lissamine bisacetal 2.26: Lissamine derivative 2.25 (85.0 
mg, 142 mol, 1.00 eq.) was dissolved in methanol (10 
mL) and 4M HCl in 1,4-dioxane (10 mL). The reaction 
mixture was stirred at room temperature for 4 h. The 
solvent was removed under reduced pressure and the 
residue was further treated with NEt3 (193 L, 139 mol, 
0.98 eq.), acid 2.23 (48.0 mg, 213 mol, 1.50 eq.) and 
DCC (44.0 mg, 213 mol, 1.50 eq.) in dry MeCN. The 
reaction mixture was stirred at room temperature 
overnight and the solvent was removed under reduced 
pressure. The residue was purified by flash chromatography (CH2Cl2/MeOH) to afford the target 
product 2.26 (40 mg, 49.6 mol, 35%) as a dark purple solid. 1H-NMR (500 MHz, DMSO-d6) δ/ppm: 
8.71 (t, J = 5.4 Hz, 1 H), 8.44 (d, J = 1.8 Hz, 1 H), 8.16 (t, J = 5.8 Hz, 1 H), 7.95 (dd, J = 8.0 Hz, J = 
1.8 Hz, 1 H), 7.89 (s, 1 H), 7.50-7.44 (m, 2H), 7.04-6.93 (m, 7H), 6.33 (s, 1 H), 6.08 (s, 1 H), 3.67-
3.59 (m, 8H), 3.35-3.24 (m, 8H), 3.08-3.03 (m, 2H), 1.20 (t, J = 7.0 Hz, 12 H). 
13
C-NMR (126 MHz, 
DMSO-d6) δ/ppm: 165.67, 157.38, 157.06, 154.97, 148.02, 141.42, 140.85, 138.45, 135.75, 133.06, 
132.68, 130.67, 128.90, 126.50, 125.68, 122.99, 121.94, 113.60, 113.42, 105.57, 104.57, 95.33, 54.02, 
53.90, 47.47, 45.22, 41.76, 12.43. HRMS (ESI): C40H47N4O10S2
+ 
calcd.: 807.2728, found: 807.2732 
[M+H]
+
. (This compound was synthesized and characterized by Dr. Linna Zhou). 
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Lissamine-tagged OPA derivative 2.27: Compound 2.26 (20.0 
mg, 24.8 mol, 1.00 eq.) was treated with TFA (2 mL) and 
H2O (2 mL) at room temperature for 2 h. TLC 
(CH2Cl2/MeOH, 10:1) indicated full conversion of the 
starting material. The solvent was removed under reduced 
pressure and the residue purified by preparative RP-HPLC 
(MeCN and 0.1% TFA in H2O). The product fractions were 
lyophilized to give the product 2.27 (8.00 mg, 10.5 mmol, 
42%) as a dark purple solid. 
1
H-NMR (600 MHz, DMSO-d6) 
δ/ppm: 10.51 (s, 1 H),  10.51 (s, 1 H), 8.98 (t, J = 5.6 Hz, 1 
H), 8.43 (dd, J = 8.6 Hz, J = 1.7 Hz, 2 H), 8.27 (d, J = 8.0 Hz, 1 H), 8.17 (t, J = 6.3 Hz, 1 H), 8.06 (d, J 
= 8.0 Hz, 1 H), 7.95 (dd, J = 8.0 Hz, J = 1.8 Hz, 1 H), 7.47 (d, J = 8.0 Hz, 1 H), 7.03-6.93 (m, 6H), 
3.67-3.59 (m, 8H), 3.43-3.39 (m, 2H), 3.10-3.05 (m, 2H), 1.20 (t, J = 6.9 Hz, 12 H). 
13
C-NMR (126 
MHz, DMSO-d6) δ/ppm: 192.73, 192.62, 164.72, 157.39, 157.08, 154.99, 148.05, 141.43, 138.54, 
137.95, 136.27, 133.11, 132.69, 132.19, 130.70, 130.13, 128.72, 126.52, 125.68, 113.61, 113.44, 
95.36, 45.23, 41.66, 40.05, 12.45. LRMS (ESI): C38H41N4O9S2
+ 
calcd.: 761.2309, found: 761.2310 
[M+H]
+
. (This compound was synthesized and characterized by Dr. Linna Zhou). 
 
N-Boc protected dabsyl derivative 2.29: 4-(Dimethylamino)azobenzen-4’-
sulfonyl chloride 2.28 (324 mg, 1.00 mmol, 1.00 eq.) and N-Boc-
ethylenediamine (160 L, 1.00 mmol, 1.00 eq.) were dissolved in EtOH (30 
mL). NEt3 (278 L, 2.00 mmol, 1.00 eq.) was added dropwise and the reaction 
mixture was stirred at room temperature under N2 atmosphere overnight. The 
solvent was removed under reduced pressure and the residue purified by flash 
chromatography (CH2Cl2/MeOH) to afford the target product 2.29 (240 mg, 537 
mol, 54%) as an orange solid. 1H-NMR (500 MHz, DMSO-d6) δ/ppm: 7.91 (sbr, 
4H), 7.83 (d, J = 9.1 Hz, 2H), 7.76 (t, J = 5.8 Hz, 1H), 6.86 (d, J = 9.1 Hz, 2H), 
6.79 (t, J = 5.8 Hz, 1H), 3.09 (s, 6H), 2.99-2.95 (m, 2H), 2.82-2.78 (m, 2H), 1.34 
(s, 9H).
 13
C-NMR (101 MHz, DMSO-d6) δ/ppm: 155.42, 154.46, 153.08, 142.57, 140.13, 127.73, 
125.35, 122.21, 111.57, 77.75, 42.25, 39.82, 39.81, 28.13. HRMS (ESI): C21H30N5O4S
+ 
calcd.: 
448.2013, found: 448.2013 [M+H]
+
. (This compound was synthesized and characterized by Dr. Linna 
Zhou). 
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Bis(carbamate) 2.30: Compound 2.29 (100 mg, 288 mol, 1.25 eq.) 
was dissolved in methanol (10 mL) and 4M HCl in 1,4-dioxane (10 
mL). The reaction was stirred at room temperature for 4 h and the 
solvent removed under reduced pressure. The residue was further 
treated with compound 2.10 (74.0 mg, 231 mol, 1.00 eq.) and 
NaBH3CN (21.0 mg, 346 mol, 1.50 eq.) in dry MeOH. The reaction 
mixture was stirred at room temperature overnight and the solvent 
removed under reduced pressure. The residue was purified by flash 
chromatography (CH2Cl2/MeOH) to afford the target product 2.30 
(50.0 mg, 76.7 mol, 27%) as a yellow solid. 1H-NMR (400 MHz, 
CDCl3) δ/ppm: 7.97 (d, J = 8.6 Hz, 2H), 7.91-7.89 (m, 4H), 7.65 (sbr, 
1H), 6.75 (d, J = 9.2 Hz, 2H), 3.92-3.88 (m, 2H), 3.81-3.77 (m, 2H), 
3.11 (s, 6H), 3.10-3.07 (m, 2H), 2.97-2.91 (m, 1H), 2.82-2.78 (m, 2H), 1.47 (s, 18H).
 13
C-NMR (101 
MHz, CDCl3) δ/ppm: 157.04, 155.50, 153.04, 143.58, 139.68, 128.04, 125.67, 122.54, 111.44, 82.06, 
76.28, 54.73, 45.83, 42.89, 40.29, 28.22. HRMS (ESI): C29H46N7O8S
+ 
calcd.: 652.3123, found: 
652.3129 [M+H]
+
. (This compound was synthesized and characterized by Dr. Linna Zhou). 
 
Bishydroxylamine 2.31: Compound 2.30 (25.0 mg, 38.3 mol, 1.00 eq.) 
was dissolved in TFA/TIS/H2O (95:2.5:2.5) and the reaction mixture was 
stirred at 0
o
C for 1h. The solvent was removed under reduced pressure 
and the residue purified by RP-HPLC (MeCN and 0.1% TFA in H2O). 
The product fractions were lyophilized to give the product 2.31 (8.00 mg, 
17.7 mol, 46%) as a yellow solid. 1H-NMR (600 MHz, DMSO-d6) 
δ/ppm: 8.12 (t, J = 5.8 Hz, 1H), 8.06-8.03 (m, 4H), 7.93 (d, J = 9.1 Hz, 
2H), 6.96 (d, J = 9.2 Hz, 2H), 4.02 (sbr, 4H), 3.85-3.83 (m, 1H), 3.27-
3.25 (t, J = 6.8 Hz, 2H), 3.19-3.17 (m, 8H).
 13
C-NMR (126 MHz, 
DMSO-d6) δ/ppm: 154.82, 153.20, 142.57, 139.04, 127.97, 125.47, 
122.35, 111.60, 70.84, 54.76, 44.77, 40.05, 39.81. HRMS (ESI): 
C19H30N7O4S
+ 
calcd.: 452.2074,  found: 452.2072 [M+H]
+
. (This 
compound was synthesized and characterized by Dr. Linna Zhou). 
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4.2.2.2 Synthesis of LYRAG pentapeptide hydroxylamine substrates 
 
The LYRAG pentapeptide mono- 2.6 and bishydroxylamine 2.7 were obtained via Fmoc-based 
automated and manual solid phase peptide synthesis (SPPS) on a rink amide AM resin from 
Novabiochem (0.17 mmol scale). The solid-phase bound LYRAG pentapeptide containing all 
protecting groups was readily synthesized on a Syro I Peptide Synthesizer (MultiSynTech GmbH, 
Witten, Germany) according to the following protocol: 
 
1) swelling the resin in DMF (1 mL/100 mg) for 12 min. 
2) Fmoc deprotection with 40% piperidine in DMF for 5 min., repeat with a fresh portion for 10 
min. 
3) wash with DMF 5 x 1 min. 
4) coupling with 4.0 eq. of Fmoc-Gly-OH dissolved in DMF (0.7 M)/4.0 eq. HCTU in DMF (0.7 
M)/4.0 eq. DIPEA in NMP (4.21 M) for 1 h. 
5) wash with DMF 2 x 2 min. 
6) capping with DIPEA in NMP (4.21 M)/Ac2O in DMF (0.44 M) for 21 min. 
7) wash with DMF 3 x 1 min. 
8) repeat steps 3-7 using Fmoc-Ala-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Tyr(tBu)-OH, Fmoc-Leu-
OH including a final wash with DMF 5 x 1 min. A small sample of resin (1 mg) was treated 
with a freshly prepared cleavage cocktail containing TFA/TIPS/H2O (95:2.5:2.5, 0.2 mL) for 
30 min. An aliquot of the cleavage cocktail was analyzed by UPLC-MS which confirmed the 
peptide mass of H-Gly-Ala-Arg-Tyr-Leu-NHFmoc. 
 
H-Gly-Ala-Arg-Tyr-Leu-NHFmoc: LRMS (ESI): C41H54N9O8
+
 calcd.: 800.4, found: 800.4 [M+H]
+
. 
 
The final hydroxylamine terminated peptides (2.6 and 2.7) were manually synthesized in a 2 mL 
polyethylene syringe equipped with a fritted disk and luer stopper according to the following protocol: 
1) swelling the LYRAG-containing resin (32 mg for 2.6, 10 mg for 2.7) in NMP (2 mL) for 1 h. 
2) Fmoc deprotection with 40% piperidine in DMF 2 x 10 min.  
3) wash with DMF/NMP (1:1) 3 x 1 min. 
4) coupling with 4.0 eq. of Boc-AOAc-OH 1.9 or bishydroxylamine 2.8/4.0 eq. HATU/4.0 eq. 
DIPEA in DMF (0.1 M) for 30 min. 
5) wash with CH2Cl2/NMP (1:1) 3 x 1 min. 
6) wash with CH2Cl2 3 x 1 min. 
7) peptide cleavage and deprotection of all protecting groups was performed with a freshly 
prepared cleavage cocktail containing TFA/TIPS/H2O (95:2.5:2.5, 1 mL) 2 x 30 min. The 
cleavage solutions containing the peptides were collected in a 2 mL Eppendorf tube. The 
peptide masses were confirmed by UPLC-MS analysis of the cleavage solutions.  
152 
 
8) the cleavage solutions were concentrated under reduced pressure to ~0.1 mL and the peptides 
were precipitated with cold Et2O (1.5 mL). The samples were centrifuged (10,000 rpm, 2 
min.) and the supernatant was carefully discarded. The peptides were washed with a fresh 
portion of Et2O (1.5 mL), sonicated and centrifuged again (10,000 rpm, 2 min.). This process 
was repeated once more and the peptide pellets were carefully dried with a gentle nitrogen 
stream. 
 
Both 2.6 and 2.7 (dissolved in 200 L H2O) were purified employing preparative RP-HPLC over a 
C18 column (Gemini NX5u, 110Å, AXIA, 250 x 21.2 mm) from Phenomenex (gradient: 0-60% (for 
2.6), 0-40% (for 2.7) MeCN in H2O, 1% MeCN, 0.1% formic acid in 25 min.) with a flow rate of 20 
mL/min monitoring and collecting the products at 280 nm. The product fractions were re-analyzed by 
UPLC-MS and lyophilized. Stock solutions were prepared in Milli-Q water and the concentration was 
determined using a NanoDrop 2000 spectrophotometer from Thermo Scientific with a path length of 1 
mm and LYRAG) = 1490 M
-1
 cm
-1
. All peptide stock solutions were stored at -20°C. 
 
 
 
Peptide 2.6: LRMS (ESI): C28H46N10O8
+
 calcd.: 651.3, found: 651.3 [M+H]
+
. tR = 0.99 min. 
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Peptide 2.7: LRMS (ESI): C32H56N12O9
+
 calcd.: 753.4, found: 753.5 [M+H]
+
. tR = 0.80 min. 
 
 
 
 
4.2.2.3 HPLC assays 
 
For all experiments fresh stock solutions of ortho-phthalaldehyde (2.1), benzaldehyde, 2-
formylbenzoic acid, O-benzylhydroxylamine (2.4), 3-formyl benzaldehyde, 4-formyl benzaldehyde, 2-
acetyl acetophenone and bishydroxylamine 2.15 were prepared in HPLC grade MeCN and directly 
used in the condensation reactions. Commercial 2-naphthaldehyde (Sigma) was dissolved in 
MeCN/H2O (3:2) and directly used in the condensation reactions. As reaction media a 100 mM 
aqueous KPi buffer (pH = 7.2) was used. The peptide stock solutions for condensation were allowed to 
warm to room temperature, vortexed and centrifuged prior to mixing and combined in a PP HPLC vial 
(BGB, Part Number: PPSV0903K) in the following order: 1) 100 mM KPi buffer pH = 7.2, 2) O-
alkylhydroxylamine, 3) L-tryptophan (Sigma) or lysozyme (Roth) and 4) aldehyde. The resulting 
solution was briefly mixed with a Gilson Pipetman and transferred into a HPLC vial. The reactions 
(Table 3.1/E1 entries 1-7) were analyzed by UPLC-MS on an Agilent device using a C18 column 
(ZORBAX RRHD) 1.8 , 2.1 x 50 mm from Agilent (gradient: 5-90% MeCN in H2O, 1% MeCN, 
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0.1% formic acid in 3.5 min., flow rate 0.45 mL/min, 40°C) at different time intervals (1 min then 
every 10 min for 1 h and after 1.5 h) by injecting 4 L (100 M reactants) or 20 L (10 M reactants) 
of the reaction mixture. Reactions (Table 3.1/E1 entries 8-9 and Table 3.2/E2 entries 1-6) were 
followed by RP-HPLC on a Shimadzu device using a C18 column (ECLIPSE XDB) 5 m, 4.6 x 150 
mm from Agilent (gradient: 2-55% MeCN, 1% H2O in H2O, 1% MeCN, 0.1% TFA in 13 min, flow 
1.0 mL/min, room temperature) at different time intervals (1 min, 30 min, 1 h and 1.5 h) by injecting 
20 L (100 M reactants) of the reaction mixture. The conversion was determined by integration of 
the signal at 280 nm of the starting LYRAG pentapeptide hydroxylamine or at 254 nm for all 
remaining reactions (Note: in cases where the starting materials were not UV active the product 
formation was monitored). The formation of the corresponding oximes was confirmed by ESI-MS 
spectra directly extracted from the UPLC-MS runs or by direct injection of the collected product 
peaks. 
 
Table E1: Comparison of oxime ligation reactions with different aromatic aldehydes and mono- or bishydroxylamines. 
 
 
Entry Aldehyde RONH2 Product (t = 1.5 h) 
Product tR 
[min] 
calc. mass 
[M+H]
+
 
found mass 
[M+H]
+
 
1   
 
-
[a]
 212.1 - 
2 
 
 
 
2.49
[b]
 256.1 256.1 
3 
 
 
 
2.44 205.1 205.1 
4 
 
 
 
2.84 240.1 240.1 
5 
  
 
2.41/3.12
[c]
 267.1 267.1/401.2 
6 
 
 
 
2.82 240.1 240.1 
7 
 
 
 
2.83 240.1 240.1 
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8 
 
 
 
-
[a]
 268.1 - 
9 
 
 
 
18.5
[d]
 290.1 290.3 
 
[a] No product formation was observed under these conditions after 1.5 h. [b] Conversion less than 10% after 1.5 h. [c] Bis-
monooxime (product of two molecules of ortho-phthalaldehyde (2.1) and one molecule of O-benzylhydroxylamine (2.4)). [d] 
Reactions were monitored by RP-HPLC and characterized by ESI-MS direct injection of the collected peaks. 
 
Table E2: Comparison of oxime ligation reactions with peptide substrates.  
 
 
Entry Aldehyde RONH2 Product (t = 1.5 h) 
Product tR 
[min] 
calc. mass 
[M+H]
+
 
found mass 
[M+H]
+
 
1
[a]
  2.6 
 
-
[d]
 739.4 - 
2
[a]
  2.7 
 
-
[d]
 840.5/928.5
[e]
 - 
3
[a]
 
 
2.6 
 
1.38 783.4 783.3 
4
[a]
 
 
2.6 
 
1.52 767.4 767.4 
5
[a]
 
 
2.7 
 
1.41 851.4
[f]
 851.4 
6
[b]
 
 
2.6 
 
1.52 767.4 767.4 
7
[b]
 
 
2.7 
 
1.44 851.4
[f]
 851.4 
156 
 
8
[c]
 
 
2.7 
 
-
[g]
 869.4/851.4 851.4 
 
[a] Substrate concentrations: 100 M. [b] Substrate concentrations: 10 M. [c] Human serum (20% v/v) was added to the 
reaction mixture; aldehyde concentration in this experiment is 50 M. [d] No product formation was observed under these 
conditions after 1.5 h. [e] Masses for monooxime/bisoxime. [f] Also observed: monooxime (tR = 1.20 min, 869.4 Da) and bis 
monooxime (peptide/dialdehyde 1:2, tR = 1.86 min, 985.3 Da). [g] Product peak collapses with peaks introduced by the 
human serum, approximate tR = 1.35 min. 
 
4.2.2.4 1H-NMR studies 
 
General Information 
All NMR experiments for the mechanistic and kinetic studies were performed at 298.15 K on a 
BrukerAvance III NMR spectrometer operating at 700.09 MHz, equipped with a 
1
H-
13
C/
15
N-D TCI 
cryo probe head with z-axis pulsed field gradients. All 1D proton experiments were recorded using 
exactly the same parameters (256 scans, relaxation delay of 1.5 s and an acquisition time of 2.78 s) 
and were processed similarly using line broadening of 0.3 Hz and after manual phase correction 
automated baseline correction was applied. The same integration regions were used for every spectrum 
and chemical shifts were referenced to the residual solvent peak of MeCN (1.94 ppm) and integrals 
were referenced to internal TMSP-d4 (3-(trimethylsilyl)-2,2',3,3'-tetradeuteropropionic acid). For every 
spectrum time points were corrected by half the experiment time, relative to the individual starting 
time. Ortho-phthalaldehyde (2.1) was purchased from Acros and O-benzylhydroxylamine (2.4) was 
neutralized from its HCl salt according to a published procedure.
300
 The pH (no correction for 
deuterium) was adjusted using a 827 pH Lab – Metrohm equipped with a glass minitrode which was 
pre-rinsed with D2O. 
 
Experimental 
Stock solutions for both ortho-phthalaldehyde (2.1) and O-benzylhydroxylamine (2.4) were freshly 
prepared in CD3CN. A KPi buffer stock solution was freshly prepared in D2O adjusting the pH to 7.1 
with concentrated DCl from ABCR (DCl, 38% wt% in D2O, 99.5% atom%D). A TMSP-d4 stock 
solution was freshly prepared in D2O. All experiments were conducted in standard NMR tubes (throw 
away quality) which were rinsed thoroughly with D2O and oven dried prior to use. After every 
addition of substrates the NMR tube was vortexed followed by sonication and finally centrifuged to 
assure a homogenous mixing prior to the respective NMR experiment. All experiments were setup as 
follows: 
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1. 440 L of KPi buffer (12.5 mM) were mixed inside of the NMR tube with 50 L of O-
benzylhydroxylamine (2.4, 1.10 mM) and 10 L of TMSP-d4 (0.275 mM). The sample was 
then locked to MeCN and shimmed before the addition of the OPA. 
2. 50 L of ortho-phthalaldehyde (2.1, 1.10 mM) was then added and the sample was shimmed 
again before conducting the first measurement. 
The final volume of the NMR sample was 550 L with the following final concentrations: 
100 M in each O-benzylhydroxylamine (2.4) and ortho-phthalaldehyde (2.1), respectively. 10mM 
KPi buffer and 5 M TMSP-d4 with a ratio of 4:1 (D2O KPi buffer/CD3CN). 
The time dependent 
1
H-NMR analysis with a full stack of the spectrum (10.5 – 4.7 ppm) containing all 
signals of interest is shown in Figure 3.5. A mechanistic overview of the processes is shown in 
Scheme 3.10. 
Since the IBHA intermediates could not be isolated in a pure form, a preparative scale of the oxime 
condensation was envisioned for full characterization. The following procedure was followed: 
 
A 10 mL flask under inert atmosphere equipped with a stir bar was charged with ortho-phthalaldehyde 
(53.0 mg, 0.39 mmol, 1.00 eq, 98% purity) dissolved in 1 mL of dry MeCN. To the stirring solution 
was added O-benzylhydroxylamine (48.5 mg, 0.39 mmol, 1.00 eq, 98% purity) as a solution in dry 
MeCN (0.50 mL) at room temperature. The reaction was stopped as soon as a white solid precipitated 
(45 seconds) which prevented efficient stirring. The stir bar was removed and washed with MeCN and 
the solvent was removed under reduced pressure and extensively dried under high vacuum to give 97 
mg of a white fluffy solid which turned out to be a 1:1.5 mixture of oxime 2.5 and IBHA 2.16 (as a 9:1 
mixture of diastereomers). It is important to mention that this mixture of oxime 2.5 and IBHA 2.16 
needs to be stored under inert atmosphere at -20°C since it was found that leaving a sample for several 
hours at room temperature will lead to full conversion of the IBHA 2.16 to the oxime 2.5. 
1
H (16 
scans), 
13
C (1024 scans) and DEPT135 (128 scans) spectra were recorded in CD3CN at 298.15 K on a 
BrukerAvance III NMR spectrometer operating at 500.13 MHz, equipped with a 5mm BBI probe head 
with z-axis pulsed field gradients. 
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Oxime 2.5: 
1
H-NMR (500 MHz, CD3CN) δ/ppm: 10.19 (s, 1H), 8.85 (s, 
1H), 7.88 (dd, J = 7.3 Hz, J = 1.2 Hz, 1H), 7.81 (dd, J = 7.6 Hz, J = 0.97 
Hz, 1H), 7.65 (dt, J = 7.5 Hz, J = 1.5 Hz, 1H), 7.61 (dt, J = 7.6 Hz, J = 1.4 
Hz, 1H), 7.45-7.41 (m, 2H), 7.41-7.37 (m, 2H), 7.36-7.30 (m, 1H), 5.22 
(s, 2H). 
13
C-NMR (126 MHz, CD3CN) δ/ppm: 193.94, 148.20, 138.75, 135.07, 134.62, 133.61, 
132.95, 131.00, 129.42, 129.41, 128.97, 128.88, 77.19. 
 
IBHA 2.16: 
1
H-NMR (500 MHz, CD3CN) δ/ppm: 7.51-7.46 (m, 2H), 
7.41-7.37 (m, 4H, overlapping), 7.36-7.30 (m, 3H, overlapping), 5.57 (d, 
J = 8.6 Hz, 2H), 5.08 (s, 2H), 4.16 (d, J = 8.5 Hz, 2H). 
13
C-NMR (126 
MHz, CD3CN) δ/ppm: 139.04, 138.92, 129.96, 129.73, 129.24, 128.81, 
123.85, 90.62, 79.21. 
 
Determining Keq and k2 
To estimate a value for Keq equation 4 was used. 
 
    
      
              
  
      
      
 (4) 
 
Equation 4: Keq = equilibrium constant [M
-1], [OPA] = [BnONH2] [M]. 
 
For all 
1
H-NMR measurements the corresponding integrals were converted into concentrations with 
reference to the internal standard TMSP-d4. All Keq values (10
7
 M
-1
) were then plotted against the time 
(sec) and from the steady-state region (between 7000-22000 sec) the average of these values was taken 
for Keq = 2 x 10
7
 M
-1
 (Figure E1, top). This analysis was done using Microsoft Excel 2010. 
 
To determine k2 a plot of ln[oxime] versus the time (sec) was performed where the slope of the straight 
line is a direct measure for the rate constant (Figure E1, bottom). A slight increase in ln[oxime] was 
found in the first 15000 seconds of the reaction which can be attributed to the initial build-up of the 
IBHA species. Therefore only the linear region (15000-50000 sec) was used for a best fit and the slope 
of the obtained trend line was determined to be k2 = 1.2 ± 0.2 x 10
-5
 s
-1
. The value is an average of two 
separate 
1
H-NMR experiments and was determined using Microsoft Excel 2010. 
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Figure E1: Time course NMR analysis; estimation of Keq and determination of k2. Top: steady-state region of the reaction 
allowing for an estimate of Keq. Bottom: Best fit of ln[oxime] over time in the linear region gives a direct measure of k2 as 
the slope. 
 
Equilibrium studies 
To determine whether the IBHA 2.16 is in a reversible equilibrium with another ortho-dialdehyde time 
dependent 
1
H-NMR spectra were recorded where the naphthalene IBHA 2.20 (see section 4.2.2.1 for 
synthetic details) was treated with a tenfold excess of ortho-phthalaldehyde (2.1). The 
1
H-NMR 
spectra were recorded as follows: The corresponding mixture of 2.20 was dissolved in 1:1 (D2O 
phosphate buffer/DMSO-d6) at 0.1 mM and a proton NMR was recorded. Then OPA (1 mM, 10 eq.) 
was added and time dependent 
1
H-NMR were recorded over 75 min. No interconversion of 2.20 to 
2.16 was observed (see Figure 3.8, panel D) thus supporting that this reaction is not in equilibrium. 
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4.2.2.5 Fluorescence quenching assay 
 
The assay and data analysis were performed by Dr. Linna Zhou. 
The fluorescence quenching experiments were conducted using a TECAN fluorescence plate reader 
and data was analyzed with the Megallan software. The fluorescence was monitored at the maximum 
absorption of lissamine-tagged OPA derivative 2.27 (567 nm) in KPi buffer (100 mM, pH 7.2). The 
bleaching effect was monitored at the excitation wavelength (567 nm) at concentrations of 5 M or 2 
M over 35 minutes. As shown in Figure E2, less than 5% and 8% bleaching was observed when 
quadruple measurements were performed at the concentration of 5 M and 2 M respectively. The 
data is therefore uncorrected for bleaching. 
 
Figure E2: Bleaching effect of lissamine-tagged OPA derivative 2.27 over 35 minutes at 5 M (A) and 2 M (B). 
 
The quenching experiments were conducted by mixing 2 L of lissamine-tagged OPA derivative 2.27 
(500 M or 200 M, in MeCN) with 2 L of dabsyl quencher 2.31 (500 M or 200 M, in DMSO) in 
196 L KPi buffer, followed by monitoring the fluorescence at 567 nM. The decrease in concentration 
over 80 minutes at final concentrations of 5 M or 2 M is shown in Figure E3 and Figure E4 
respectively. 
 
Figure E3: Two independent quadruple quenching experiments with lissamine-tagged OPA derivative 2.27 and dabsyl 
quencher 2.31 at 5 M. 
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Figure E4: Two independent quadruple quenching experiments with lissamine-tagged OPA derivative 2.27 and dabsyl 
quencher 2.31 at 2 M. 
 
 
Figure E5: Second order plots at 5 M and 2 M, respectively. 
HPLC analysis was also conducted and showed ~90% conversion of the starting material after 10 min 
at 10 M. Corresponding MS analysis confirmed the formation of the corresponding bisoxime and 
IBHA. 
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Figure E6: HPLC and MS analysis of the quenching reaction between lissamine-tagged OPA 
derivative 2.27 and dabsyl quencher 2.31 at 10 M. Lissamine-tagged OPA derivative 2.27 has a 
retention time of around 10.3 min, while the corresponding bisoxime product has a retention time of 
11.7 min containing the mass of 1176.3 [M+H]
+
. The observed mass of 1194.3 (DM = +18) is 
attributed to the IBHA. 
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4.2.2.6 DNA bioconjugation 
 
The synthesis and analysis of compounds as well as the DNA bioconjugation assay was performed by 
Dr. Kiril Tishinov. 
 
Native polyacrylamide gel electrophoresis (Native PAGE)  
Native PAGE was done in 15% gel (29:1 w/w acrylamide/bisacrylamide) in 1×TBE (89 mM Tris-
borate, 2 mM EDTA) with Orange G, Bromophenol blue and XylenCynol FF as tracer dyes. The 
electrophoretic samples were prepared by mixing 5 L of sample with 2.5 L 4×TBE in 40% (v/v) 
glycerol. Five microliters from the resulting mixtures were then applied on the gel without further pre-
treatment. Trace dye mixtures were applied on separate wells. The gels were run at 30 V/cm until the 
Orange G migrated to approximately 1 cm from the end of the gel. The gels were then washed briefly 
with deionized H2O and visualized using Bio-Rad ChemiDoc MP system, equipped with Image Lab 
5.0 software. The labeled species on the gels were traced by the intrinsic lissamine fluorescence (the 
device set-up for Blot/Rhodamine or Blot/Alexa488). The gels were then soaked in ethidium bromide 
solution in H2O for 15 min and then visualized again (set-up Nucleic Acids/Ethidium bromide) to 
detect all nucleic acid species present. 
 
Phosphoramidite synthesis 
MMT alcohol: tert-butyl N-(2-hydroxyethoxy)carbamate (310 mg, 
1.75 mmol, 1.00 eq.) was dissolved in Et2O (2 mL), saturated with 
HCl in Et2O  (6 mL) and the mixture was left at room temperature for 
6 h. The white crystalline precipitate that formed was recovered by 
centrifugation, washed with diethyl ether and dried under high 
vacuum. It was then dissolved in DMF (5 mL), NEt3 (1.90 mL, 14.1 mmol, 7.94 eq.) was added and 
the mixture was stirred under nitrogen at room temperature for 1 h. Monomethoxytrityl chloride (710 
mg, 2.30 mmol, 1.31 eq.) as a solution in 2 mL of DMF was added and the mixture stirred at room 
temperature overnight. The solvent was then removed under reduced pressure and the residue purified 
by flash chromatography (n-pentane/EtOAc, containing 1% NEt3) to yield the desired MMT alcohol as 
a yellow oil (406 mg, 1.16 mmol, 66%). 
1
H-NMR (250 MHz, CD3CN) δ/ppm: 7.18-7.35 (m, 12 H), 
6.82-6.88 (m, 3H), 3.76 (s, 3H), 3.64-3.68 (m, 2H), 3.50-3.54 (m, 2H).
 13
C-NMR (62.5 MHz, CD3CN) 
δ/ppm: 159.39, 146.01, 137.72, 131.22, 129.91, 129.87, 128.57, 128.53, 127.68, 113.80, 76.07, 74.21, 
61.31, 55.83. 
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MMT phosphoramidite: The MMT alcohol (220 mg, 
630 mol, 1.00 eq.) was dissolved in CH2Cl2 (8 mL) 
under nitrogen, 3-(bis(diisopropylamino)phosphanyl) 
oxy)propanenitrile (300 mg, 995 mol, 1.58 eq.) as a 
solution in 2 mL of CH2Cl2 and diisopropylammonium 
tetrazolide (61.0 mg, 356 mol, 0.56 eq.) were added and 
the mixture was stirred at room temperature overnight. 
The solvent was removed under reduced pressure and the residue purified by flash chromatography (n-
pentane/EtOAc, containing 1% NEt3) to yield the desired MMT phosphoramidite product as a yellow 
oil (231 mg, 420 mol, 67%). 1H-NMR (250 MHz, CD3CN) δ/ppm: 7.17-7.34 (m, 12 H), 6.79-6.87 
(m, 3H), 3.49-3.81 (m, 11H), 2.50-2.56 (m, 2H), 1.13 (d, J = 11.1 Hz, 6H), 1.11 (d, J = 11.1 Hz, 6H).
 
13
C-NMR (62.5 MHz, CD3CN) δ/ppm: 159.39, 146.03, 137.74, 131.21, 129.90, 128.58, 127.69, 
118.26, 118.21, 113.81, 74.60, 74.49, 74.15, 62.67, 62.41, 59.54, 59.24, 55.84, 43.90, 43.70, 24.98, 
24.85, 21.02, 20.91. 
31
P{
1
H} (CD3CN) δ/ppm: 147.57. HRMS (ESI): C31H40N3NaO4P
+ 
calcd.: 
572.2654,  found: 572.2659 [M+Na]
+
. 
 
Oligonucleotide synthesis and purification 
 
5’-O-alkylhydroxylamine-terminated DNA 41-mer 2.32: Solid-phase synthesis 
of d(XAG GTG CGA CTT GAT GAA GGA CTA CTG GAT TGA GGC TTA 
AAC) was carried out on 1-mol CPG columns using standard 
phosphoramidite chemistry with 0.3 M 5-benzylthio-1-H-tetrazole as activator. 
The 5′-hydroxylamine termination (position X) was introduced with MMT phosphoramidite with an 
extended coupling cycle (900 s) in DMT-ON regime. The oligonucleotide was cleaved and 
deprotected as the MMT-derivative. Cleavage of the MMT-group to obtain the free 5′-hydroxylamine 
was done with 20% (v/v) acetic acid in H2O for 1 h at room temperature. Semi-preparative HPLC was 
carried out on a LiChroCART 250-10, packed with Purospher STAR RP-18e (5 m) in 100 mM 
triethylammonium acetate, pH 7.0/MeCN gradient: 0-16% MeCN in 15 min, 16-80% MeCN in 5 min; 
flow rate 5 mL/min, detection by absorption at 254 nm. 
 
Fluorescent labeling with lissamine-tagged OPA derivative 2.27 
For initial screening of the labeling efficacy 40 M oligonucleotide 2.32 and 100 M fluorescent 
dialdehyde 2.27 (1 mM stock in DMSO) were mixed in H2O in a final volume of 10 L and the 
mixture was left in the dark for 1 h at room temperature, then analyzed by native PAGE. For 
concentration dependence studies 1, 5, 10, 20 and 40 M concentrations of oligonucleotide 2.32 were 
incubated with 100 M lissamine-tagged OPA derivative 2.27 for 1 h at room temperature in the dark. 
All reaction mixtures were analyzed by native PAGE (see Figure 3.10, right).  
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4.2.3 Boronic acid studies 
 
4.2.3.1 Synthesis of small molecules 
 
Oxime 2.35: 2-Formylphenylboronic acid (2.34) (49.0 mg, 310 mol, 
1.00 eq.) was dissolved in dry MeOH (3 mL) followed by the addition of 
O-benzylhydroxylamine ∙ HCl (50.0 mg, 310 mol, 1.00 eq.) which was 
washed down the flask with another 2 mL of dry MeOH. The progress of 
the reaction was monitored by UPLC-MS. After 15.5 h full conversion of the starting aldehyde was 
achieved and the solvent was removed under reduced pressure. The crude was purified employing 
preparative RP-HPLC (gradient: 5% MeCN in H2O, 0.1% TFA for 3 min, 5-95% MeCN in H2O, 0.1% 
TFA for 25 min) with a flow rate of 20 mL/min monitoring and collecting the product at 254 nm (tR = 
20.7 min). The product fractions were re-analyzed by UPLC-MS and lyophilized. The oxime was 
obtained as a fluffy white solid (52.0 mg, 203 mol, 65%). TLC (cyclohexane/EtOAc 1:1) Rf = 0.45. 
1
H NMR (400 MHz, CD3CN) ppm: 8.49 (s, 1H), 7.74-7.70 (m, 1H), 7.63-7.60 (m, 1H), 7.46-7.36 
(m, 6H), 7.36-7.31 (m, 1H), 6.49 (s, 2H) 5.17 (s, 2H). It has to be mentioned that the 
1
H-NMR spectral 
data of the boronic acid oxime 2.35 in CDCl3 contained product signals along with some boroxine or 
other unidentified boronic acid related signals. Measuring the sample in CD3CN proved to give a 
cleaner spectrum with no other species present. 
13
C-NMR (101 MHz, CDCl3) /ppm: 153.93, 138.31, 
136.47, 134.99, 133.29, 130.93, 129.97, 128.78, 128.76, 128.67, 128.59, 76.73. 
11
B-NMR (128 MHz, 
CDCl3) ppm: 29.00. 
11
B-NMR (128 MHz, CD3CN) ppm: 29.37. HRMS (ESI): C14H14BNNaO3
+ 
calcd.: 278.0959, found: 278.0963 [M+Na]
+
. 
 
Oxime 2.39: 2-Acetylphenylboronic acid (21.5 mg, 129 mol, 1.00 eq.) 
was dissolved in dry MeOH (1.5 mL) followed by the addition of O-
benzylhydroxylamine ∙ HCl (21.0 mg, 130 mol, 1.01 eq.) which was 
washed down the flask with another 1 mL of dry MeOH. The progress of 
the reaction was monitored by UPLC-MS. After 18 h full conversion of the starting ketone was 
achieved and the solvent was removed under reduced pressure. The crude was purified employing 
preparative RP-HPLC (gradient: 2% MeCN in H2O, 0.1% TFA for 3 min, 2-80% MeCN in H2O, 0.1% 
TFA for 25 min) with a flow rate of 20 mL/min monitoring and collecting the product at 254 nm (tR = 
22.4 min). The product fractions were re-analyzed by UPLC-MS and lyophilized. The oxime 2.39 was 
obtained as a fluffy white solid (20.0 mg, 74.0 mol, 58%, 98% purity). TLC (19:1 CH2Cl2/MeOH) Rf 
= 0.36. 
1
H-NMR (400 MHz, DMSO-d6) ppm: 7.70-7.60 (m, 1H), 7.47-7.37 (m, 3H), 7.30-7.19 (m, 
5H), 5.13 (s, 2H), 2.21 (s, 3H). 
13
C-NMR (101 MHz, DMSO-d6) /ppm: 162.62, 139.55, 136.63, 
132.02, 129.51, 128.98, 128.32, 128.12, 128.01, 126.43, 75.31, 14.70 (one signal for the carbon atom 
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directly attached to the boron was not observed due to the quadrupolar relaxation of the boron atom). 
11
B-NMR (128 MHz, DMSO-d6) ppm: 25.15 (after background spectrum subtraction). HRMS (ESI): 
C15H16BNNaO3
+ 
calcd.: 292.1115, found: 292.1120 [M+Na]
+
, C16H18BNNaO3
+ 
calcd.: 306.1272, 
found: 306.1277 [M+CH2Na]
+
, C17H20BNNaO3
+ 
calcd.: 320.1428, found: 320.1433 [M+C2H4Na]
+
. 
 
Pinacol ester 2.40: A 25 mL flask equipped with a Dean-Stark apparatus was 
charged with 2-formylphenylboronic acid (250 mg, 1.67 mmol, 1.00 eq.) and 
pinacol (216.7 mg, 1.83 mmol, 1.10 eq.) in benzene (10 mL). The mixture was 
refluxed for 5 h whereupon a 
1
H-NMR aliquot indicated full conversion of the 
starting boronic acid. The mixture was dried with Na2SO4 (~2 g), filtered and washed with benzene. 
The solvent was removed under reduced pressure to give the pinacol ester 2.40 as light yellow oil (387 
mg, 1.67 mmol, quantitative). TLC (cyclohexane/EtOAc 5:1) Rf = 0.50. 
1
H-NMR (400 MHz, CDCl3) 
ppm: 10.54 (s, 1H), 7.97-7.94 (m, 1H), 7.87-7.84 (m, 1H), 7.62-7.53 (m, 2H), 1.40 (s, 12H). 13C-
NMR (101 MHz, CDCl3) /ppm: 194.79, 141.39, 135.61, 133.13, 130.88, 128.04, 84.55, 25.02. (one 
signal for the carbon atom directly attached to the boron was not observed due to the quadrupolar 
relaxation of the boron atom). 
11
B-NMR (128 MHz, CDCl3) ppm: 31.28. HRMS (ESI): C13H18BO3
+ 
calcd.: 233.1344, found: 233.1344 [M+H]
+
, C13H17BNaO3
+ 
calcd.: 255.1163, found: 255.1164 
[M+Na]
+
. (This compound was synthesized and characterized by Cedric Stress). 
 
Oxime 2.41: Compound 2.40 (25.0 mg, 106 mol, 1.00 eq.) was dissolved 
in dry MeOH (2 mL) followed by the addition of O-benzylhydroxylamine 
∙ HCl (17.0 mg, 106 mol, 1.00 eq.) which was washed down the flask 
with another 1 mL of dry MeOH. The progress of the reaction was 
monitored by UPLC-MS. After 14.5 h full conversion of the starting 
aldehyde was achieved and the solvent was removed under reduced pressure. The crude was purified 
by flash chromatography (10:1 cyclohexane/EtOAc). The oxime 2.41 was obtained as a colorless oil 
(33.0 mg, 98.0 mol, 92%, 98% purity). TLC (cyclohexane/EtOAc 5:1) Rf = 0.63. 
1
H-NMR (400 
MHz, CDCl3) ppm: 8.95 (s, 1H), 7.98-7.95 (m, 1H), 7.86-7.83 (m, 1H), 7.47-7.41 (m, 3H), 7.41-7.35 
(m, 3H), 7.35-7.32 (m, 1H), 5.24 (s, 2H), 1.34 (s, 12H). 
13
C-NMR (101 MHz, CDCl3) /ppm: 150.46, 
138.03, 137.97, 136.31, 131.18, 128.84, 128.53, 127.98, 125.45, 84.15, 76.39, 25.01 (HMQC 
indicated that the protons at 7.47 and 7.37 ppm show a cross peak for the carbon at 128.84 ppm which 
is an overlay of two carbon signals - one signal for the carbon atom directly attached to the boron was 
not observed due to the quadrupolar relaxation of the boron atom). 
11
B-NMR (128 MHz, CDCl3) 
ppm: 31.09. HRMS (ESI): C20H25BNO3
+ 
calcd.: 338.1922, found: 338.1923 [M+H]
+
, 
C20H24BNNaO3
+ 
calcd.: 360.1741, found: 360.1744 [M+Na]
+
, C20H24BKNO3
+ 
calcd.: 376.1481, found: 
376.1479 [M+K]
+
. 
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Pincol ester 2.42: To a mixture of bis-(pinacolato)diboron (280 mg, 1.10 mmol, 
1.50 eq.), NaOAc (241 mg, 2.94 mmol, 4.00 eq.) and Pd(PPh3)2Cl2 (25.8 mg, 37.0 
mol, 5 mol%) in 1,4-dioxane (5.0 mL) was added 2-Bromoacetophenone (100 
L, 734 mol, 1.00 eq.). The resulting mixture was stirred at 90°C for 15 h and the 
solvent was removed under reduced pressure to give a grey semisolid. The crude 
was purified by flash chromatography on a Biotage Isolera Four device (5:1 to 4:1 
cyclohexane/EtOAc). The product 2.42 was isolated as yellow oil (83 mg, 331 mol, 45%, 98% 
purity). TLC (cyclohexane/EtOAc 5:1) Rf = 0.18. 
1
H-NMR (400 MHz, CDCl3) ppm: 7.83 (dt, J = 
7.8, 0.9 Hz, 1H), 7.57-7.49 (m, 2H), 7.47-7.40 (m, 1H), 2.61 (s, 3H), 1.44 (s, 12H). 
13
C-NMR (101 
MHz, CDCl3) /ppm: 199.94, 140.63, 132.62, 132.35, 129.00, 128.57, 83.85, 25.63, 25.04 (one signal 
for the carbon atom directly attached to the boron was not observed due to the quadrupolar relaxation 
of the boron atom). 
11
B-NMR (128 MHz, CDCl3) ppm: 31.26. HRMS (ESI): C8H9BNaO3
+ 
calcd.: 
187.0537, found: 187.0540 (free Boronic acid), C14H19BNaO3
+ 
calcd.: 269.1319, found: 269.1320. 
LRMS (ESI): 147.1 [M-C6H11O]
+
, 247.1 [M+H]
+
, 269.2 [M+Na]
+
, 285.1 [M+K]
+
, 515.4 [2M+Na]
+
. 
 
Oxime 2.43: Compound 2.42 (20.0 mg, 80.0 mol, 1.00 eq.) was 
dissolved in dry MeOH (1.5 mL) followed by the addition of O-
benzylhydroxylamine ∙ HCl (13.0 mg, 81.0 mol, 1.01 eq.) which was 
washed down the flask with another 1 mL of dry MeOH. The progress of 
the reaction was monitored by UPLC-MS. After 18 h full conversion of 
the starting ketone was achieved and the solvent was removed under reduced pressure. The crude was 
purified by flash chromatography (6:1 cyclohexane/EtOAc). The early fractions contained 12 mg of 
desired product. The fractions which had to be eluted with (19:1 CH2Cl2/MeOH) didn’t contain the 
free boronic acid product as expected, instead another 10 mg of desired product were isolated. This 
observation is probably attributed to a charged product species containing an additional methoxy 
group on the boron atom which changes its polarity significantly. The oxime 2.43 was obtained as 
colorless oil (22.0 mg, 63.0 mol, 79%). TLC (6:1 cyclohexan/EtOAc) Rf = 0.52. NMR spectroscopy 
indicated a mixture of stereoisomers of 11:1.  
 
Major stereoisomer: 
1
H-NMR (400 MHz, CDCl3) ppm: 7.72 (dd, J = 7.5, 0.9 Hz, 1H), 7.49-7.37 (m, 3H), 7.37-7.26 (m, 
4H), 7.25-7.06 (m, 1H), 5.23 (s, 2H), 2.27 (s, 3H), 1.34 (s, 12H). 
13
C-NMR (101 MHz, CDCl3) /ppm: 
159.26, 143.32, 138.37, 134.98, 130.44, 128.43, 127.99, 127.72, 127.59, 127.38, 83.95, 75.94, 24.98, 
17.11. 
11
B-NMR (128 MHz, CDCl3) ppm: 31.65. HRMS (ESI): C21H27BNO3
+ 
calcd.: 352.2079, 
found: 352.2085 [M+H]
+
, C21H26BNNaO3
+ 
calcd.: 374.1898, found: 374.1906 [M+Na]
+
. 
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Minor stereoisomer: 
1
H-NMR (400 MHz, CDCl3) ppm: 7.84 (dd, J = 7.2, 1.0 Hz, 1H), 7.49-7.37 (m, 3H), 7.37-7.26 (m, 
4H), 7.25-7.06 (m, 1H), 5.04 (s, 2H), 2.18 (s, 3H), 1.30 (s, 12H). 
13
C-NMR (101 MHz, CDCl3) /ppm: 
142.84, 138.92, 135.41, 130.94, 128.19, 127.32, 127.96, 127.23, 126.14, 83.88, 75.15, 24.90, 23.02. 
11
B-NMR (128 MHz, CDCl3) ppm: 31.65. 
 
 
LYRAG pentapeptide oxime 2.44 was exclusively analyzed by LC-
MS: 
LRMS (ESI): C35H52BN10O10
+ 
calcd.: 783.4, found: 783.7 [M+H]
+
. 
RP-HPLC: 2-98% MeCN containing 1% H2O in H2O containing 1% MeCN over 18 min, 1 mL/min, tR 
= 10.2 min.  
 
Pinacol ester 2.45: A flame dried 50 mL flask under argon was charged with 2-
bromoisophtaldehyde (250 mg, 1.16 mmol, 1.00 eq.) and dissolved in 5 mL of 1,4-
dioxane. Pd(dppf)Cl2 (42.5 mg, 58.0 mol, 5 mol%), bis-(pinacolato)diboron (295 
mg, 1.16 mmol, 1.00 eq.) and KOAc (342 mg, 3.49 mmol, 3.00 eq.) were added as 
solids. The reagents were washed down the flask with 5 mL of 1,4-dioxane and the mixture heated at 
95°C. The mixture was stirred for 6.5 h and allowed to cool down to room temperature. The mixture 
was filtered over Celite and the cake washed with CH2Cl2 (50 mL). The filtrate was concentrated 
under reduced pressure to give a brown oil which was purified employing preparative RP-HPLC 
(gradient: 1% MeCN in H2O, 0.1% TFA for 3 min, 1-50% MeCN in H2O, 0.1% TFA for 25 min) with 
a flow rate of 20 mL/min monitoring and collecting the product at 254 nm (tR = 8.5 min). The product 
fractions were re-analyzed by UPLC-MS and lyophilized to give the product 2.45 as a fluffy white 
solid (104 mg, 400 mol, 34%). It is noteworthy to mention that the recorded NMR data suggested a 
mixture of at least two product species; one which was the pinacol ester 2.45 the other which seemed 
to be the boronic acid. 
1
H-NMR (400 MHz, DMSO-d6) δ/ppm: 10.07 (2 x s, 2H), 8.26 and 8.19 (2 x d, 
J = 7.6 Hz, 2H), 7.89 and 7.76 (t, J = 7.7 Hz, 1H), 3.52 (sbr, 2H), 1.41 (s, 12H). 
13
C-NMR (101 MHz, 
DMSO-d6) δ/ppm: 193.49, 193.24, 140.28, 138.91, 136.98, 135.26, 130.34, 128.87, 83.88, 25.24. 
11
B-
NMR (128 MHz, DMSO-d6) δ/ppm: 31.35. LRMS (ESI): C14H18BO4
+ 
calcd.: 261.1, found: 261.1 
[M+H]
+
. 
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Monooxime 2.46 was exclusively analyzed by LC-MS: 
LRMS (ESI): C15H15BNO4
+ 
calcd.: 284.1, found: 284.2 [M+H]
+
. RP-
HPLC: 2-98% MeCN containing 1% H2O in H2O containing 1% MeCN 
over 18 min, 1 mL/min. tR = 13.8 min. 
 
Bisoxime 2.47 was exclusively analyzed by LC-MS: 
LRMS (ESI): C22H20BN2O3
+ 
calcd.: 371.2, found: 371.3 [M-OH]
+
. RP-
HPLC: 2-98% MeCN containing 1% H2O in H2O containing 1% MeCN 
over 18 min, 1 mL/min. tR = 15.0 min.  
 
 
 
 
Dabsyl hydroxylamine 2.49: An oven dried flask 
under argon was charged with 4-
(dimethylamino)azobenzen-4’-sulfonyl chloride 
(111 mg, 333 mol, 1.00 eq.), O,O’-1,3-
propanediylbishydroxylamine  dihydrochloride 
(66.0 mg, 365 mol, 1.10 eq.) and dry EtOH (12 mL). NEt3 (170 L, 1.22 mmol, 3.67 eq.) was added 
and the resulting mixture was stirred at room temperature for 2 h. The solvent was removed under 
reduced pressure to give a red solid. The crude was adsorbed onto RP-C18 silica gel and purified by 
flash chromatography on a Biotage Isolera Four device (gradient: 0% MeCN for 4 min, 0-78% MeCN 
for 32 min, 78-100% MeCN for 4 min) with a flow rate of 50 mL/min monitoring and collecting the 
product at 254 nm (tR = 27.0 min). The pure fractions were lyophilized to give dabsyl hydroxylamine 
2.49 as an orange crystalline solid (51.0 mg, 130 mol, 39%). 1H-NMR (400 MHz, DMSO-d6) ppm: 
10.46 (s, 1H), 8.00-7.91 (m, 4H), 7.88-7.80 (m, 2H), 6.90-6.82 (m, 2H), 5.92 (s, 2H), 3.93 (t, J = 6.4 
Hz, 2H), 3.53 (t, J = 6.4 Hz, 2H), 3.10 (s, 6H), 1.76 (quint., J = 6.4 Hz, 2H). 
13
C-NMR (101 MHz, 
DMSO-d6) /ppm: 155.25, 153.24, 142.62, 136.80, 129.40, 125.55, 122.01, 111.62, 73.55, 71.30, 
39.85, 26.93. HRMS (ESI): C17H24N5O4S
+ 
calcd.: 394.1544, found: 394.1542 [M+H]
+
, 
C17H23N5NaO4S
+ 
calcd.: 416.1363, found: 416.1358 [M+Na]
+
. 
 
Carbamate 2.51: 3-bromopropylamine hydrobromide (2.00 g, 8.95 mmol, 1.00 
eq.) was added to a solution of di-tert-butyl dicarbonate (1.97 g, 8.95 mmol, 
1.00 eq.) in CH2Cl2 (30 mL) followed by NEt3 (1.25 mL, 8.95 mmol, 1.00 eq.). The mixture was 
stirred at room temperature for 1 h and diluted with another 20 mL of CH2Cl2. The mixture was 
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washed with saturated KHSO4 (3 x 50 mL, aqueous). The combined organic layers were dried over 
Na2SO4, filtered and concentrated under reduced pressure to give the product 2.51 as a colorless to 
slightly yellow oil (2.09 g, 8.79 mmol, 98%). 
1
H-NMR (400 MHz, CDCl3) ppm: 4.69 (sbr, 1H), 3.43 
(t, J = 6.6 Hz, 2H), 3.31-3.19 (m, 2H), 2.03 (quint., J = 6.6 Hz, 2H), 1.43 (s, 9H). 
13
C-NMR (101 
MHz, CDCl3) ppm: 156.06, 79.53, 39.11, 32.2, 30.93, 28.51. HRMS (ESI): C8H16BrNNaO2
+ 
calcd.: 
260.0257, found: 260.0258 [M+Na]
+
. 
 
Ether 2.52: An oven dried 25 mL flask equipped with a stir bar was 
charged with 2-bromo-5-hydroxybenzaldehyde (480 mg, 2.34 
mmol, 1.00 eq.), tert-butyl (3-bromopropyl)carbamate (2.51) (575 
mg, 2.37 mmol, 1.01 eq.) which were dissolved in 6 mL of dry DMF. To the stirring solution was 
added K2CO3 (970 mg, 7.02 mmol, 3.00 eq.) whereupon the color turned to bright yellow. The 
heterogeneous mixture was stirred at 80°C and the progress of the reaction was monitored by UPLC-
MS. After 21 h (still starting benzaldehyde derivative) H2O (50 mL) was added and the mixture 
extracted with EtOAc (3 x 15 mL). The combined organics were dried over Na2SO4, filtered and the 
solvent removed under reduced pressure to give a slightly orange oil. The crude was purified twice by 
flash chromatography (5:1 cyclohexane/EtOAc) but the starting benzaldehyde derivative (8% 
according to 
1
H-NMR) could not be removed efficiently from the product. Compound 2.52 was 
obtained as slightly yellow oil (654 mg, 1.68 mmol, 72%) in 92% purity. TLC (cyclohexane/EtOAc 
5:1) Rf = 0.22. 
1
H-NMR (400 MHz, CDCl3) ppm: 10.30 (s, 1H), 7.52 (d, J = 8.8 Hz, 1H), 7.40 (d, J 
= 3.2 Hz, 1H), 7.03 (dd, J = 8.8, 3.2 Hz, 1H), 4.69 (sbr, 1H), 4.05 (t, J = 6.0 Hz, 2H), 3.36-3.27 (m, 
2H), 1.99 (quint., J = 6.3 Hz, 2H), 1.44 (s, 9H). 
13
C-NMR (101 MHz, CDCl3) /ppm: 191.90, 158.60, 
156.15, 134.75, 134.09, 123.54, 118.18, 113.51, 79.59, 66.36, 37.91, 29.60, 28.55. HRMS (ESI): 
C10H13BrNO2
+ 
calcd.: 258.0124, found: 258.0121 [M-C5H7O2]
+
, C15H20BrNNaO4
+ 
calcd.: 380.0468, 
found: 380.0465 [M+Na]
+
, C16H24BrNNaO5
+ 
calcd.: 412.0730, found: 412.0727 [M+CH4O]
+
. 
 
Amine 2.53: A 2.5 mL screw cap vial was charged with 2.52 (70.0 mg, 
162 mol, 1.00 eq.) and dissolved in 250 L of CH2Cl2. To the stirring 
solution was added 250 L of TFA whereupon the color changed 
immediately to light orange/yellow. The mixture was stirred at rt for 1 h 
(UPLC-MS indicated full conversion to the free amine). The solvent mixture was carefully removed 
under reduced pressure and co-evaporated once with toluene followed by extensive drying under HV 
to give 97 mg of an orange oil. The sample was pure enough according to 
1
H-NMR and contained 
around 20% (w/w) of toluene and still 10% (w/w) of unreacted 2-bromo-5-hydroxybenzaldehyde. It 
was assumed that the TFA salt was obtained since the sample was not neutralized and purified. 
1
H-
NMR (500 MHz, CDCl3) /ppm: 10.22 (s, 1H), 7.72 (sbr, 2H), 7.52 (d, J = 8.6 Hz, 1H), 7.37-7.32 (m, 
1H), 7.04-7.00 (m, 1H), 4.16 (t, J = 5.0 Hz, 2H), 3.40-3.26 (m, 2H), 2.29-2.20 (m, 2H). 
13
C-NMR (126  
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MHz, CDCl3) /ppm: 192.43, 157.72, 134.98, 133.96, 123.20, 119.12, 113.84, 66.59, 39.04, 26.74. 
UPLC-MS (ESI): tR = 0.925 min, C10H13BrNO2
+ 
calcd.: 258.0, found: 258.0 [M+H]
+
. 
 
Lissamine aldehyde 2.55: A 2.5 mL screw cap vial was charged 
with 2-bromo-5-hydroxybenzaldehyde (20.6 mg, 100 mol, 1.00 
eq.), NEt3 (17.0 L, 122 mol, 1.21 eq.) and DMAP (3.00 mg, 
25.0 mol, 0.25 eq.) and dissolved in 1 mL of dry CH2Cl2. At 
0°C lissamine™ rhodamine B sulfonylchloride (2.54) (61.0 mg, 
100 mol, 1.00 eq.) was added as a solid and washed down the 
flask with another 1 mL of dry CH2Cl2. The mixture was allowed 
to warm to room temperature and the progress of the reaction was monitored by UPLC-MS. After 1.5 
h full conversion was observed and the solvent was removed under reduced pressure to give 111 mg of 
a purple solid. The crude was purified by flash chromatography on a Biotage Isolera Four device (5% 
MeOH in CH2Cl2, isocratic) with a flow rate of 50 mL/min monitoring and collecting the product at 
254 nm (tR = 3.8 min). The fractions were re-analyzed by UPLC-MS and pure fractions were 
combined to give the product 2.55 as a green/purple metallic solid (39.0 mg, 50 mol, 50%, 95% 
purity). 
1
H-NMR (400 MHz, MeOD-d4) /ppm: 10.25 (s, 1H), 8.63 (d, J = 1.8 Hz, 1 H), 8.53 (d, J = 
1.9 Hz, 1 H), 8.50 (m, 1H), 8.10 (dd, J = 8.0, 1.9 Hz, 1 H), 8.06 (dd, J = 8.0, 1.9 Hz, 1H), 7.98 (sbr, 
1H), 7.89 (d, J = 8.8 Hz, 1H), 7.67 (d, J = 8.7 Hz, 1H), 7.60 (d, J = 8.0 Hz, 1H), 7.56 (d, J = 8.0 Hz, 
1H), 7.54-7.50 (m, 1H), 3.76-3.62 (m, 8H), 1.35-1.26 (m, 24H). The 
1
H-NMR spectrum indicated a 
mixture of rotamers of the aromatic 9-phenylxanthene core and the four ethyl groups since only one 
aldehyde proton was observed. 
13
C-NMR data could not be recorded in MeOD-d4 since the solubility 
limit was reached and the product precipitate in the NMR tube. UPLC-MS (ESI): tR = 2.800 min, 
C34H34BrN2O8S2
+ 
calcd.: 741.1, found: 741.1 [M+H]
+
.  
 
Boronic ester 2.60 was prepared according to a slightly modified literature 
procedure by SELLA et al.
301
 
An oven dried 25 mL flask under argon was charged with 2-bromo-5-
hydroxybenzaldehyde (253 mg, 1.25 mmol, 1.00 eq.) and dissolved in 4 mL 
of 1,4-dioxane. Pd(dppf)Cl2 (92.0 mg, 126 mol, 10.1 mol%), bis-(pinacolato)diboron (380 mg, 1.50 
mmol, 1.20 eq.) and KOAc (367 mg, 3.74 mmol, 3.00 eq.) were added as solids. The reagents were 
washed down the flask with 2 mL of 1,4-dioxane and the mixture heated at 95°C. The mixture was 
stirred for 3 h (
1
H-NMR aliquot indicated full conversion) and allowed to cool down to room 
temperature and diluted with 10 mL of CH2Cl2. The mixture was washed with H2O (20 mL) but the 
phases didn’t separate. The organics were removed under reduced pressure and the residue diluted 
again with 30 mL of CH2Cl2. The addition of brine (20 mL) and chloroform (20 mL) didn’t improve 
phase separation and therefore the “bottom” phase was carefully separated while extracting the 
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“aqueous” phase with chloroform (2 x 20 mL). The combined organics were then treated with 
activated charcoal (~3 g) and dried over Na2SO4, filtered and concentrated under reduced pressure to 
give a brown oil which was dried extensively under high vacuum overnight. The crude was purified by 
flash chromatography (cyclohexane/EtOAc, 6:1) to give the product 2.60 as an orange oil which 
crystallized upon standing (147 mg, 587 mol, 46%). 1H-NMR (400 MHz, CDCl3) /ppm: 10.65 (s, 
1H), 7.86 (d, J = 8.2 Hz, 1H), 7.51 (d, J = 2.6 Hz, 1H), 7.10 (dd, J = 8.2, 2.6 Hz, 1H), 5.95 (sbr, 1H), 
1.37 (s, 12H). 
13
C-NMR (101 MHz, CDCl3) /ppm: 195.32, 158.52, 143.68, 138.59, 120.55, 113.33, 
84.36, 25.01 (one signal for the carbon atom directly attached to the boron was not observed due to the 
quadrupolar relaxation of the boron atom). 
11
B-NMR (128 MHz, CDCl3) ppm: 30.93. HRMS (ESI): 
C13H17BNaO4
+ 
calcd.: 271.1112, found: 271.1111 [M+Na]
+
. 
 
Lissamine boronic acid 2.61: A flame dried 5 mL flask was 
charged with lissamine™ rhodamine B sulfonylchloride 
(2.54) (50.0 mg, 82.0 mol, 1.00 eq.) and dissolved in 2 mL 
of dry CH2Cl2. Boronic acid pinacol ester 2.60 (23.8 mg, 
86.0 mol, 1.05 eq.) was added followed by NEt3 (13.0 L, 
93.0 mol, 1.13 eq.). The progress of the reaction was 
monitored by UPLC-MS. After a total of 17 h at room 
temperature the reaction was stopped and the solvent was 
removed under reduced pressure to give 81 mg of a purple solid. The crude was purified by flash 
chromatography on a Biotage Isolera Four device (0-8% MeOH in CH2Cl2) with a flow rate of 25 
mL/min monitoring and collecting the product at 254 nm (tR = 10.5 min). The fractions were re-
analyzed by UPLC-MS but were found to be still impure containing a major impurity with the mass of 
679 Da. The crude (35 mg) was purified employing preparative RP-HPLC (gradient: 5% MeCN in 
H2O, 0.1% TFA for 3 min, 5-95% MeCN in H2O, 0.1% TFA for 30 min) with a flow rate of 20 
mL/min monitoring and collecting the product at 254 nm (tR = 22.8 min). The product fractions were 
re-analyzed by UPLC-MS and lyophilized to give the product 2.61 as a purple film (3.00 mg, 3.80 
mol, 4%, 97% purity). Characterization by 1H and 13C-NMR failed in various solvents (DMSO-d6, 
CDCl3 and MeOD-d4). It is noteworthy to mention that the isolated product 2.61 was pure according to 
UPLC-MS containing the desired mass. The boronic acid moiety however was found to be oxidized 
within days to give the corresponding aromatic alcohol 2.62 (679 Da). UPLC-MS (ESI): tR = 2.394 
min, C34H36BN2O10S2
+ 
calcd.: 707.2, found: 707.2 [M+H]
+
. 
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Dabsyl bromide 2.64: Compound 2.52 
(113 mg, 284 mol, 1.00 eq., 90% purity) 
was dissolved in dry CH2Cl2 (2 mL) 
followed by the addition of TFA (0.50 
mL). The mixture was stirred at room 
temperature and the progress of the 
reaction was monitored by UPLC-MS. After 25 min full conversion of the starting material was 
observed. The solvents were removed under reduced pressure to give a orange oil which was 
extensively dried under high vacuum. The mass balance was too high which was attributed to residual 
TFA in the sample. Without further purification the crude TFA salt of the free amine was dissolved in 
dry EtOH (10 mL) and cooled to 0°C. To the stirring solution was added dabsyl chloride (123 mg, 323 
mmol, 1.00 eq., 97.5% purity) followed by NEt3 (2 mL). It has to be noticed that the excess of base 
was chosen to neutralize the TFA salt of the free amine as well as the residual TFA which could not be 
removed by high vacuum treatment. The mixture was allowed to warm to room temperature and the 
progress of the reaction was monitored by UPLC-MS. The starting amine was still present after 18 h at 
which point the reaction was stopped and the solvent was removed under reduced pressure. The crude 
was purified by flash chromatography on a Biotage Isolera Four device (3:1 cyclohexane/EtOAc, 
isocratic). The product was isolated as a red solid (41.0 mg, 69.2 mol, 21%, 92% purity). An 
analytical sample was purified employing preparative RP-HPLC (gradient: 20% MeCN in H2O, 0.1% 
TFA for 3 min, 20-95% MeCN in H2O, 0.1% TFA for 25 min) with a flow rate of 20 mL/min 
monitoring and collecting the product at 254 nm (tR = 23.9 min). The product fractions were re-
analyzed by UPLC-MS and lyophilized to give 2.64 as a dark red crystalline solid. TLC 
(cyclohexane/EtOAc 1:1) Rf = 0.55. 
1
H-NMR (400 MHz, CDCl3) ppm: 10.24 (s, 1H), 7.96-7.89 (m, 
4H), 7.88-7.82 (m, 2H), 7.49 (d, J = 8.8 Hz, 1H), 7.30 (d, J = 3.2, 1H), 6.95 (dd, J = 8.8, 3.2 Hz, 1H), 
6.82-6.76 (m, 2H), 4.80 (t, J = 6.6 Hz, 1H), 3.98 (t, J = 5.8 Hz, 2H), 3.23 (q, J = 6.2 Hz, 2H), 3.14 (s, 
6H), 1.97 (quint., J = 6.2 Hz, 2H). 
13
C-NMR (101 MHz, CDCl3) /ppm: 191.78, 158.21, 155.17, 
153.44, 143.54, 139.23, 134.78, 134.05, 128.18, 126.37, 123.36, 122.59, 118.37, 113.46, 112.00, 
65.81, 40.63, 40.61, 29.16. HRMS (ESI): C24H26BrN4O4S
+ 
calcd.: 545.0853, found: 545.0842 [M+H]
+
, 
C24H25BrN4NaO4S
+ 
calcd.: 567.0672, found: 567.0666 [M+Na]
+
,  C25H29BrN4NaO5S
+ 
calcd.: 
599.0934, found: 599.0929 [M+CH4NaO]
+
. 
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Dabsyl boronic acid 2.65: A flame 
dried 5 mL Schlenk tube under argon 
equipped with a stir bar was charged 
with compound 2.64 (9.00 mg, 17.0 
mmol, 1.00 eq.) and dissolved in 1 mL 
of freshly distilled 1,4-dioxane. To the 
stirring solution was added bis-(pinacolato)diboron (8.60 mg, 34.0 mmol, 2.05 eq.), NaOAc (4.30 mg, 
52 mmol, 3.18 eq.) and Pd(PPh3)2Cl2 (1.20 mg, 2.0 mmol, 10 mol%) and washed down the pressure 
tube with 0.5 mL of 1,4-dioxane. The pressure tube was closed and the mixture heated to 90°C. The 
progress of the reaction was monitored by UPLC-MS and after 16 h the mixture was allowed to cool 
to room temperature and filtered over a plug of cotton. The solvent was removed under reduced 
pressure to give 23 mg of a crude orange residue. The crude was purified employing preparative RP-
HPLC (gradient: 10% MeCN in H2O, 0.1% TFA for 13 min, 10-98% MeCN in H2O, 0.1% TFA for 30 
min) with a flow rate of 20 mL/min monitoring and collecting the product at 254 nm (tR = 31.4 min). 
The product fractions were re-analyzed by UPLC-MS and lyophilized to give 2.65 as a fluffy dark red 
solid (3.7 mg, 6.25 mol, 38%). 1H-NMR (400 MHz, DMSO-d6) ppm: 10.18 (s, 1H),  7.94-7.85 (m, 
4H), 7.85-7.76 (m, 3H), 7.58 (d, J = 8.1 Hz, 1H), 7.32 (d, J = 2.5 Hz, 1H), 7.14 (dd, J = 8.3, 2.5 Hz, 
1H), 6.88-6.84 (m, 2H), 4.03 (t, J = 6.2 Hz, 2H), 3.09 (s, 6H), 3.01-2.93 (m, 2H), 1.89-1.80 (m, 2H). 
13
C-NMR (101 MHz, DMSO-d6) /ppm: 194.22, 159.14, 154.49, 153.14, 142.62, 141.35, 140.17, 
135.58, 127.80, 125.44, 122.27, 119.61, 112.99, 111.63, 64.77, 39.88, 39.35 (overlapping with DMSO 
signal - identified by DEPT135), 28.79 (one signal for the carbon atom directly attached to the boron 
was not observed due to the quadrupolar relaxation of the boron atom).
 11
B-NMR (128 MHz, DMSO-
d6) ppm: 20.11 (measured in a 701-PQ NMR tube using 2048 scans and after background spectrum 
subtraction). HRMS (ESI): C24H28BN4O6S
+ 
calcd.: 511.1817, found: 511.1826 [M+H]
+
, 
C25H30BN4O6S
+ 
calcd.: 525.1974, found: 525.1979 [M+CH3]
+
, C24H27BN4NaO6S
+ 
calcd.: 533.1637, 
found: 533.1638 [M+Na]
+
. 
 
Lissamine hydroxylamine 2.66: An oven dried 10 mL flask 
under argon was charged with O,O’-1,3-
propanediylbishydroxylamine dihydrochloride (13.0 mg, 72.0 
mol, 1.10 eq.) and dry EtOH (4 mL). The suspension was 
cooled to 0°C before NEt3 (46 L, 330 mol, 5.00 eq.) was 
added. After 5 min lissamine™ rhodamine B sulfonylchloride 
(2.54) (40.0 mg, 66.0 mol, 1.00 eq.) was added as a solid and 
the reaction allowed to warm to room temperature. The mixture 
was stirred for 2 h and UPLC-MS indicated a product peak (647.3 Da) along with a peak 
corresponding to the dimer (1187.3 Da). The solvent was removed under reduced pressure to give a 
purple solid (86 mg). The crude was purified employing preparative RP-HPLC (gradient: 25% MeCN 
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in H2O, 0.1% TFA for 3 min, 25-80% MeCN in H2O, 0.1% TFA for 25 min) with a flow rate of 20 
mL/min monitoring and collecting the product at 254 nm (tR = 13.0 min). The product fractions were 
re-analyzed by UPLC-MS and lyophilized to give 2.66 as a dark purple fluffy solid (11.6 mg, 18.0 
mol, 27%). 1H-NMR (400 MHz, DMSO-d6) ppm: 10.78 (s, 1H), 10.50 (sbr, 2H), 8.50 (d, J = 1.9 
Hz, 1H), 8.01 (dd, J = 8.0, 1.9 Hz, 1H), 7.57 (d, J = 8.0 Hz, 1H), 7.06 (dd, J = 9.5, 2.4 Hz, 2H), 6.96 
(d, J = 2.4 Hz, 2H), 6.93 (d, J = 9.4 Hz, 2H), 4.07-4.00 (m, 4H), 3.70-3.58 (m, 8H), 1.94 (quint., J = 
6.2 Hz, 2H), 1.21 (t, J = 7.0 Hz, 12H). 
13
C-NMR (101 MHz, DMSO-d6) /ppm: 157.08, 156.76, 
155.04, 147.51, 138.12, 134.29, 132.41, 130.83, 127.52, 113.77, 113.34, 95.47, 72.80, 71.26, 45.27, 
26.32, 12.48. HRMS (ESI): C30H39N4O8S2
+ 
calcd.: 647.2204, found: 647.2206 [M+H]
+
, 
C30H38N4NaO8S2
+ 
calcd.: 669.2023, found: 669.2021 [M+Na]
+
.  
 
 
Oxime 2.68: Salicylaldehyde (31.0 mg, 249 mol, 1.00 eq.) was dissolved 
in dry MeOH (3 mL) followed by the addition of O-benzylhydroxylamine 
∙ HCl (40.0 mg, 0.248 mmol, 1.00 eq.) which was washed down the flask 
with another 2 mL of dry MeOH. The progress of the reaction was 
monitored by UPLC-MS. After 21 h full conversion of the starting aldehyde was achieved and the 
solvent was removed under reduced pressure. The crude was passed through a short plug of silica 
eluting the desired compound with cyclohexane/EtOAc (6:1). The oxime 2.68 was obtained as 
colorless oil which crystallized upon drying under high vacuum (56.0 mg, 248 mol, 99%). TLC 
(cyclohexane/EtOAc 6:1) Rf = 0.59. 
1
H-NMR (400 MHz, CDCl3) ppm: 9.80 (s, 1H), 8.22 (s, 1H), 
7.44-7.32 (m, 5H), 7.30-7.24 (m, 1H), 7.14 (dd, J = 7.7, 1.6 Hz, 1H), 6.99-6.94 (m, 1H), 6.92-6.87 (dt, 
J = 7.6, 1.1 Hz, 1H), 5.18 (s, 2H). 
13
C-NMR (101 MHz, CDCl3) /ppm: 157.56, 152.05, 136.66, 
131.41, 130.93, 128.77, 128.74, 128.54, 119.73, 116.88, 116.44, 77.02. HRMS (ESI): C14H14NO2
+ 
calcd.: 228.1019, found: 228.1021.  
176 
 
4.2.3.2 1H-NMR studies 
 
General Information 
The NMR experiments on boron-assisted oxime formation were performed at 288 K on a 
BrukerAvance III NMR spectrometer operating at 600.27 MHz, equipped with a 
1
H-
13
C/
15
N/
19
F-D 
cryogenic QCI probe head with z-axis pulsed field gradients. All 1D proton experiments were 
recorded using exactly the same parameters (relaxation delay of 0.5 s and an acquisition time of 2.0 s). 
The data was processed using TopSpin software from Bruker with a line broadening of 0.5 Hz and 
manually baseline corrected. Chemical shifts were referenced to the residual solvent peak of MeCN 
(1.94 ppm) and TMSP-d4 (3-(trimethylsilyl)-2,2',3,3'-tetradeuteropropionic acid) was used as an 
internal standard. 2-FPBA 2.34 was purchased from ABCR and O-benzylhydroxylamine (2.4) was 
neutralized from its HCl salt according to a published procedure.
300
 The pH (no correction for 
deuterium) was adjusted using a 827 pH Lab – Metrohm equipped with a glass minitrode which was 
pre-rinsed with D2O. 
The NMR experiments on the stability and reversibility of oxime 2.35 were performed at 298 K on a 
BrukerAvance III NMR spectrometer operating at 600.13 MHz and equipped with a direct observe 5-
mm BBFO smart probe. All 1D proton experiments were recorded using exactly the same parameters 
(256 scans, relaxation delay of 4.0 s and an acquisition time of 2.00 s) and were processed using 
TopSpin software from Bruker using line broadening of 0.5 Hz and after manual phase correction 
automated baseline correction was applied. Chemical shifts were referenced to the residual solvent 
peak of MeCN (1.94 ppm) and TMSP-d4 (3-(trimethylsilyl)-2,2',3,3'-tetradeuteropropionic acid) was 
used as an internal standard. The pH (no correction for deuterium) was adjusted using a 827 pH Lab – 
Metrohm equipped with a glass minitrode which was pre-rinsed with D2O. (These experiments were 
performed by Cedric Stress) 
 
Experimental – boron-assisted oxime formation 
Stock solutions for both 2-FPBA 2.34 and O-benzylhydroxylamine (2.4) were freshly prepared in 
CD3CN. A KPi buffer stock solution was freshly prepared in D2O adjusting the pH to 7.2 with 
concentrated DCl from ABCR (DCl, 38% wt% in D2O, 99.5% atom%D). A TMSP-d4 stock solution 
was freshly prepared in D2O. All experiments were conducted at 15°C (288 K) in standard NMR tubes 
(throw away quality) which were rinsed thoroughly with D2O and oven dried prior to the respective 
NMR experiment.  
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Setup for the 
1
H-NMR experiment at 10 M: 
1. 440 L of KPi buffer (12.5 mM) were mixed inside the NMR tube with 50 L of O-
benzylhydroxylamine (2.4, 110 M) and 10 L of TMSP-d4 (0.275 mM). The sample was 
then locked to MeCN and shimmed before the addition of the 2-FPBA 2.34. 
2. 50 L of 2-FPBA (2.4, 110 M) were then added and the reaction followed by 1H-NMR (32 
scans) without additional shimming. The time between adding 2-FPBA 2.34 to the NMR tube 
and recording of the last scan was determined to be ~3.5 min. 
The final volume of the NMR sample was 550 L with the following final concentrations: 
10 M in each O-benzylhydroxylamine (2.4) and 2-FPBA 2.34, respectively. 10mM KPi buffer and 5 
M TMSP-d4 with a ratio of 4:1 (10 mM KPi in D2O/CD3CN). 
For comparison a reference spectrum of 2-FPBA 2.34 was recorded at 10 M with the same solvent 
ratio of 4:1 (10 mM KPi in D2O/CD3CN). The setup for the 
1
H-NMR experiment at 1 M was 
identical using the same stock solutions except that the final solvent ratio was 54:1 (10 mM KPi in 
D2O/CD3CN) and scans were increased to 128. The time between adding 2-FPBA 2.34 to the NMR 
tube and recording of the last scan was determined to be ~8.5 min. An overview of the three 
1
H-NMR 
spectra (selected region of 10.2 – 6.9 ppm) is shown in Figure 3.12. 
 
Stability assay 
A stock solution of oxime 2.35 was freshly prepared in CD3CN. A KPi buffer stock solution was 
freshly prepared in D2O adjusting the pH to 7.20 with concentrated DCl from ABCR (DCl, 38% wt% 
in D2O, 99.5% atom%D). A TMSP-d4 stock solution was freshly prepared in D2O. All experiments 
were conducted at 298 K in standard NMR tubes (throw away quality) which were rinsed thoroughly 
with D2O and oven dried prior to the respective NMR experiment. 
Setup for the 
1
H-NMR stability experiment at 100 M: 
1. 430 L of KPi buffer (12.8 mM) were mixed inside the NMR tube with 110 L of oxime 2.35 
(500 M) and 10 L of TMSP-d4 (275 M). The sample was then locked to MeCN and 
shimmed before recording the first 
1
H-NMR spectrum. 
The final volume of the NMR sample was 550 L with the following final concentrations: 
100 M of oxime 2.35, 10mM KPi buffer and 5 M TMSP-d4 with a ratio of 4:1 (10 mM KPi in 
D2O/CD3CN). 
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The stability of oxime 2.35 was followed by recording 
1
H-NMR spectra every 7 h for the first day and 
then one spectrum every day for another two days. The integration of the oxime proton (blue) was 
compared to the internal standard (pink) integral at 1, 24, 48 and 72 h (see Figure 3.16).  
 
Reversibility assay 
Stock solutions of oxime 2.35 (in CD3CN) and Methoxyamine hydrochloride (Supelco) in D2O were 
freshly prepared the day they were used. A KPi buffer stock solution was freshly prepared in D2O 
adjusting the pH to 7.20 with concentrated DCl from ABCR (DCl, 38% wt% in D2O, 99.5% 
atom%D). A TMSP-d4 stock solution was freshly prepared in D2O. All experiments were conducted at 
298 K in standard NMR tubes (throw away quality) which were rinsed thoroughly with D2O and oven 
dried prior to use.  
Setup for the 
1
H-NMR reversibility experiment at 100 M: 
1. 420 L of KPi buffer (13.1 mM) were mixed inside the NMR tube with 110 L of oxime 2.35 
(500 M), 10 L of TMSP-d4 (275 M) and 10 L of Methoxyamine hydrochloride (27.5 
mM). The sample was then sonicated, locked to MeCN and shimmed before recording the first 
1
H-NMR spectrum. 
The final volume of the NMR sample was 550 L with the following final concentrations: 
100 M of oxime 2.35, 10mM KPi buffer, 5 M TMSP-d4 and 500 M of Methoxyamine 
hydrochloride with a ratio of 4:1 (10 mM KPi in D2O/CD3CN). 
The reversibility of oxime 2.35 was followed by recording 
1
H-NMR spectra every 2 h for a total of 30 
measurements (60 h) tracing the oxime protons Ha and Hb (see Figure 3.17, panel A). A stack of 
selected 
1
H-NMR spectra is presented in panel B of Figure 3.17 and shows the process of oxime 
interconversion which reaches equilibrium between 9 and 19 h. The final ratio of the newly formed 
oxime 2.68 and oxime 2.35 was found to be 3:1. 
 
 
For establishing the equilibration pathway oxime 2.35 was treated with a fivefold excess of aldehyde 
2.69 in a NMR tube as described above. Final reaction conditions: 100 mM 2.35, 500 mM 2.68, 5 M 
TMSP-d4, 4:1 (10 mM KPi in D2O/CD3CN).  
 
The interconversion of oxime 2.35 to 2.69 was followed by recording 
1
H-NMR spectra every 2 h for a 
total of 24 h at 298 K (Figure 3.18). A stack of selected 
1
H-NMR spectra is presented in panel B of 
Figure 3.18. According to the respective integrals the equilibration process was reached after 10 h.  
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The integral values were converted into a concentration and a first order plot (using OriginPro 8 
software) for the reverse reaction was performed to determine k-1 (Figure E7). 
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Figure E7: Plot of ln[2.35] (determined from the oxime proton Ha integral values) versus time. To evaluate the rate constant 
k-1 for the reverse reaction only time points between 0.5 and 5 h were considered. 
 
The slope of the trend line (▬) represents the rate constant k-1 for the reverse reaction of 2.35. Its 
value of 4.2 ± 0.4 x 10
-5
 s
-1
 is obtained directly from the graph along with the standard error. Using 
equations 5 and 6 the equilibrium constant Keq and its uncertainty can be calculated inserting the 
following values: 
k1 = 11113 ± 284 M
-1
 s
-1
 (see section 4.2.3.4), k-1 = 4.2 ± 0.4 x 10
-5
 s
-1
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Equation 5 and 6: Calculating Keq = equilibrium constant [M
-1] and its uncertainty Dk [M-1].  
 
This gives an equilibrium constant Keq = 2.6 ± 0.3 x 10
8
 M
-1
 for this particular type of oxime formation 
which clearly emphasizes the equilibrium being almost exclusively on the side of the product.  
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4.2.3.3 HPLC studies 
 
Boron-accelerated oxime formation 
All substrate stock solutions were prepared in HPLC grade MeCN except for the LYRAG 
pentapeptide monohydroxylamine 2.6 which was prepared in Milli-Q water and stored at -20°C. The 
concentration of the peptide was determined using a NanoDrop 2000 spectrophotometer from Thermo 
Scientific with a path length of 1 mm and LYRAG 280 nm) = 1490 M
-1
 cm
-1
. The different stock solutions 
for condensation were allowed to warm to room temperature, vortexed and centrifuged prior to mixing 
and combined in the following order in a PP HPLC vial (BGB, Part Number: PPSV0903K): 1) 100 
mM KPi buffer pH = 7.2, 2) O-alkylhydroxylamine, 3) aldehyde or ketone. The resulting solution was 
briefly mixed with a Gilson Pipetman before injection (time between mixing and injection was 
determined to be around 30 seconds). The reactions (Table 3.4 entries 1-9) were followed by RP-
HPLC on a Shimadzu Prominence UFLC Liquid Chromatograph using a C18 column (Eclipse XDB, 5 
m, 4.6 x 150 mm) from Agilent (gradient: 2-98% MeCN containing 1% H2O in H2O containing 1% 
MeCN over 18 min, flow rate 1 mL/min, room temperature, injection volume of 20 L, neutral 
conditions) monitoring and collecting the products at 254 nm or 280 nm if not otherwise specified. It 
is noteworthy to mention that O-benzylhydroxylamine (2.4) was not UV active and could not be 
monitored under these HPLC conditions. The slight excess of 1.10 eq. is used to discriminate pipetting 
errors from the establishment of an equilibrium; a small excess will not affect the equilibrium but will 
negate the possibility of small pipetting errors leading to incomplete conversion. All conversion 
numbers are related to the disappearance of the peak area of the aldehyde species at 254 nm or the 
pentapeptide monohydroxylamine 2.6 at 280 nm on the first injection after ~1 min. 
 
Boron-assisted ligation in complex media 
Stock solutions of 2-FPBA 2.34 and O-benzylhydroxylamine (2.4) were prepared in HPLC grade 
MeCN. Stock solutions of L-glutathione (reduced, Sigma Aldrich), sucrose (Fluka) and lysozyme (hen 
eggwhite, Roth) were prepared in Milli-Q water. The lysozyme concentration was determined using a 
NanoDrop 2000 spectrophotometer from Thermo Scientific with a path length of 1 mm and lysozyme 
oxidized cystein 280 nm) = 37970 M
-1
 cm
-1
. Human Serum (male) type AB was purchased from Sigma Aldrich 
and stored at -20°C. The different stock solutions for condensation were allowed to warm to room 
temperature, vortexed and centrifuged prior to mixing and combined in the following order in a PP 
HPLC vial (BGB, Part Number: PPSV0903K): 1) 100 mM KPi buffer pH = 7.2, 2) O-
benzylhydroxylamine (2.4), 3) interfering additive 4) 2-FPBA 2.34. The resulting solution was briefly 
mixed with a Gilson Pipetman before injection (time between mixing and injection was determined to 
be around 30 seconds). The reactions (Table 3.5 entries 1-5) were analyzed by RP-HPLC on a 
Shimadzu Prominence UFLC Liquid Chromatograph using a C18 column (Eclipse XDB, 5 m, 4.6 x 
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150 mm) from Agilent (gradient: 2-98% MeCN containing 1% H2O in H2O containing 1% MeCN 
over 18 min, flow rate 1 mL/min, room temperature, neutral conditions) monitoring and collecting the 
products at 254 nm. 
 
 
 
Figure E8: Top: Chromatogram of the reaction mixture of 100 M 2-FPBA (2.34) and 110 M O-benzylhydroxylamine 
(2.4) containing Human serum (20% v/v) as interfering additive in 100 mM KPi, pH 7.20 recorded at 254 nm after 1 min 
under neutral HPLC conditions. The conversion of 2-FPBA is >98% and the peak at tR = 17.5 min is the oxidation product 
2.68. Bottom: Chromatogram of the reaction mixture recorded after 18 h; clearly the oxime 2.35 gets continuously oxidized 
in human serum and oxime 2.68 is the major product. 
  
Table 3.5 entry 5 
Human serum 20 % (v/v) 
after 1 min 
Table 3.5 entry 5 
Human serum 20 % (v/v) 
after 18 h 
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The reaction with interfering lysozyme additive was also analyzed by UPLC-MS under acidic 
conditions (0.1% formic acid additive in the elution buffer) which showed no protein modification 
even after 12 h and complete conversion to the oxime 2.35 (see Figure E9 and Figure E10). 
 
 
 
 
Figure E9: Top: Chromatogram of a 100 M lysozyme solution in 100 mM KPi, pH 7.20 recorded at 254 nm under acidic 
UPLC-MS conditions. Bottom: ESI-MS spectra of the unmodified lysozyme peak at tR = 1.401 min containing the masses 
for the molecular ions with different protonation states.   
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Figure E10: Top: Chromatogram of the reaction mixture of 100 M 2-FPBA 2.34 and 110 M O-benzylhydroxylamine 
(2.4) containing 100 M of lysozyme as interfering additive in 100 mM KPi, pH 7.20 recorded at 254 nm after 12 h under 
acidic UPLC-MS conditions. Middle: ESI-MS spectra of the unmodified lysozyme peak at tR = 1.409 min. Bottom: ESI-MS 
spectra of the oxime 2.35 peak at tR = 2.424 min and its characteristic ionization adducts. 
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4.2.3.4 Fluorescence quenching assay 
 
General Information 
The fluorescence quenching experiments were conducted using a TECAN Infinite M1000 PRO 
fluorescence plate reader and the data was analyzed with the TECAN i-control software. All 
experiments were performed using a Nunclon flat black 96-well Microplate from Thermo Scientific. 
The fluorescence was monitored at the maximum absorption of lissamine derivative 2.66 (566 nm) in 
KPi buffer (100 mM, pH 3.02, 3.89, 4.49, 5.00, 5.53, 6.14, 7.20 and 8.05). Stock solutions of the 
reaction partners in DMSO were freshly prepared and data was recorded the same day. The higher 
concentrated stock solutions were stored at -20°C and wrapped in aluminum foil to minimize 
bleaching. Prior to analysis all samples were gently allowed to warm up to room temperature in the 
absence of light and vortexed for 30 seconds to allow homogeneity. 
 
Validation of oxime formation 
In a scouting experiment dabsyl hydroxylamine 2.49 was mixed with an equimolar amount of 2-FPBA 
tagged lissamine 2.61 and the mixture analyzed after 10 min by UPLC-MS. The oxime product 2.63 
could cleary be identified along with its oxidized form (Figure E11). 
 
Figure E11: UPLC chromatogram of the reaction mixture after 10 min. The number in parenthesis indicates the mass 
observed by ESI-MS after elution of the respective UV peak. The axis represents the retention time in minutes. The extracted 
mass spectrometry data of oxime 2.63 is shown as a zoom for clear visualization. 
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Experimental 
2 L of a lissamine derivative 2.66 stock solution (50 M or 10 M, in DMSO) were added to a well 
filled with 196 L of KPi solution (100 mM) with the respective pH followed by 2 L of a dabsyl 
derivative 2.65 stock solution (50 M or 10 M, in DMSO) to give a final volume of 200 L (500 nM 
or 100 nM). The mixture was immediately mixed with a pipette to ensure homogeneity followed by 
monitoring the fluorescence at 566 nm. The control experiment was set up in analogy by adding 2 L 
of a lissamine derivative 2.66 stock solution (50 M or 10 M, in DMSO) to a well filled with 196 L 
of KPi solution (100 mM, pH = 5.00) followed by 2 L of a dabsyl derivative 2.65 stock solution (10 
M in DMSO). The mixture was immediately mixed with a pipette to ensure homogeneity followed 
by monitoring the fluorescence at 566 nm and 26°C. Both wells were analyzed simultaneously over a 
period of 7 minutes with data points recorded every 15 seconds. The time delay between mixing the 
samples and recording the first data point was determined to be 30 seconds.  
 
Data processing 
All experiments were triplicates and the data was processed in Microsoft Excel 2010 and plotted in 
OriginPro 8. The collected readout (fluorescence signal) was corrected by subtracting the control 
measurement with lissamine derivative 2.49 as well as for the 30 seconds delay time (see Figure 3.14, 
panel B). The corrected readout was then converted into a concentration [Lissamine] and the triplicate 
average of 1/[Lissamine] in M-1 was plotted against the corrected time points in seconds. Only data 
points which lie within the linear region of the plot were considered (435 seconds for 0.1 M). All 
error bars represent the standard deviation of the respective data series and were determined with 
OriginPro 8. The value for k1 [M
-1
 s
-1
] was determined as the slope of the linear fit of the respective 
graph. 
 
  
186 
 
Determining k1 
The reaction from Figure 3.15 shows second order behavior up to 405 seconds and excellent linearity 
in inverse concentration plot (Figure E12). The collected data is corrected for the time and the control 
measurement.  
 
 
 
Figure E12: Fluorescence quench assay at 100 nM in 100 mM KPi at pH 5.00 and 26°C. • Data points (corrected for time 
and the control measurement) recorded over 435 seconds are fitted by a trend line (▬). The slope multiplied by 106 gives the 
rate constant k1 [M
-1 s-1] for this particular oxime condensation reaction at the respective pH. 
 
All pH profile measurements were evaluated in Microsoft Excel 2010 and plotted in OriginPro 8. All 
data presented is the average of triplicates and the error represents the standard error [M
-1
 s
-1
]. Values 
for k1 [M
-1
 s
-1
] represent the slope of the trend line which was obtained from the average data points 
collected in the first 405 seconds. Table E3 summarizes the results for the kinetic pH dependency of 
the oxime formation. These results are additionally plotted in a graph for better visualization (Figure 
E13).  
Table E3: Results of the pH profile measurements at 100 nM. Values determined from triplicate measurements at 26°C. 
 pH k1 [M
-1
 s
-1
] standard error [M
-1
 s
-1
]  
     
     
 3.02 9386 ± 325  
 3.89 11259 ± 244  
 4.49 13839 ± 328  
 5.00 14263 ± 405  
 5.53 12161 ± 377  
 6.14 11181 ± 360  
 7.20 11113 ± 284  
 8.05 10180 ± 310  
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The following eight inverse concentration plots (pH 3.02 – 8.05) were generated in OriginPro 8 from 
processing raw data in Microsoft Excel 2010. Average data points ■ include standard error bars and a 
trend line (▬). The slope represents the rate constant [M-1 s-1] and is multiplied by a factor of 106 to 
obtain the final magnitude for k1 [M
-1
 s
-1
]. The standard error in k1 is evaluated in the same manner. 
 
pH 3.02 pH 3.89 
 
 
pH 4.49 pH 5.00 
  
 
  
188 
 
pH 5.53 
 
pH 6.14 
 
 
pH 7.20 
 
pH 8.05 
 
 
Figure E13: pH depencence of the rate constant at 100 nM. Inverse concentration plots obtained from triplicate 
measurements including the standard errors and the trendline. 
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4.3 Appendix  
4.3.1 X-ray data 
 
 
Crystal data for 2.3b: formula C22H24N4O4, M = 408.46, F(000) = 432, colorless needle, size 0.030 · 
0.050 · 0.270 mm
3
, monoclinic, space group P 21/n, Z = 2, a = 14.0072(10) Å, b = 4.5247(3) Å, c = 
15.7406(11) Å, α = 90°, β = 90.463(3)°, γ = 90°, V = 997.58(12) Å3, Dcalc. = 1.360 Mg · m
-3
. The 
crystal was measured on a Bruker Kappa Apex2 diffractometer at 123K using graphite-
monochromated Cu Kα-radiation with λ = 1.54178 Å, Θmax = 69.073°. Minimal/maximal transmission 
0.96/0.98, μ = 0.782 mm-1. The Apex2 suite has been used for datacollection and integration. From a 
total of 7553 reflections, 1808 were independent (merging r = 0.023). From these, 1783 were 
considered as observed (I>2.0σ(I)) and were used to refine 136 parameters. The structure was solved 
by other methods using the program Superflip. Least-squares refinement against F was carried out on 
all non-hydrogen atoms using the program CRYSTALS. R = 0.0308 (observed data), wR = 0.0329 (all 
data), GOF = 1.1123. Minimal/maximal residual electron density = -0.17/0.25 e Å
-3
. Chebychev 
polynomial weights were used to complete the refinement. Plots were produced using CAMERON. 
 
Crystal data for 2.19: formula C15H13N1O2, M = 239.27, F(000) = 252, colorless plate, size 0.010 · 
0.130 · 0.190 mm
3
, triclinic, space group P -1, Z = 2, a = 5.8350(3) Å, b = 7.7208(4) Å, c = 13.5719(7) 
Å, α = 106.446(3)°, β = 92.161(3)°, γ = 92.767(3)°, V = 584.88(5) Å3, Dcalc. = 1.359 Mg · m
-3
. The 
crystal was measured on a Bruker Kappa Apex2 diffractometer at 123K using graphite-
monochromated Cu Kα-radiation with λ = 1.54178 Å, Θmax = 68.712°. Minimal/maximal transmission 
0.91/0.99, μ = 0.731 mm-1. The Apex2 suite has been used for datacollection and integration. From a 
total of 5236 reflections, 1993 were independent (merging r = 0.020). From these, 1822 were 
considered as observed (I>2.0σ(I)) and were used to refine 163 parameters. The structure was solved 
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by other methods using the program Superflip. Least-squares refinement against F was carried out on 
all non-hydrogen atoms using the program CRYSTALS. R = 0.0347 (observed data), wR = 0.0457 (all 
data), GOF = 1.1138. Minimal/maximal residual electron density = -0.17/0.21 e Å
-3
. Chebychev 
polynomial weights were used to complete the refinement. Plots were produced using CAMERON. 
 
Crystal data for 2.35: formula C14H14B1N1O3, M = 255.08, F(000) = 2144, colourless block, size 0.100 
· 0.120 · 0.140 mm
3
, monoclinic, space group C 2/c , Z = 16, a = 18.5248(15) Å, b = 15.2275(12) Å, c 
= 18.9615(16) Å, α = 90°, β = 94.102(4)°, γ = 90°, V = 5335.1(5) Å3, Dcalc. = 1.270 Mg · m
-3
. The 
crystal was measured on a Bruker Kappa Apex2 diffractometer at 123K using graphite-
monochromated Cu Kα-radiation with λ = 1.54178 Å, Θmax = 68.196°. Minimal/maximal transmission 
0.88/0.93, μ = 0.718 mm-1. The Apex2 suite has been used for datacollection and integration. From a 
total of 17258 reflections, 4673 were independent (merging r = 0.020). From these, 4673 were 
considered as observed (I>2.0σ(I)) and were used to refine 427 parameters. The structure was solved 
by other methods using the program Superflip. Least-squares refinement against Fsqd was carried out 
on all non-hydrogen atoms using the program CRYSTALS. R = 0.0386 (observed data), wR = 0.0884 
(all data), GOF = 0.8971. Minimal/maximal residual electron density = -0.20/1.03 e Å
-3
. Chebychev 
polynomial weights were used to complete the refinement. Plots were produced using CAMERON. 
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